# This Page Is Inserted by IFW Operations and is not a part of the Official Record

### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

### IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

4			

#### WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONA	L APPLICATION PUBLIS	SHED	UNDER THE PATENT COOPERATION TREATY (PCT)
(51) International Patent Classification <sup>6</sup> :  C07C 45/41, C07D 301/03, 303/04, 311/74, C12P 1/02			(11) International Publication Number: WO 00/01650
		A1	(43) International Publication Date: 13 January 2000 (13.01.00)
(21) International Appli	cation Number: PCT/U	S99/152	1 \ 7 = == g-moon = moon + 12, 12, 111, 110, 112, DA, DB, B()
(22) International Filing	<b>Date:</b> 6 July 1999	(06.07.9	
	,		KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
(30) Priority Data:			SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW,
60/091,983	6 July 1998 (06.07.98)	Ę	US ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG,
60/091,951	6 July 1998 (06.07.98)	ŧ	US ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ,
60/091,964	6 July 1998 (06.07.98)	Ţ	US TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI

#### (71) Applicant: DCV, INC. doing business as BIO-TECHNICAL RESOURCES [US/US]; 1035 South Seventh Street, Manitowoc, WI 54220 (US).

- (72) Inventors: MILLIS, James, R.; 512 Audubon Road, Kohler, WI 53044 (US). SAUCY, Gabriel, G.; 125 Fells Road, Essex Fells, NJ 07021 (US). MAURINA-BRUNKER, Julie; 825 Covenant Lane, Appleton, WI 54915 (US). McMULLIN, Thomas, W.; 1010 West Crescent Dr., Manitowoc, WI 54220 (US).
- (74) Agents: CONNELL, Gary, J. et al.; Sheridan Ross P.C., Suite 1200, 1560 Broadway, Denver, CO 80202-5141 (US).

#### Published

SN, TD, TG).

With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE,

(54) Title: METHOD OF VITAMIN PRODUCTION

(57) Abstract

Application of the second seco

مرين پخين

The invention provides a method of producing  $\alpha$ -tocopherol and  $\alpha$ -tocopheryl esters and a method of producing vitamin A or  $\beta$ -carotene. The methods comprise using a biological system to produce farmesol or geranylgeraniol. Then, the farmesol or geranylgeraniol is chemically converted into  $\alpha$ -tocopherol, an  $\alpha$ -tocopheryl ester, vitamin A or  $\beta$  carotene.

### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

15

20

THE PARTY OF THE P

. 1:

#### METHOD OF VITAMIN PRODUCTION "

#### FIELD OF THE INVENTION

The present invention relates to methods of producing vitamins, particularly vitamins A and E and related compounds.

#### BACKGROUND OF THE INVENTION

Vitamin E (d-alpha-tocopherol, 1) is an important nutritional supplement in humans and animals. Compound 1 is obtained commercially by isolation from a variety of plant oils, or semisynthetically by ring methylation of the related naturally occurring d-gamma-tocopherol 2. A more important source of vitamin E is total synthesis, which provides d,l-alpha-tocopherol 3. Although a mixture of isomers, 3 provides much of the biological activity of 1 and is widely used due to its lower cost and greater availability. For a general discussion of vitamin E, see L. Machlin, ed., "Vitamin E: A Comprehensive Treatise", Marcel Dekker, NY, 1980.

d,1-alpha-Tocopherol 3 is obtained by reacting trimethylhydroquinone 4 with either phytol 5 or isophytol 6 in the presence of an acid catalyst, often a Lewis acid such as zinc chloride. This technology was reviewed by S. Kasparek in L. Machlin, ed., Vitamin E: A Comprehensive Treatise, chapter 2, pp. 8-65, Marcel Dekker, NY, 1965. References 140 - 166 of this chapter provide the primary references to detailed methods of preparing compound 3.

10

THE PROPERTY OF THE PROPERTY O

5

The isophytol 6 or phytol 5 required for the preparation of 3 are obtained through multistep synthesis. Starting materials typically include acetone (see Kasparek, in Machlin, Vitamin E: A Comprehensive Treatise, pp. 44-45, Dekker, NY 1980, and references cited therein) and cyclic

10

20

25

A CAMPAGNA AND THE STATE OF THE

isoprene trimer (Pond et al., US 3,917,710 and 3,862,988 (1975).

In addition, gamma-tocopherol was first made by total synthesis by Jacob, Steiger, Todd and Wilcox (J. Chem. Soc. 1939, 542). These workers produced the vitamin by reacting the monobenzoate ester of 2,3-dimethylhydroquinone with phytyl bromide in the presence of zinc chloride, followed by removal of the benzoate to give a low yield (22%) of gamma-tocopherol. Published syntheses of the tocopherols and tocotrienols were reviewed by S. Kasparek in L. Machlin, "Vitamin E - A Comprehensive Treatise", Dekker, NY, 1980; however, no further methods of preparing gamma-tocopherol have been recorded.

Despite the various known methods for preparing or isolating members of the vitamin E family of compounds, there remains a need for improved and more efficient methods of production.

Vitamin A (retinol) and the provitamin A β-carotene are used in pharmaceuticals, food fortification and dietary supplements. Vitamin A acetate (retinyl acetate), propionate (retinyl propionate) and palmitate (retinyl palmitate) are the vitamin A derivatives most generally used. All of the vitamin A, vitamin A esters and β-carotene currently produced commercially are produced by total chemical synthesis, except for some vitamin A which is isolated from food sources. See generally Kirk-Othmer Encyclopedia of Chemical Technology, volume 24, pages 140-158 (3rd ed. 1984).

and the second s

There remains a need for improved and economical methods of production of vitamin A and vitamin A esters.

### BRIEF DESCRIPTION OF THE DRAWINGS

- Fig. 1A illustrates a diagramatic representation of the mevalonate-dependent isoprenoid biosynthetic pathway.
  - Fig. 1B illustrates a diagramatic representation of the mevalonate-independent isoprenoid biosynthetic pathway.
- Fig. 2 illustrates an embodiment of a route for chemical synthesis of vitamin E from geranylgeraniol.
  - Fig. 3 illustrates an embodiment of a route for chemical synthesis of vitamin E from farnesol.
  - Fig. 4 illustrates the growth and farnesol production of strains derived from strain MBNA1-13.
- Fig. 5 illustrates the growth of wild-type, erg9 and repaired ERG9 strains.
  - Fig. 6 illustrates the production of farnesol in microorganisms with amplified production of HMG CoA reductase.
- Fig. 7 illustrates the production of farnesol and GG in strains overexpressing GGPP synthases.
  - Fig. 8 illustrates the effect of amplified production of FPP synthase on farnesol and GG production.
- Fig. 9 illustrates the pathway for metabolic conversion of isoprenol and prenol to farnesol.
  - Fig. 10 illustrates a chemical synthesis route for the production of vitamin A acetate from farnesol.

Fig. 11 illustrates an alternative chemical synthesis route for the production of vitamin A acetate from farnesol.

Fig. 12 illustrates a method for preparing  $\beta$ -carotene from retinal using a carbonyl coupling reaction.

Fig. 13 illustrates a method for preparing  $\beta$ -carotene using an alkylation reaction.

#### DETAILED DESCRIPTION OF THE INVENTION

#### 1.0 <u>Introduction</u>

The second secon

:...

- The present invention provides a method for producing  $\alpha$ -tocopherol and  $\alpha$ -tocopheryl esters in which a biological system is used to produce farnesol or geranylgeraniol (GG). Farnesol can be used as a starting material to chemically synthesize the final product,  $\alpha$ -tocopheryl esters.
- Alternatively, the farnesol can be converted chemically to GG. GG, produced biologically or by synthesis from farnesol, can then be used as a starting material to make  $\alpha$ -tocopheryl and  $\alpha$ -tocopheryl esters. The present invention also includes various aspects of biological materials and intermediates useful in the production of farnesol or GG by biological production. The present invention also includes methods of producing  $\alpha$ -tocopherol
- The present invention is also directed to a method for producing vitamin A from farnesol. In a preferred embodiment, farnesol is produced biologically.

and  $\alpha$ -tocopheryl esters using farnesol and/or GG produced

#### 2.0 Biological Production of Farnesol and GG

by any means as the starting material.

Isoprenoids are the largest family of natural products, with about 22,000 different structures known. All isoprenoids are derived from the  $C_5$  compound isopentylpyrophosphate (IPP). Thus, the carbon skeletons of all isoprenoid compounds are created by sequential additions of the  $C_5$  units to the growing polyprenoid chain.

While the biosynthetic steps leading from IPP to isoprenoids are universal, two different pathways leading to IPP exist. Fungi (such as yeast) and animals possess 10 the well known mevalonate-dependent pathway (depicted in Fig. 1A) which uses acetyl CoA as the initial precursor. Bacteria and higher plants, on the other hand, possess a newly discovered mevalonate independent pathway, also referred to herein as the non-mevalonate pathway, (depicted 15 in Fig. 1B) leading from pyruvate and glyceraldehyde 3phosphate [Lois et al., Proc. Natl. Acad. Sci. USA, 95, 2105-2110 (1998); Rohmer et al., J. Am. Chem. Soc. 118, 2564-2566 (1996); Arigoni, et al., Proc. Natl. Acad. Sci. USA, 94, 10600-10605 (1997); Lange et al., Proc. Natl. 20 Acad. Sci. USA, 95, 2100-2104 (1998)]. (including microalgae), there is evidence that both the In plants . mevalonate-dependent and -independent pathways exist, the former being cytosolic and the latter being plastidial [Arigoni, et al., Proc. Natl. Acad. Sci. USA, 94, 10600-25 10605 (1997); Lange et al., Proc. Natl. Acad. Sci. USA, 95, 2100-2104 (1998)]. Several steps of the mevalonateindependent pathway have been established. The first step, catalyzed by D-1-deoxyxylulose 5-phosphate synthase, forms

WO 00/01650 PCT/US99/15264

7

D-1-deoxyxylulose 5-phosphate from pyruvate glyceraldehyde 3-phosphate. The second and third steps, catalyzed bу D-1-deoxyxylulose 5-phosphate reductoisomerase, catalyze the conversion of deoxyxylulose 5-phosphate to 2-C-methyl D erythritol-4-P (MEP). Several further reactions are required to convert MEP to IPP, and these enzymes are unknown at this time [Lois et al., Proc. Natl. Acad. Sci. USA, 95, 2105-2110 (1998); Takahashi et al., Proc. Natl. Acad. Sci. USA, 95, 2100-2104 (1998); Duvold et al. Tetrahedron Letters, 38, 4769-4772 (1997)].

The state of the s

The second of th

18:50

5

10

15

20

25

Farnesol and GG are prenyl alcohols produced by dephosphorylation of farnesylpryrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP), respectively. FPP and GGPP are intermediates in the biosynthesis of isoprenoid compounds, including sterols, ubiquinones, heme, dolichols, and carotenoids, and are used in the post-translational prenylation of proteins. Both FPP and GGPP are derived from IPP. Embodiments of the present invention include the biological production of farnesol or GG in prokaryotic or eukaryotic cell cultures and cell-free systems, irrespective of whether the organism utilizes the mevalonate-dependent or -independent pathway for biosynthesis of the precursor of all isoprenoids, IPP. Reference herein to farnesyl phosphate or geranylgeranyl phosphate refers to the respective mono-, di- and triphosphate compounds, unless one specific form specifically designated.

's that the actor's are a compared on the compared of the comp

25

### 2.1 Modified Microorganism

Suitable biological systems for producing farnesol and GG include prokaryotic and eukaryotic cell cultures and cell-free systems. Preferred biological systems include fungal, bacterial and microalgal systems. More preferred 5 biological systems are fungal cell cultures, preferably a yeast cell culture, and most preferably a Saccharomyces cerevisiae cell culture. Fungi are preferred since they have a long history of use in industrial processes and can be manipulated by both classical 10 microbiological and genetic engineering techniques. Yeast, in particular, are well-characterized genetically. Indeed, the entire genome of S. cerevisiae has been sequenced, and the genes coding for enzymes in the isoprenoid pathway have already been cloned. Also, S. cerevisiae grows to high 15 cell densities, and amounts of squalene and ergosterol (see Fig. 1) up to 16% of cell dry weight have been reported in genetically-engineered strains. For a recent review of the isoprenoid pathway in yeast, see Parks and Casey, Annu. Rev. Microbiol. 49:95-116 (1995). 20

The preferred prokaryote is *E. coli*. *E. coli* is well established as an industrial microorganism used in the production of metabolites (amino acids, vitamins) and several recombinant proteins. The entire *E. coli* genome has also been sequenced, and the genetic systems are highly developed. As mentioned above, *E. coli* uses the mevalonate-independent pathway for synthesis of IPP. The *E. coli* dxs, dxr, idi, and ispA genes, encoding D-1-deoxyxylulose 5-phosphate synthase, D-1-deoxyxylulose 5-

10

15

20

25

THE PROPERTY OF THE PROPERTY O

phosphate reductoisomerase, IPP isomerase, and FPP synthase, respectively, have been cloned and sequenced [Fujisaki, et. al, *J. Biochem.* 108, 995-1000 (1990); Lois et al., *Proc. Natl. Acad. Sci. USA*, 95, 2105-2110 (1998); Hemmi et al., *J. Biochem.*, 123, 1088-1096 (1998)].

Preferred microalga for use in the present invention include Chlorella and Prototheca.

Suitable organisms useful in producing farnesol and GG are available from numerous sources, such as the American Type Culture Collection (ATCC), Rockville, MD, Culture Collection of Algae (UTEX), Austin, TX, the Northern Regional Research Laboratory (NRRL), Peoria, IL and the E. coli Genetic Stock Center (CGSC), New Haven, CT. In particular, there are culture collections of S. cerevisiae that have been used to study the isoprenoid pathway which are available from, e.g., Jasper Rine at the University of California, Berkeley, CA and from Leo Parks at North Carolina State University, Raleigh, NC.

Preferably the cells used in the cell culture are genetically modified to increase the yield of farnesol or GG. Cells may be genetically modified by genetic engineering techniques (i.e., recombinant technology), classical microbiological techniques, or a combination of such techniques and can also include naturally occurring genetic variants. Some of such techniques are generally disclosed, for example, in Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Labs Press. The reference Sambrook et al., ibid., is incorporated by reference herein in its entirety. A

and the same of the same of

22.

genetically modified microorganism can include microorganism in which nucleic acid molecules have been inserted, deleted or modified (i.e., mutated; e.g., by insertion, deletion, substitution, and/or inversion of nucleotides), in such a manner that such modifications 5 provide the desired effect of increased yields of farnesol or GG within the microorganism or in the culture supernatant. As used herein, genetic modifications which result in a decrease in gene expression, in the function of the gene, or in the function of the gene product (i.e., the 10 protein encoded by the gene) can be referred to as inactivation (complete or partial), deletion, interruption, blockage or down-regulation of a gene. For example, a genetic modification in a gene which results in a decrease 15 in the function of the protein encoded by such gene, can be the result of a complete deletion of the gene (i.e., the gene does not exist, and therefore the protein does not exist), a mutation in the gene which results in incomplete or no translation of the protein (e.g., the protein is not expressed), or a mutation in the gene which decreases or 20 abolishes the natural function of the protein (e.g., a protein is expressed which has decreased or no enzymatic activity). Genetic modifications which result in an increase in gene expression or function can be referred to 255 as amplification, overproduction, overexpression, activation, enhancement, addition, or up-regulation of a gene. Addition of cloned genes to increase gene expression can include maintaining the cloned gene(s) on replicating plasmids or integrating the cloned gene(s) into the genome

医甲酰胺 医克里克氏病 医克里克氏 经收益 医克里克氏

111

the major of the contraction control of the desired of the page of the control of

e destruit en este en esta de la companya de la proposition de la destruit de la companya del companya de la companya de la companya de la companya de la companya del companya de la companya del company

. Tanana kalendari dari baran 1977 of the production organism. Furthermore, increasing the expression of desired cloned genes can include operatively linking the cloned gene(s) to native or heterologous transcriptional control elements.

#### 2.1.1 Squalene Synthase Modifications

Embodiments of the present invention include biological production of farnesol or GG by culturing a microorganism, preferably yeast, which has been genetically modified to modulate the activity of one or more of the enzymes in its isoprenoid biosynthetic pathway. In one 10 embodiment, a microorganism has been genetically modified by decreasing (including eliminating) the action of squalene synthase activity (see Fig. 1). For instance, yeast erg9 mutants that are unable to convert mevalonate into squalene, and which accumulate farnesol, have been 15 Karst and Lacroute, Molec. Gen. Genet., 154, produced. 269-277 (1977); U.S. Patent No. 5,589,372. As used herein, reference to erg9 mutant or mutation generally refers to a genetic modification that decreases the action of squalene synthase, such as by blocking or reducing the production of 20 squalene synthase, reducing squalene synthase activity, or inhibiting the activity of squalene synthase, which results in the accumulation of farnesyl diphosphate (FPP) unless the FPP is otherwise converted to another compound, such as 25 farnesol by phosphatase activity. Blocking or reducing the production of squalene synthase can include placing the ERG9 gene under the control of a promoter that requires the presence of an inducing compound in the growth medium. By establishing conditions such that the inducer becomes

depleted from the medium, the expression of  $\it ERG9$  (and therefore, squalene synthase synthesis) could be turned off. Also, some promoters are turned off by the presence of a repressing compound. For example, the promoters from the yeast CTR3 or CTR1 genes can be repressed by addition 5 of copper. Blocking or reducing the activity of squalene synthase could also include using an excision technology approach similar to that described in U.S. Patent No. 4,743,546, incorporated herein by reference. approach, the ERG9 gene is cloned between specific genetic 10 sequences that allow specific, controlled excision of the ERG9 gene from the genome. Excision could be prompted by, for example, a shift in the cultivation temperature of the culture, as in U.S. Patent No. 4,743,546, or by some other physical or nutritional signal. Such a genetic modification 15 includes any type of modification and specifically includes modifications made by recombinant technology and by classical mutagenesis. Inhibitors of squalene synthase are known (see U.S. Patent No. 4,871,721 and the references cited in U.S. Patent No. 5,475,029) and can be added to 20 cell cultures. In another embodiment, an organism having the mevalonate-independent pathway of biosynthesis (such as  $E.\ coli$ ) is genetically modified so isoprenoid that it accumulates FPP and/or farnesol. decreasing the activity of octaprenyl pyrophosphate For example, 25 synthase (the product of the ispB gene) would be expected to result in FPP accumulation in E. coli. (Asai, et al., Biochem. Biophys. Res. Comm. 202, 340-345 (1994)).

:

10

15

20

25

Andrew Control of the Control of the

The second of the second secon

action of a phosphatase could further result in farnesol accumulation in *E. coli*.

Yeast strains need ergosterol for cell membrane fluidity, so mutants blocked in the ergosterol pathway, such as erg9 mutants, need extraneous ergosterol or other sterols added to the medium for the cells to remain viable. The cells normally cannot utilize this additional sterol unless grown under anaerobic conditions. Therefore, a further embodiment of the present invention is the use of in which the action of squalene synthase is a yeast reduced, such as an erg9 mutant, and which takes up exogenously supplied sterols under aerobic conditions. Genetic modifications which allow yeast to utilize sterols under aerobic conditions are demonstrated below in the Examples section (see Example 1) and are also known in the For example, such genetic modifications include upc (uptake control mutation which allows cells to take up sterols under aerobic conditions) and hem1 (the HEM1 gene encodes aminolevulinic acid synthase which is the first committed step to the heme biosynthetic pathway from FPP, and hem1 mutants are capable of taking up ergosterol under aerobic conditions following a disruption in the ergosterol biosynthetic pathway, provided the cultures are supplemented with unsaturated fatty acids). Yeast strains having these mutations can be produced using known techniques and also are available from, e.g., Dr. Leo Parks, North Carolina State University, Raleigh, NC. Haploid cells containing these mutations can be used to generate other mutants by genetic crosses with other

haploid cells. Also, overexpression of the SUT1 (sterol uptake) gene can be used to allow for uptake of sterols under aerobic conditions. The SUT1 gene has been cloned and sequenced. Bourot and Karst, Gene, 165: 97-102 (1995).

5 In a further embodiment, microorganisms of the present invention can be used to produce farnesol and/or GG by culturing microorganisms in the presence of a squalene synthase inhibitor. In this manner, the action of squalene synthase is reduced. Squalene synthase inhibitors are known to those skilled in the art. (See, for example, U.S. 10 Patent No. 5,556,990.

## 2.1.2 HMG-CoA Reductase Modifications

: ;

Controlle plenters recommendence con service communication described and recommendence of the service of the se

20

25

÷,:.

A further embodiment of the present invention is the use of a microorganism which has been genetically modified to increase the action of HMG-CoA reductase. It should be 15 noted that reference to increasing the action of  ${\tt HMG-CoA}$ reductase and other enzymes discussed herein refers to any genetic modification in the microorganism in question which results in increased functionality of the enzymes and includes higher activity of the enzymes, reduced inhibition or degradation of the enzymes and overexpression of the enzymes. For example, gene copy number can be increased, expression levels can be increased by use of a promoter that gives higher levels of expression than that of the native promoter, or a gene can be altered by genetic engineering or classical mutagenesis to increase the activity of an enzyme. One of the key enzymes in the mevalonate-dependent isoprenoid biosynthetic pathway is HMG-CoA reductase which catalyzes the reduction of 3-

20

25

The state of the s

hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). This is the primary rate-limiting and first irreversible step in the pathway, and increasing HMG-CoA reductase activity leads to higher yields of squalene and ergosterol in a wild-type strain of S. cerevisiae, and farnesol in an erg9 strain. One mechanism by which the action of HMG-CoA reductase can be increased is by reducing inhibition of the enzyme, by either genetically modifying the enzyme or by modifying the system to remove the inhibitor. For instance, both sterol and non-sterol products of the isoprenoid pathway feedback 10 inhibit this enzyme (see, e.g., Parks and Casey, Annu. Rev. Microbiol. 49:95-116 (1995). Alternatively or in addition, the gene(s) coding for HMG-CoA reductase can be altered by genetic engineering or classical mutagenesis techniques to decrease or prevent inhibition. Also, the action of HMG-CoA reductase can be increased by increasing the gene copy number, by increasing the level of expression of the HMG-CoA reductase gene(s), or by altering the HMG-CoA reductase gene(s) by genetic engineering or classical mutagenesis to increase the activity of the enzyme. See U.S. Patent No. 5,460,949, the entire contents of which are incorporated herein by reference. For example, truncated HMG-CoA reductases have been produced in which the regulatory domain has been removed and the use of gene copy numbers up to about six also gives increased activity. also, Downing et al., Biochem. Biophys. Res. Commun., 94, 974-79 (1980) describing two yeast mutants having increased levels of HMG-CoA reductase. Two isozymes of HMGCoA reductase, encoded by the HMG1 and HMG2 genes, exist in S.

cerevisiae. The activity of these two isozymes is regulated by several mechanisms including regulation of transcription, regulation of translation, and for Hmg2p, degradation of the enzyme in the endoplasmic reticulum (Hampton and Rine, 1994; Donald, et. al. 1997). In both 5 Hmglp and Hmg2p, the catalytic domain resides in the COOH terminal portion of the enzyme, while the regulatory domain resides in the membrane spanning  $\mathrm{NH}_2 ext{-terminal}$  region. It has been shown that overexpression of just the catalytic domain of Hmglp in S. cerevisiae increases carbon flow 10 through the isoprenoid pathway, resulting in overproduction of squalene (Saunders, et. al. 1995; Donald, et. al., 1997). The present inventors have expressed the catalytic domain of the S. cerevisiae Hmg2p in strains having a normal (i.e., unblocked) isoprenoid pathway and observed a 15 significant increase in the production of squalene. Furthermore, overexpression of the catalytic domain of Hmg2p resulted in increased farnesol production in an erg9mutant, and increased farnesol and GG production in an erg9mutant overexpressing GGPP synthase, grown in fermentors. 20

### 2.1.3 GGPP Synthase Modifications

A further embodiment of the present invention is the use of a microorganism which has been genetically modified to increase the action of GGPP synthase. Genes coding for this enzyme from a variety of sources, including bacteria, fungi, plants, mammals, and archaebacteria, have been identified. See, Brinkhaus et al., Arch. Biochem. Biophys., 266, 607-612 (1988); Carattoli et al., J. Biol.

THE STANDARD CONTRACT CONTRACT OF THE SECOND STANDARD STA

e de displaca e e date com de

Chem., 266, 5854-59 (1991); Chen et al., J. Biol. Chem., 268, 11002-11007 (1993); Dogbo et al., Biochim. Biophys. Acta, 920, 140-148 (1987); Jiang et al., J. Biol. Chem., 270, 21793-99 (1995); Kuntz al., Plant J., 2, 25-34 (1992); Laferriere, et al., Biochim. Biophys. Acta, 1077, 167-72 5 (1991); Math et al., Proc. Natl. Acad. Sci. USA, 89, 6761-64 (1992); Ohnuma et al., J. Biol. Chem., 269, 14792-97 (1994); Sagami et al., Arch. Biochem. Biophys., 297, 314-20 (1992); Sagami et al., J. Biol. Chem., 269, 20561-66 (1994); Sandmann et al., J. Photochem. Photobiol. B: Biol., 10 18, 245-51 (1993); Scolnik et al., Plant Physiol., 104, 1469-70 (1994); Tachibana et al., Biosci. Biochem., 7, 1129-33 (1993); Tachibana et al., J. Biochem., 114, 389-92 (1993); Wiedemann et al., Arch. Biochem. 15 Biophys., 306, 152-57 (1993). Some organisms have a bifunctional enzyme which also serves as an FPP synthase, so it is involved in the overall conversion of IPP and DMAPP to FPP to GGPP (see Fig. 1). Some enzymes, such as those found in plants, have relaxed specificity, converting 20 IPP and DMAPP to GGPP (see Fig. 1). Genetic modifications of GGPP synthase, as used herein, encompass engineering a bifunctional FPP/GGPP synthase to enhance the GGPP synthase activity component of the enzyme. A preferred GGPP synthase gene is the BTS1 gene from S. cervisiae. The BTS1 25 gene and its isolation are described in Jiang et al., J. Biol. Chem., 270, 21793-99 (1995) and copending application Serial No. 08/761,344, filed on December 6, 1996, the complete disclosure of which incorporated herein by

reference. However, GGPP synthases of other hosts can be used, and the use of the bifunctional GGPP synthases may be particularly advantageous in terms of channeling carbon flow through FPP to GGPP, thereby avoiding loss of FPP to competing reactions in the cell.

In further embodiments of the invention, in addition to the modifications of GGPP synthase described above, the wild type GGPP synthase is eliminated from the production organism. This would serve, for example, to eliminate competition between the modified GGPP synthase and the wild type enzyme for the substrates, FPP and IPP. Deletion of the wild-type gene encoding GGPP synthase could also improve the stability of the cloned GGPP synthase gene by removing regions of high genetic sequence homology, thereby avoiding potentially detrimental genetic recombination.

### 2.1.4 FPP Synthase Modifications

5

فيسيب ومميقاه الكافية والمافية والمتعاوي ومعالكالماليون ورواده والمار الداء والمالية المار والمارة والمارة والمارة المارة

A further embodiment of the present invention is the use of a microorganism which has been genetically modified to increase the action of FPP synthase .

Genes coding for this enzyme from a variety of sources have been identified. See, Anderson et al., J. Biol. Chem., 264, 19176-19184 (1989); Attucci, et al., Arch. Biochem. Biophys., 321, 493-500 (1995); Cane et al., J. Am. Chem. Soc., 105, 122-124 (1983); Chambon et al., Current Genetics, 18, 41-46 (1990);, Chambon et al., Lipids, 26, 633-36 (1991); Chen al., Protein Science, 3, 600-607 (1994); Davisson, et al., J. Am. Chem. Soc., 115, 1235-45 (1993); Ding et al., Biochem. J., 275, 61-65 (1991); Hugueney et al., FEBS Letters, 273, 235-38 (1990); Joly et

のでは、これのでは、10mm

.....

al., J. Biol. Chem., 268, 26983-89 (1993); Koyama al., J. Biochem., 113, 355-63 (1993); Sheares, et al., Biochem., 28, 8129-35 (1989); Song et al., Proc. Natl. Acad. Sci. USA, 91, 3044-48 (1994); Spear et al., J. Biol. Chem., 267, 14662-69 (1992); Spear et al., J. Biol. Chem., 269, 25212-18 (1994). Anderson et al., J. Biol. Chem., 264, 19176-19184 (1989) reported a 2-3 fold overexpression of FPP synthase with the S. cerevisiae gene in a yeast shuttle vector.

As described in the Examples section, it has been surprisingly found that overexpression of FPP synthase did not lead to an increase in farnesol production, but unexpectedly lead to an increase in the production of GG in the absence of any overexpression of GGPP synthase.

In further embodiments of the invention, in addition 15 to the modifications of FPP synthase described above, the wild type FPP synthase is eliminated from the production This would serve, for example, to eliminate organism. competition between the modified FPP synthase and the wild type enzyme for the substrates, IPP, DMAPP and GPP. 20 Deletion of the wild-type gene encoding FPP synthase could also improve the stability of the cloned FPP synthase gene by removing regions of high genetic sequence homology, thereby avoiding potentially detrimental genetic 25 recombination.

### 2.1.5 Phosphatase Modifications

A further embodiment of the present invention is the use of a microorganism which has been genetically modified to increase phosphatase action to increase conversion of

v\*\*

FPP to farnesol or GGPP to GG. For example, both S. cerevisiae and E. coli contain numerous phosphatase activities. By testing several phosphatases for efficient dephosphorylation of FPP or GGPP, one could select an appropriate phosphatase and express the gene encoding this 5 enzyme in a production organism to enhance farnesol or GG production. In addition to (or instead of) increasing the action of a desired phosphatase to enhance farnesol or GG production, one could eliminate, through genetic means, undesirable phosphatase activities. For example, one could eliminate through mutation the activity of a phosphatase that specifically acts on FPP, so that the FPP that was spared would be available for conversion to GGPP and subsequently GG.

## 2.1.6 <u>Additional Genetic Modifications</u>.

Modifications of Other Isoprenoid Pathway Enzymes. Modifications that can be made to increase the action of HMGCoA reductase, GGPP synthase and phosphatases are described above. Modification of the action of isoprenoid pathway enzymes is not limited to those specific examples, 20 and similar strategies can be applied to modify the action of other isoprenoid pathway enzymes such as acetoacetyl Cothiolase, HMG-COA synthase, mevalonate phosphomevalonate kinase, phosphomevalonate decarboxylase, IPP isomerase, farnesyl pyrophosphate synthase or D-1-25 deoxyxylulose 5-phosphate synthase D-1-deoxyxylulose 5phosphate reductoisomerase.

phosphate reductoisomerase.

Engineering of Central Metabolism to Increase

Precursor Supply to the Isoprenoid Pathway. In organisms

having the mevalonate-dependent isoprenoid pathway, the biosynthesis of farnesol or GG begins with acetyl CoA (refer to Figure 1). One embodiment of the present invention is genetic modification of the production organism such that the intracellular level of acetyl CoA is increased, thereby making more acetyl CoA available for direction to the isoprenoid pathway (and hence to farnesol and/or GG). For example, the supply to acetyl CoA can be increased by increasing the action of the pyruvate 10 dehydrogenase complex. The supply of acetyl CoA can, be further increased by increasing the level of pyruvate in the cell by increasing the action of pyruvate kinase. organisms having the mevalonate-independent isoprenoid pathway, the biosynthesis of isoprenoids begins with pyruvate and glyceraldehyde 3-phosphate. 15 The supply of pyruvate and glyceraldehyde 3-phosphate available for isoprenoid biosynthesis can be increased by increasing the action of pyruvate kinase and triophosphate isomerase, respectively.

The examples above are provided only to illustrate the concept of engineering central metabolism for the purpose of increasing production of isoprenoid compounds, and are not an exhaustive list of approaches that can be taken.

Numerous other strategies could be successfully applied to achieve this goal.

Blocking Pathways that Compete for FPP or GGPP. In yeast, FPP is a branch point intermediate leading to the biosynthesis of sterols, heme, dolichol, ubiquinone, GGPP and farnesylated proteins. In E. coli, FPP serves as the

WO 00/01650 PCT/US99/15264

22

substrate for octaprenyl pyrophosphate synthase in the pathway leading to ubiquinone. In bacteria that synthesize carotenoids, such as Erwina uredovora, FPP is converted to GGPP by GGPP synthase in the first step leading to the carotenoids. To increase the production of farnesol or GG, 5 it is desirable to inactivate genes encoding enzymes that use FPP or GGPP as substrate, or to reduce the activity of the enzymes themselves, either through mutation or the use of specific enzyme inhibitors (as was discussed above for squalene synthase). In S. cerevisiae, for example, it may 10 be advantageous to inactivate the first step in the pathway from FPP to heme, in addition to inactivating ERG9. discussed earlier, in E. coli, partial or complete inactivation of the octaprenyl pyrophosphate synthase could increase the availability of FPP for conversion of 15 farnesol. Finally, in bacteria that produce carotenoids, such as Erwina uredovora, elimination of GGPP synthase can increase the level of FPP for conversion of farnesol, while inactivating or reducing the activity of phytoene synthase (the crtB gene product) can increase the level of GGPP 20 available for conversion to GG.

It is possible that blocking pathways leading away from FPP or GGPP could have negative effects on the growth and physiology of the production organism. It is further contemplated that additional genetic modifications required to offset these complications can be made. The isolation of mutants of *S. cerevisiae* that are blocked in the isoprenoid pathway and take up sterols under aerobic conditions, as described above, illustrates that

25

10

15

20

25

extilibration production to the experience of the end week of the supplication of the order of the order of the

The second of the second secon

compensating mutations can be obtained that overcome the effects of the primary genetic modifications.

<u>Isolation of Production Strains that are Resistant to</u> Farnesol or GG. In the Examples section, production of high levels of farnesol and GG by genetically modified strains of S. cerevisiae is described. It is recognized that as further increases in farnesol or GG production are made, these compounds may reach levels that are toxic to the production organism. Indeed, product toxicity is a common problem encountered in biological production However, just as common are the genetic processes. modifications made by classical methods or recombinant technology that overcome product toxicity. The present invention anticipates encountering product toxicity. Thus a further embodiment of this invention is the isolation of mutants with increased resistance to farnesol and/or GG.

Isolation of Production Organisms with Improved Growth Properties. One effect of blocking the isoprenoid pathway in S. cerevisiae is that the mutant organisms (in the present invention, erg9 mutants) grow more slowly than their parent (unblocked) strains, despite the addition of ergosterol to the culture medium. That the slower growth of the erg9 mutants is due to the block at erg9 is illustrated in Example 1.G, which shows that repairing the erg9 mutation restores the growth rate of the strain to about that of the wild-type parent. The slower growth of the erg9 mutants could be due to differences related to growing on exogenously supplied ergosterol vs. ergosterol synthesized in the cell, or could be due to other

#### SUBSTITUTE SHEET (RULE 26)

. जिल्लासम्बद्धारामा सङ्गाद्धा १८५८ १८ अस्तरे १८०० । ज्ञानामा सङ्गाद्धा । १८०० । अस्तरे १८०० ।

dikan nakatin an anan nakan manan menangan di kabahan menengan di kabahan di kabahan sa da bahara

. . .

physiological factors. One embodiment of the present invention is to isolate variants of the farnesol or GG producing strains with improved growth properties. This could be achieved, for example by continuous culture, selecting for faster growing variants. Such variants could occur spontaneously or could be obtained by classical mutagenesis or molecular genetic approaches.

### 2.2 <u>Incorporation of Prenol and Isoprenol</u>

In a further embodiment of the present invention, farnesol or GG is produced by the introduction of isoprenol 10 and/or prenol into a fermentation medium. With reference to Fig. 9, each of these compounds, when taken up by an organism is phosphorylated with a pyrophosphate group to respectively, 3-isopentenyl pyrophosphate 3,3-dimethylallyl pyrophosphate. 15 These two compounds interconvert by the action of isopentenyl pyrophosphate isomerase. These compounds are then converted to farnesyl pyrophosphate by the action of FPP synthase. Farnesol is formed by dephosphorylation of farnesyl pyrophosphate. Farnesyl pyrophosphate can be further converted to 20 geranylgeranyl pyrophosphate. Geranylgeraniol is formed be dephosyphorylation of geranylgeranyl pyrophosphate. would be formed from FPP by the combined action of GGPP synthase and a phosphatase. Isoprenol and prenol are commercially available compounds and can be produced by 25 methods known in the art

In this embodiment, the microorganism used in the fermentation can be any microorganism as described elsewhere herein. In addition, the microorganism can be

the same of

genetically modified to increase the action dimethylallyl transferase to promote the production of geranyl pyrophosphate and farnesol pyrophosphate. coding for this enzyme from a variety of sources have been identified [Chen et al., Protein Sci., 3, 600-607 (1994)]. In addition a microorganism can be genetically modified to increase the action of isoprenol kinase or prenol kinase. Although these enzymes have not been discovered, similar enzymes that phosphorylate farnesol and geranylgeraniol have been described [Bentinger et al., Arch. Biochem. Biophys., 353, 191-198 (1998); Ohnuma et al., J. Biochem., **119**, 541-547 (1996)].

### 2.3 <u>Fermentation Media and Conditions</u>

5

10

In the method for production of farnesol or GG, a microorganism having a genetically modification, 15 discussed above is cultured in a fermentation medium for production of farnesol or GG. An appropriate, effective, fermentation medium refers to any medium in which a genetically modified microorganism of the present 20 invention, when cultured, is capable of producing farnesol or GG. Such a medium is typically an aqueous medium comprising assimilable carbon, nitrogen and phosphate sources. Such a medium can also include appropriate salts, minerals, metals and other nutrients. In addition, when an 25 organism which is blocked in the ergosterol pathway and requires exogenous sterols, the fermentation medium must contain such exogenous sterols. Appropriate exemplary media are shown in the discussion below and in the Examples section. It should be recognized, however, that a variety

WO 00/01650 PCT/US99/15264

26

of fermentation conditions are suitable and can be selected by those skilled in the art.

Sources of assimilable carbon which can be used in a suitable fermentation medium include, but are not limited to, sugars and their polymers, including, dextrin, sucrose, maltose, lactose, glucose, fructose, mannose, sorbose, arabinose and xylose; fatty acids; organic acids such as acetate; primary alcohols such as ethanol and n-propanol; and polyalcohols such as glycerine. Preferred carbon sources in the present invention include monosaccharides, disaccharides, and trisaccharides. The most preferred carbon source is glucose.

5

10

•: :

The concentration of a carbon source, such as glucose, in the fermentation medium should promote cell growth, but not be so high as to repress growth of the microorganism 15 Typically, fermentations are run with a carbon source, such as glucose, being added at levels to achieve desired level of growth and biomass, but at undetectable levels (with detection limits being about <0.1g/1). In other embodiments, the concentration of a 20 carbon source, such as glucose, in the fermentation medium is greater than about 1 g/L, preferably greater than about 2 g/L, and more preferably greater than about 5 g/L. addition, the concentration of a carbon source, such as glucose, in the fermentation medium is typically less than 25 about 100 g/L, preferably less than about 50 g/L, and more preferably less than about 20 g/L. It should be noted that references to fermentation component concentrations can refer to both initial and/or ongoing

concentrations. In some cases, it may be desirable to allow the fermentation medium to become depleted of a carbon source during fermentation.

Sources of assimilable nitrogen which can be used in a suitable fermentation medium include, but are not limited to, simple nitrogen sources, organic nitrogen sources and complex nitrogen sources. Such nitrogen sources include anhydrous ammonia, ammonium salts and substances of animal, vegetable and/or microbial origin. Suitable nitrogen sources include, but are not limited to, protein hydrolysates, microbial biomass hydrolysates, peptone, yeast extract, ammonium sulfate, urea, and amino acids. Typically, the concentration of the nitrogen sources, the fermentation medium is greater than about 0.1 g/L, preferably greater than about 0.25 g/L, and more preferably greater than about 1.0 g/L. Beyond certain concentrations, however, the addition of a nitrogen source to the fermentation medium is not advantageous for the growth of the microorganisms. As a result, the concentration of the nitrogen sources, in the fermentation medium is less than about 20 g/L, preferably less than about 10 g/L and more preferably less than about 5 g/L. Further, in some instances it may be desirable to allow the fermentation medium to become depleted of the nitrogen sources during fermentation.

THE PROPERTY OF THE PROPERTY O

· ...

: پيد

5

10

15

20

25

Alternation of the measure of the Control of the Co

The effective fermentation medium can contain other compounds such as inorganic salts, vitamins, trace metals or growth promoters. Such other compounds can also be present in carbon, nitrogen or mineral sources in the

1.300

WO 00/01650 . PCT/US99/15264

28

effective medium or can be added specifically to the medium.

The fermentation medium can also contain a suitable phosphate source. Such phosphate sources include both inorganic and organic phosphate sources. 5 Preferred phosphate sources include, but are not limited to, phosphate salts such as mono or dibasic sodium and potassium phosphates, ammonium phosphate and mixtures thereof. Typically, the concentration of phosphate in the fermentation medium is greater than about 1.0 g/L, 10 preferably greater than about 2.0 g/L and more preferably greater than about 5.0 g/L. Beyond certain concentrations, however, the addition of phosphate to the fermentation medium is not advantageous for the growth of the 15 microorganisms. Accordingly, the concentration of phosphate in the fermentation medium is typically less than about 20 g/L, preferably less than about 15 g/L and more preferably less than about 10 g/L.

A suitable fermentation medium can also include a source of magnesium, preferably in the form of a 20 physiologically acceptable salt, such as magnesium sulfate heptahydrate, although other magnesium sources in concentrations which contribute similar amounts magnesium can be used. Typically, the concentration of magnesium in the fermentation medium is greater than about 25 0.5 g/L, preferably greater than about 1.0 g/L, and more preferably greater than about 2.0 g/L. Beyond certain concentrations, however, the addition of magnesium to the fermentation medium is not advantageous for the growth of

THE PARTY OF THE P

....

the strategist of a complete co

the microorganisms. Accordingly, the concentration of magnesium in the fermentation medium is typically less than about 10 g/L, preferably less than about 5 g/L, and more preferably less than about 3 g/L. Further, in some instances it may be desirable to allow the fermentation medium to become depleted of a magnesium source during fermentation.

The fermentation medium can also include biologically acceptable chelating agent, such as the dihydrate of trisodium citrate. In such instance, the concentration of a chelating agent in the fermentation medium is greater than about 0.2 g/L, preferably greater than about  $0.5\ \text{g/L}$ , and more preferably greater than about 1 q/L. Beyond certain concentrations, however, the addition of a chelating agent to the fermentation medium is not advantageous for the growth of the microorganisms. Accordingly, the concentration of a chelating agent in the fermentation medium is typically less than about 10 g/L, preferably less than about 5 g/L, and more preferably less than about 2 g/L.

Commence of the contract of th

Comparison (see a contract)

5

10

15

20

25

The fermentation medium can also initially include a biologically acceptable acid or base to maintain the desired pH of the fermentation medium. Biologically acceptable acids include, but are not limited to, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid and mixtures thereof. Biologically acceptable bases include, but are not limited to, ammonium hydroxide, sodium hydroxide, potassium hydroxide and mixtures thereof. In a

10

15

preferred embodiment of the present invention, the base used is ammonium hydroxide .

The fermentation medium can also include a biologically acceptable calcium source, including, but not limited to, calcium chloride. Typically, the concentration of the calcium source, such as calcium chloride, dihydrate, in the fermentation medium is within the range of from about 5 mg/L to about 2000 mg/L, preferably within the range of from about 20 mg/L to about 1000 mg/L, and more preferably in the range of from about 50 mg/L to about 500 mg/L.

The fermentation medium can also include sodium chloride. Typically, the concentration of sodium chloride in the fermentation medium is within the range of from about 0.1 g/L to about 5 g/L, preferably within the range of from about 1 g/L to about 4 g/L, and more preferably in the range of from about 2 g/L to about 4 g/L.

also include trace metals. Such trace metals can be added to the fermentation medium as a stock solution that, for convenience, can be prepared separately from the rest of the fermentation medium. A suitable trace metals stock solution for use in the fermentation medium is shown below in Table 1. Typically, the amount of such a trace metals solution added to the fermentation medium is greater than about 1 ml/L, preferably greater than about 5 mL/L, and more preferably greater than about 10 mL/L. Beyond certain concentrations, however, the addition of a trace metals to

10

15

the fermentation medium is not advantageous for the growth of the microorganisms. Accordingly, the amount of such a trace metals solution added to the fermentation medium is typically less than about 100 mL/L, preferably less than about 50 mL/L, and more preferably less than about 30 mL/L. It should be noted that, in addition to adding trace metals in a stock solution, the individual components can be added separately, each within ranges corresponding independently to the amounts of the components dictated by the above ranges of the trace metals solution.

As shown below in Table 1, a suitable trace metals solution for use in the present invention can include, but is not limited to ferrous sulfate, heptahydrate; cupric sulfate, pentahydrate; zinc sulfate, heptahydrate; sodium molybdate, dihydrate; cobaltous chloride, hexahydrate; and manganous sulfate, monohydrate. Hydrochloric acid is added to the stock solution to keep the trace metal salts in solution.

20

TABLE 1
TRACE METALS STOCK SOLUTION

COMPOUND	CONCENTRATION (mg/L)
Ferrous sulfate heptahydrate	280
Cupric sulfate, pentahydrate	80
Zinc (II) sulfate, heptahydrate	290
Sodium molybdate, dihydrate	240
Cobaltous chloride, hexahydrate	240
Manganous sulfate, monohydrate	170
Hydrochloric acid	0.1 ml

25

30

The Control of the Co

The fermentation medium can also include vitamins. Such vitamins can be added to the fermentation medium as a stock solution that, for convenience, can be prepared separately from the rest of the fermentation medium. suitable vitamin stock solution for use in the fermentation 5 medium is shown below in Table 2. Typically, the amount of such vitamin solution added to the fermentation medium is greater than 1 ml/L, preferably greater than 5 ml/L and more preferably greater than 10 ml/L. Beyond certain concentrations, however, the addition of vitamins to the fermentation medium is not advantageous for the growth of the microorganisms. Accordingly, the amount of such a vitamin solution added to the fermentation medium is typically less than about 50 ml/L, preferably less than 30  $\,$ ml/L and more preferably less than 20 ml/L. It should be noted that, in addition to adding vitamins in a stock solution, the individual components can be added separately each within the ranges corresponding independently to the amounts of the components dictated by the above ranges of the vitamin stock solution.

As shown in Table 2, a suitable vitamin solution for use in the present invention can include, but is not limited to, biotin, calcium pantothenate, pyridoxine-HCl and thiamine-HCl.

10

. 15

20

10

15

20

the first of the second of the first of the first of the first of the second of the se

: ÷

Table 2

COMPOUND	CONCENTRATION (mg/L)
Biotin	10
Calcium pantothenate	120
Inositol	600
Pyridoxine-HCl	120
Thiamine-HCl	120

As stated above, when an organism is blocked in the sterol pathway, an exogenous sterol must be added to the fermentation medium. Such sterols include, but are not limited to, ergosterol and cholesterol. Such sterols can be added to the fermentation medium as a stock solution is prepared separately from the rest of fermentation medium. Sterol stock solutions can be prepared using a detergent to aid in solubilization of the sterol. A typical ergosterol stock solution is described in Example 1.D. Typically, an amount of sterol stock solution is added to the fermentation medium such that the final concentration of the sterol in the fermentation medium is within the range of from about 1 mg/L to 3000 mg/L, preferably within the range from about 2 mg/L to 2000 mg/L, and more preferably within the range from about 5 mg/L to 2000 mg/L.

Microorganisms of the present invention can be cultured in conventional fermentation modes, which include, but are not limited to, batch, fed-batch, cell recycle, and continuous. It is preferred, however, that the

10

15

20

the second state of the second second

- 5

fermentation be carried out in fed-batch mode. In such a case, during fermentation some of the components of the medium are depleted. It is possible to initiate the fermentation with relatively high concentrations of such components so that growth is supported for a period of time before additions are required. The preferred ranges of these components are maintained throughout the fermentation by making additions as levels are depleted by fermentation. Levels of components in the fermentation medium can be monitored by, for example, sampling the fermentation medium periodically and assaying for concentrations. Alternatively, once a standard fermentation procedure is developed, additions can be made at timed intervals corresponding to known levels at particular throughout the fermentation. As will be recognized by those in the art, the rate of consumption of nutrient increases during fermentation as the cell density of the medium increases. Moreover, to avoid introduction of foreign microorganisms into the fermentation medium, addition is performed using aseptic addition methods, as are known in the art. In addition, a small amount of antifoaming agent may be added during the fermentation.

The temperature of the fermentation medium can be any temperature suitable for growth and production of farnesol or GG. For example, prior to inoculation of the fermentation medium with an inoculum, the fermentation

s Wassersets in a

medium can be brought to and maintained at a temperature in the range of from about 20°C to about 45°C, preferably to a temperature in the range of from about 25°C to about 40°C, and more preferably in the range of from about 28°C to about 32°C.

5

10

15

20

25

The pH of the fermentation medium can be controlled by the addition of acid or base to the fermentation medium. In such cases when ammonia is used to control pH, it also conveniently serves as a nitrogen source in the fermentation medium. Preferably, the pH is maintained from about 3.0 to about 8.0, more preferably from about 3.5 to about 7.0, and most preferably from about 4.0 to about 6.5.

The fermentation medium can also be maintained to have dissolved oxygen content during the fermentation to maintain cell growth and to maintain cell metabolism for production of farnesol or GG. concentration of the fermentation medium can be monitored using known methods, such as through the use of an oxygen electrode. Oxygen can be added to the fermentation medium using methods known in the art, for , through agitation and aeration of the medium by stirring, shaking or sparging. Preferably, the oxygen concentration in the fermentation medium is in the range of from about 20% to about 100% of the saturation value of oxygen in the medium based upon the solubility of oxygen in the fermentation medium at atmospheric pressure and at a temperature in the range of

WO 00/01650 PCT/US99/15264

from about 20°C to about 40°C. Periodic drops in the oxygen concentration below this range may occur during fermentation, however, without adversely affecting the fermentation.

Although aeration of the medium has been described herein in relation to the use of air, other sources of oxygen can be used. Particularly useful is the use of an aerating gas which contains a volume fraction of oxygen greater than the volume fraction of oxygen in ambient air.

In addition, such aerating gases can include other gases which do not negatively affect the fermentation.

In an embodiment of the fermentation process of the present invention, a fermentation medium is prepared as described above and in Example 1.H. This fermentation medium is inoculated with an actively growing culture of 15 microorganisms of the present invention in an amount sufficient to produce, after a reasonable growth period, a high cell density. Typical inoculation cell densities are within the range of from about 0.01 g/L to about 10 g/L, preferably from about 0.2 g/L to about 5 g/L and more 20 preferably from about 0.05 g/L to about 1.0 g/L, based on the dry weight of the cells. In production scale fermentors, however, greater inoculum cell densities are preferred. The cells are then grown to a cell density in the range of from about 10 g/L to about 100 g/L preferably 25 from about 20 g/L to about 80 g/L, and more preferably from

interiorismente de la companie de l La companie de la companie del la companie de la companie de

を関われている。 A Septiment of Control of Contro

.

about 50 g/L to about 70 g/L. The residence times for the microorganisms to reach the desired cell densities during fermentation are typically less than about 200 hours, preferably less than about 120 hours, and more preferably less than about 96 hours.

In one mode of operation of the present invention, the carbon source concentration, such as the concentration, of the fermentation medium is monitored during fermentation. Glucose concentration of the 10 fermentation medium can be monitored using techniques, such as, for example, use of the glucose oxidase enzyme test or high pressure liquid chromatography, which can be used to monitor glucose concentration in the supernatant, e.g., a cell-free component of 15 fermentation medium. As stated previously, the carbon source concentration should be kept below the level at which cell growth inhibition occurs. Although such concentration may vary from organism to organism, for glucose as a carbon source, cell growth inhibition occurs at glucose concentrations greater than at about 60 g/L, and 20 can be determined readily by trial. Accordingly, when glucose is used as a carbon source the glucose is preferably fed to the fermentor and maintained below detection limits. Alternatively, the glucose concentration 25 in the fermentation medium is maintained in the range of from about 1 g/L to about 100 g/L, more preferably in the

tick-oderation-control of the control of the contro

range of from about 2 g/L to about 50 g/L, and yet more preferably in the range of from about 5 g/L to about 20 g/L. Although the carbon source concentration can be maintained within desired levels by addition of, for example, a substantially pure glucose solution, it is acceptable, and may be preferred, to maintain the carbon source concentration of the fermentation medium by addition of aliquots of the original fermentation medium. The use of aliquots of the original fermentation medium may be desirable because the concentrations of other nutrients in the medium (e.g. the nitrogen and phosphate sources) can be maintained simultaneously. Likewise, the trace metals concentrations can be maintained in the fermentation medium by addition of aliquots of the trace metals solution.

# 15 2.4 <u>Farnesol and GG Recovery</u>

Once farnesol or GG are produced by a biological system, they are recovered or isolated for subsequent chemical conversion to  $% \left( 1\right) =\left( 1\right) ^{2}$  to  $\alpha -tocopherol$  or  $\alpha -tocopheryl$ esters. The present inventors have shown that for both farnesol and GG, the product may be present in culture 20 supernatants and/or associated with the yeast cells. With respect to the cells, the recovery of farnesol or GG includes some method of permeabilizing or lysing the cells. The farnesol or GG in the culture can be recovered using a 25 recovery process including, but not limited chromatography, extraction, solvent extraction, membrane

separation, electrodialysis, reverse osmosis, distillation, chemical derivatization and crystallization. When the product is in the phosphate form, i.e., farnesyl phosphate or geranylgeranyl phosphate, it only occurs inside of cells and therefore, requires some method of permeabilizing or lysing the cells.

## 3.0 Chemical Synthesis of GG and Farnesol

## 3.1 Chemical Synthesis of GG

As noted above, in one embodiment of the invention, GG 10 is produced biologically, and in alternate embodiments, GG can be produced by other methods. For example, GG can also be produced from farnesol by chemical synthesis. suitable methods are known in the art. In one such method, farnesol is converted to farnesyl bromide (PBr, in 15 ether) and subjected to displacement with acetoacetate. The resulting crude keto ester saponified, decarboxylated, and the resulting ketone purified by distillation. Following the procedure of Klinge and Demuth (Synlett 1993, 783), the ketone is subjected to Wittig-Horner reaction with disopropyl 20 ethylphosphonoacetate (NaH, glyme) to give an approximately 80/20 mixture of t,t,t- and t,t,c-ethyl geranylgeranoate. Reduction of ethyl geranylgeranoate with dissobutylaluminum hydride provides GG cleanly. The t,t,t- and t,t-c- mixture 25 can be separated at the ester (e.g., by distillation) or alcohol (e.g., by crystallization as described in EP

711749) oxidation level. The production of farnesol as a starting material for the chemical production of GG can be accomplished by biological production, such as by use of a modified microorganism having some of the modified characteristics described above.

# 3.2 Chemical Synthesis of Farnesol

ens en skildskingenes innen men mennie met mit skildsketske stille in de se

extension in the sales white with the control of th

194

. :

5

As noted above, in one embodiment of the invention, farnesol is produced biologically, and in alternate embodiments, farnesol can be produced by other methods.

For example, farnesol can also be produced by chemical synthesis. Many suitable methods are known in the art.

# 4.0 Production of Tocopherol from GG by Chemical Synthesis

In a further embodiment of the present invention, a method for producing vitamin E from geranylgeraniol is provided. Geranylgeraniol contains four olefin moieties. As used in this invention, the olefin moieties of geranylgeraniol are consecutively numbered starting from the hydroxy terminus, i.e., the first olefin moiety refers to C<sub>2</sub>-C<sub>3</sub> double bond, the second olefin moiety refers to C<sub>6</sub>-C<sub>7</sub> double bond, the third olefin moiety refers to C<sub>10</sub>-C<sub>11</sub> double bond and the fourth olefin moiety refers to C<sub>14</sub>-C<sub>15</sub> double bond.

The method of the present invention involves reducing at least one olefin moiety of geranylgeraniol to form an allylic alcohol. Preferably the allylic alcohol is phytol and/or isophytol. The formation of the allylic alcohol can

....

WO 00/01650 PCT/US99/15264

41

be achieved by a selective reduction of olefins which reduces at least one of the second, third or fourth olefin moieties without reducing the first olefin moiety. Preferably the reduction reduces all olefin moieties except the first olefin moiety. The reduction of an olefin moiety can be accomplished by any of the known alkene reduction conditions including diimide reduction; dissolving metal reduction; metal hydride reduction; and hydrogenation in the presence of a metal catalyst such as palladium, rhodium, nickel, platinum, ruthenium, copper, chromium or a combination thereof. Preferably, the second, third and fourth olefin moieties are reduced by hydrogenation.

Control of the Contro

mile mile medicine in the property of the property of the control of the control

10

15

20

25

If an enantiomerically enriched or enantiomerically pure vitamin E synthesis is desired, one can effect the reduction of olefin moiety using an asymmetric catalyst such as those known in the art for asymmetric hydrogenation reactions. Alternatively, a racemic mixture of allylic alcohol can be produced and subjected to a chiral separation to provide a desired stereo isomer of the allylic alcohol.

In one embodiment of the present invention, a protecting group is added to geranylgeraniol prior to reducing the second, third and/or fourth olefin moieties. As used in this invention, a protecting group refers to any compound which can be added to (or combined with) geranylgeraniol prior to reduction of one or more olefin

WO 00/01650 PCT/US99/15264

42

moieties and removed after the reduction to provide an allylic alcohol from geranylgeraniol. Preferably, the protecting group is a hydroxy protecting group. hydroxy protecting group is selected such that reduction of The the second, third and fourth olefin moieties can be 5 achieved selectively without reducing the first olefin moiety. A variety of hydroxy protecting groups known in the art may be employed. Examples of many of these possible groups can be found in "Protective Groups in Organic Synthesis" by T.W. Green, John Wiley and Sons, 10 1981, pp. 10-86, which is incorporated herein by reference in its entirety. Preferably, the hydroxy protecting group is an ester. More preferably, the ester is a sterically hindered (i.e., bulky) ester which provides a sufficient protection of  $C_2\text{--}C_3$  olefin moiety from being reduced under 15 the conditions of reducing geranylgeraniol to a protected allylic alcohol. Exemplary bulky ester groups include isobutyrate and pivaloate.

Vitamin E is formed from the allylic alcohol and a hydroquinone. Preferably, the hydroquinone is a trimethyl hydroquinone, more preferably, the hydroquinone is 2,3,5-trimethyl hydroquinone. It should be appreciated that a formation of compounds related to vitamin E (i.e., α-tocopherol) can be achieved using a corresponding hydroquinone for a particular tocopherol derivative. For example, β-, γ-, and δ-tocopherol can be synthesized from

State of the second of the sec

<del>e gaggera gaggaran da da</del> aki a sa 1978an 1978 M

10

15

THE PARTY OF THE P

the allylic alcohol and 2,5-dimethyl hydroquinone, 2,3dimethyl hydroquinone and 2-methyl hydroquinone, respectively. Without being bound by any theory, it is believed that contacting the allylic alcohol with an acid generates a carbonium ion which reacts with hydroquinone to form vitamin E. A similar carbonium ion can be generated from a halogen derivative of phytol. For example, contacting a halogenated phytane such as bromo-, chloro- or iodophytane with a Lewis acid such as zinc halide including zinc bromide, zinc chloride and zinc iodide; aluminum halide including aluminum bromide and aluminum chloride; boron halide including boron trichloride and boron trifluoride; silver halide including silver chloride, silver bromide and silver iodide; nickel halide such as nickel chloride and nickel bromide; and other metal halide Lewis acids can generate carbonium ions which can react with a hydroquinone to form vitamin E.

Fig. 2 illustrates a particularly preferred embodiment of vitamin E synthesis from geranylgeraniol. The hydroxy 20 group of geranylgeraniol 2-1 is protected as isobutyrate ester or other bulky ester using the corresponding acid or derivative such as its anhydride or acyl chloride. Geranylgeranylisobutyrate 2-2 is then selectively hydrogenated using a metal catalyst such as palladium on 25 carbon to produce phytylisobutyrate 2-3. Hydrogenation of geranylgeranylisobutyrate 2-2 reduces the second, third and WO 00/01650 . PCT/US99/15264

4 4

fourth olefin moieties without affecting the first olefin moiety. It is believed that the steric bulk of isobutyrate decreases the rate of hydrogenation of the first olefin moiety in protected geranylgeraniol, thus leading to a selective hydrogenation of olefin moieties. The hydroxy protecting group is then removed by hydrolysis under a basic condition to provide phytol 2-4. Reacting phytol 2-4 with 2,3,5-trimethyl hydroquinone 2-5 in the presence of an acid then results in a formation of vitamin E 2-6. Alternatively, phytylisobutyrate 2-3 can be deprotected and reacted with 2,3,5-trimethyl hydroquinone 2-5 in a single step by an acid catalyst to form vitamin E 2-6. Vitamin E 2-6 can further be transformed to a protected vitamin  ${\tt E}$ such as vitamin E acetate 2-7 by acetylation of the free hydroxy moiety.

5

10


15

An alternative method of chemical synthesis converting GG into α-tocopherol or α-tocopheryl esters includes the following steps: (a) selectively oxidizing the 2,3-carbon-carbon double bond in geranylgeraniol 7 to produce geranylgeraniol-2,3-epoxide 8; (b) hydrogenating the three remaining carbon-carbon double bonds in the epoxide 8 to produce epoxyphytol 9; (c) deoxygenating the epoxyphytol 9 to produce a mixture of phytol 5 and isophytol 6 by reaction with an oxygen acceptor; and (d) reacting the phytol 5 and isophytol 6 mixture with trimethylhydroguinone 4 to produce alpha-tocopherol 3.

10

15

- The Control of the State of State o



The step of selectively oxidizing the 2,3-carbon-carbon double bond in geranylgeraniol to produce geranylgeraniol-2,3-epoxide is carried out with any reagent known to selectively epoxidize the olefin functionality of allylic alcohols, such as combinations of tert-butyl hydroperoxide and vanadium or molybdenum catalysts as taught by the method of Sharpless and Michaelson, J. Am. Chem. Soc. 95, 6136 (1973).Hydrogen peroxide or other alkyl hydroperoxides could replace tert-butyl hydroperoxide, and inert solvents such as aromatic hydrocarbons, aliphatic hydrocarbons, cycloaliphatic hydrocarbons or aliphatic esters may be used. The term "aliphatic hydrocarbon" is used to include straight or branched chain alkanes having five to eight carbon atoms. Heptane is the most preferred aliphatic hydrocarbon. The term "cycloaliphatic hydrocarbon" is used to include  $C_5\,$  -  $C_8\,$  cycloalkanes and these substituted with one or more  $C_1$  -  $C_4$  alkyl groups.

The term "aromatic hydrocarbon" is used to include benzene and benzene substituted with one to three  $C_1$  -  $C_4$  alkyl groups. Toluene is the most preferred aromatic hydrocarbon. The term "aliphatic esters" is used to include aliphatic esters having three to nine carbon having the formula  $R_1CO_2R_2$  wherein  $R_1$  and  $R_2$  independently represent a straight or branched chain  $C_1$  -  $C_4$  alkyl group, with ethyl acetate being the preferred aliphatic ester.

i e i e la deserva esperiada e i e estre e e en en en en esta por en entre en estada e e estado e en estado estado en estado en entre estado en entre ent

ej.

The step of hydrogenating the three remaining carboncarbon double bonds in the epoxide 8 to produce epoxyphytol 10 9 can be done with any conventional heterogeneous or homogeneous catalyst under an atmosphere of hydrogen. Thus, supported catalysts such as palladium on carbon, platinum on carbon, platinum oxide, Raney nickel, and the like may be used at a level of about 0.001 to 0.2 parts by 15 weight with respect to 8, with or without an inert solvent such as aliphatic esters, alkanols, aromatic hydrocarbons, aliphatic and cycloaliphatic hydrocarbons or ethers, under a pressure of from about 1 to about 200 atmospheres of hydrogen pressure at temperatures from about 0 degrees C to 20 about 150 degrees C. The term "alkanol" is used to represent alcohols of the formulae  $R_{\rm 3}$  - OH and substituted alcohols of the formula  $R_3 O C H_2 C H_2 O H$ , wherein  $R_3$  represents a straight or branched chain  $C_1$  -  $C_4$  alkyl group. The term "ether" is used to represent ethers having the formula  $R_1$  -25 O -  $R_2$ , wherein  $R_1$ , and  $R_2$  are as defined above and

10

15

20

25

v.

The second secon

tetrahydrofuran. The step of deoxygenating the epoxyphytol 9 to produce a mixture of phytol 5 and isophytol 6 by reaction with an oxygen acceptor can be a rhenium-catalyzed oxygen transfer reaction and can be done neat or in the presence of an inert solvent such as hydrocarbons, aromatic aliphatic hydrocarbons, cycloaliphatic hydrocarbons, aliphatic esters, alkanols, ethers or water. The reaction can also be carried out in a 2-phase water-organic solvent system with or without the addition of a phase-transfer catalyst. The catalyst can be a substituted rhenium trioxide or a polymer-supported form of such a rhenium trioxide compound. The catalyst can be used at a level of from about 0.01 - 5.0 weight percent based on 9. The oxygen acceptor must be present at a level of 1.0 - 3.0 moles per mole of 9 and may be chosen from triarylphosphines, tri-C<sub>1</sub>-C<sub>6</sub> alkylphosphines, triaryl phosphites,  $tri-C_1-C_{18}$  alkylphosphites, alkali hypophosphites or hypophosphoric acid. Other compounds capable of irreversibly accepting oxygen from 9 may be used, such as  $di-C_1-C_6$  alkyl sulfides and certain nitrogen bases such as N -  $C_1$  -  $C_6$  alkylmorpholines. The term "aryl" is used to include phenyl and naphthyl and these substituted with one to three  $C_1$  -  $C_6$  alkyl groups. The term "aralkyl" is used to include monovalent radicals having the structure aryl( $CH_2$ )<sub>n</sub> -, wherein n = 1 to 4. The term "substituted rhenium trioxide" is used to include

ndindencember et schwerd von a de bestemmen en state en de bestem en sens en sens en sens en sens en sens en s

compounds of the formula R - ReO<sub>3</sub>, wherein R is a hydrocarbyl group selected from the group consisting of  $C_1$  -  $C_{10}$  alkyl,  $C_6$  -  $C_{10}$  aryl, aralkyl, cyclopentadienyl and cyclopentadienyl substituted with one to five  $C_1$  -  $C_4$  alkyl groups.

It should be noted that the step of deoxygenating the epoxyphytol in the present invention, such as by reaction with triphenylphosphine or other suitable oxygen acceptor under catalysis by a rhenium compound such as methylrhenium trioxide, is a novel and unexpected reaction. The use of 10 methylrhenium trioxide as a catalyst in a variety of organic reactions has been reviewed [Schmidt <u>(J. Prakt.</u> Chem.-Ztg. 339, 493-496 (1997)]. Espenson and Zhu [(J. Molecular Catalysis A:Chemical 103, 87-94 (1995)] gave six examples of the use of MTO to catalyze the transfer of 15 oxygen from epoxides to triphenylphosphine with the formation of olefins. It is to be noted that all of Espenson and Zhu's examples of olefin generation from epoxides involved simple, non-functional hydrocarbons such as cyclohexene, stilbene, cyclododecene, and so forth. 20 These workers did not demonstrate the feasibility of carrying out such a transformation in a molecule containing additional functionality such as a primary hydroxyl group. In fact, Espenson and Zhu subsequently showed Chem. 61, 324-328 (1996) that MTO catalyses dehydration of 25 primary alcohols with the formation of ethers and olefinic

10

15

20

25

COUNTY TO THE SERVICE OF THE SERVICE

は、ことに、一名は大きのでは、これでは、これでは、一名は、これの情報をは、本本などに

hydrocarbons. Therefore it is unexpected and surprising to discover that MTO/triphenylphosphine, when applied to epoxyphytol, give a good yield of allylic alcohol products such as isophytol and phytol.

The step of reacting the phytol 5 and isophytol 6 mixture with trimethylhydroquinone 4 to produce alphatocopherol 3 is conducted in the presence of an acid catalyst, often a Lewis acid such as zinc chloride, as is conventionally done in known processes. It has been determined that a mixture of phytol 5 and isophytol 6 can be used to prepare alpha-tocopherol in the same yield as either precursor alone.

Specific exemplary compounds of generic terms used herein which are suitable for use in the present invention are as follows. Typical aromatic solvents include benzene, toluene, and o, m or p-xylene or mixtures thereof. Toluene is the preferred aromatic solvent. Typical aliphatic solvents include n-pentane, n-hexane, n-heptane and noctane and isomers thereof, n-Heptane is the preferred aliphatic hydrocarbon. Typical cycloaliphatic hydrocarbons include cyclopentane, cyclohexane, methylcyclohexane and cycloheptane. Typical aliphatic esters include methyl acetate, ethyl acetate, n-propyl acetate, n-butyl acetate, isopropyl acetate, methyl propionate, ethyl propionate, methyl butyrate and ethyl butyrate. Ethyl acetate is the preferred aliphatic ester. Typical alkanols and

2.50

substituted alkanols include methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, 2-methoxyethanol, 2ethoxyethanol and 2-isopropoxyethanol. Typical ethers include diethyl ether, diisopropyl ether, dibutyl ether, nbutyl methyl ether, t-butyl methyl ether and tetrahydrofuran. Typical useful Lewis acids include zinc chloride, aluminum chloride, boron trifluoride, ferric chloride and phosphoric acid. Zinc chloride is the preferred Lewis acid.

# 10 5.0 <u>Farnesol to Vitamin E</u>

5

A.:

Monte interestivation of the second of the s

3

In yet another embodiment of the present invention, a method for producing vitamin E from farnesol is provided. This method generally involves converting farnesol to a first intermediate compound which comprises a sufficient number of carbon atoms to form at least a trimethyltridecyl 15 substituent group of vitamin E when the intermediate is subsequently reacted with an appropriate hydroquinone to form vitamin E. The method further includes reacting the intermediate compound with a hydroquinone to form vitamin 20 Preferably, the intermediate compound contains a E. sufficient number of carbon atoms to form both the methyl and trimethyltridecyl substituents in the 2-position of the chromane ring moiety of vitamin E. More preferably the intermediate compound is selected from the group consisting of phytol and isophytol. 25

10

15

The state of the s

The intermediate compound can be prepared by oxidizing farnesol to farnesal. Examples of oxidation of an alcohol to an aldehyde can be found in "Advanced Organic Chemistry Part B: Reactions and Synthesis" 2nd Ed., Carey and Sundberg, Plenum Press, 1983, pp. 481-490, which is incorporated herein by reference in its entirety. example, farnesol can be oxidized to farnesal using manganese dioxide; chromium oxides such as chromium trioxide and dichromates; silver oxide; Swern oxidation conditions; and Oppenauer oxidation conditions. addition, farnesol can be oxidized via a catalytic air oxidation using a catalyst as disclosed by Marko et al., Science, 1996, 274, 2044. Generally, this air oxidation of farnesol to farnesal involves using a catalytic amounts of cuprous chloride, 1,10-phenanthroline, butylhydrazodicarboxylate, and excess potassium carbonate in a relatively non-polar solvent such as toluene or benzene at about 80 °C.

The method of producing vitamin E from farnesol can

further include forming a methyl ketone from farnesal. The

methyl ketone can be formed by a variety of methods

including aldol condensation with an appropriate ketone

such as acetone or its equivalents. For example, aldol

condensation of farnesal with acetoacetate followed by a

decarboxylation reaction provides the same methyl ketone

product as an aldol condensation of farnesal with acetone.

Ξ.

- :

5

25

The methyl ketone can also be formed using an appropriate Wittig or Horner-Emmons-Wadsworth reagents. Use of these reagents are disclosed, for example, in "Advanced Organic Chemistry", 3rd Ed., J. March, John Wiley & Sons, 1985, pp. 845-854, which is incorporated by reference herein in its entirety.

The method of producing vitamin E from farnesol can further include reducing olefin moieties in the methyl ketone to form an alkyl methyl ketone. A reduction of olefin moieties is discussed above in the section regarding 10 production of vitamin E from GG and is incorporated herein by reference. Preferably, the alkyl methyl ketone is 6,10,14-trimethyl pentadecan-2-one. The alkyl methyl ketone is then converted to an allylic alcohol. allylic alcohol can be produced by adding an acetylide such 15 as lithium acetylide, sodium acetylide and magnesium halide acetylide and partially reducing the resulting acetylene group to a vinyl group. Alternatively, the allylic alcohol can be formed directly by other methods well known in the art, such as by reacting the alkyl methyl ketone with a 20 vinyl anion such as vinyl magnesium halide, vinyl lithium or vinyl sodium.

Formation of vitamin from an allylic alcohol is discussed above with regard to production of vitamin from geranylgeraniol.

The second of the second secon

20

25

A particularly preferred embodiment of synthesizing vitamin E from farnesol is illustrated in Fig. 3. Farnesol 3-8 is oxidized to farnesal 3-9 under Oppenauer oxidation conditionS using aluminum isopropoxide and Farnesal 3-9 is then converted to dehydrofarnesyl acetone 3-10 by an aldol condensation reaction with acetone. Reduction of olefin moieties on dehydrofarnesyl acetone 3hydrogenation then produces 6,10,14-trimethyl **10** by pentadecan-2-one 3-11. Addition of acetylide to the ketone 3-11 then generates propargylic alcohol 3-12 which is partially reduced using Lindlar hydrogenation condition to produce isophytol 3-13. Reaction of isophytol 3-13 with 2,3,5-trimethyl hydroquinone 3-5 in the presence of an acid catalyst then produces vitamin E.

## 15 6.0 Biological production of phytol from GGPP or GG.

The present invention provides methods for the chemical conversion of GG to phytol or a mixture of phytol and isophytol. Phytol or a phytol plus isophytol mixture can then be reacted with a hydroquinone in the presence of an acid to form vitamin E, as described elsewhere herein.

Recently, the gene encoding the enzyme geranylgeranyl reductase was cloned from Arabidopsis thaliana ecotype Columbia [Keller et al., Eur. J. Biochem. 251:413-417 (1998)]. This enzyme catalyzes the stepwise reduction of geranylgeranyl-chlorophyll to phytyl-chlorophyll as well as the reduction of GGPP to phytyl diphosphate. With regard

WO 00/01650 PCT/US99/15264

54

to the present invention, a geranylgeranyl reductase is used in a biological system to substitute for the chemical conversion of GG to phytol. For example, geranylgeranyl reductase is expressed in an erg9 mutant strain of S. cerevisiae that also expresses a GGPP synthase activity. The reductase reacts with GGPP formed in vivo to produce phytyl diphosphate. A phosphatase then converts the phytyl diphosphate to phytol, as occurs in the farnesol— and GG-producing strains described in earlier sections. The resulting microorganism produces phytol directly from a growth substrate such as glucose in a single fermentation.

5

10

15

20

25

The state of the s

erinking er den bestigt at totalar et erdelasten er en erdelasten bestigdiggen bestigten bestigt

Alternatively, for a geranylgeranyl reductase able to use GG as a substrate, a biological process is provided where GG is produced by fermentation (as described in earlier sections) and purified to the extent necessary to use it as a feedstock for a biotransformation process. The biotransformation uses geranylgeranyl reductase to convert GG to phytol in one step. This biotransformation uses either isolated geranylgeranyl reductase or whole cells containing geranylgeranyl reductase activity. The enzyme or cells are immobilized on a support or by cross-linking to enhance the biotransformation. It is anticipated that geranylgeranyl reductase would be modified by genetic manipulations to enhance its activity for the production of phytol in an industrial biological process.

the formal section of the confidence of the conf

. ...

10

15

The phytol formed in a biological process using geranylgeranyl reductase is recovered and purified to the extent necessary to allow reaction with a hydroquinone in the presence of an acid to afford vitamin E.

# 5 7.0 Chemical Production of Vitamin A from Farnesol

As noted above, the present method includes preparing an  $\alpha$ ,  $\beta$ -unsaturated polyene carbonyl compound from farnesol. As used in this invention, an  $\alpha$ ,  $\beta$ -unsaturated polyene carbonyl compound refers to a compound having two or more olefin moieties, where at least one of the olefin moieties is conjugated to the carbonyl group. A carbonyl group refers to a presence of carbon-oxygen double bond moiety. Exemplary carbonyl groups include aldehydes, ketones, esters, acids, anhydrides and acyl halides. Preferably the  $\alpha$ ,  $\beta$ -unsaturated polyene carbonyl compound is of the formula:

wherein Z is O or  $CHCO_2R$ , and R is hydrogen or  $C_1-C_{10}$  20 hydrocarbyl.

Hydrocarbyl groups according to the present invention include aliphatic, cyclic or aromatic hydrocarbons having 1 to about 10 carbon atoms. Hydrocarbyl groups can be

straight or branched. Furthermore, hydrocarbyl groups optionally can be substituted with one or more substituents, such as halo, aryl, hydroxy, alkoxy, carboxy, oxo and cycloalkyl. There may be optionally inserted along the hydrocarbyl group one or more oxygen, sulfur or 5 substituted or unsubstituted nitrogen atoms. Exemplary hydrocarbyl groups include methyl, ethyl, i-propyl, n-1butyl, t-butyl, n-pentyl, i-pentyl, heptyl and octyl.

The  $\alpha,\beta$ -unsaturated polyene carbonyl compound can be prepared from farnesol in a variety of ways. 10 particularly preferred embodiment of the present invention, farnesol is oxidized to farnesal which is then subsequently converted to the  $\alpha,\beta\mbox{-unsaturated polyene carbonyl compound.}$ Examples of oxidation of an alcohol (e.g., farnesol) to an aldehyde (e.g., farnesal) can be found in "Advanced Organic 15 Chemistry Part B: Reactions and Synthesis" 2nd Ed., Carey and Sundberg, Plenum Press, 1983, pp. 481-490, which is incorporated herein by reference in its entirety. farnesol can be oxidized to farnesal using example, manganese dioxide; chromium oxides such as chromium 20 trioxide and dichromates; silver oxide; Swern oxidation conditions; and Oppenauer oxidation conditions. addition, farnesol can be oxidized via a catalytic air oxidation using a catalyst as disclosed by Marko et al., Science, 1996, 274, 2044. Generally, this air oxidation of 25 farnesol to farnesal involves using a catalytic amounts of

and the state of t

15

20

THE PROPERTY OF THE PROPERTY O

cuprous chloride, 1,10-phenanthroline, di-t-butylhydrazodicarboxylate, and excess potassium carbonate in a relatively non-polar solvent such as toluene or benzene at about 80 °C.

The method for producing vitamin A from farnesol can further include cyclizing the  $\alpha,\beta$ -unsaturated polyene carbonyl compound o form a cyclic  $\alpha,\beta$ -unsaturated polyene carbonyl compound. Preferably the cyclic  $\alpha,\beta$ -unsaturated polyene carbonyl compound is of the formula:

where Z is O or CHCO<sub>2</sub>R, and R is  $C_1-C_{10}$  hydrocarbyl. When Z is O, the method can include transforming O to CHCO<sub>2</sub>R or CHCN. This transformation can be achieved by an aldol condensation using an appropriate reagent. For example, aldol condensation of the cyclic  $\alpha$ ,  $\beta$ -unsaturated polyene carbonyl compound with NCCH<sub>2</sub>CO<sub>2</sub>R, where R is hydrogen or  $C_1$ - $C_{10}$  hydrocarbyl, followed by removal of CO<sub>2</sub>R moiety, e.g., by decarboxylation, provides a compound in which carbonyl oxygen has been replaced by CHCN moiety. Alternatively, using R'O<sub>2</sub>CCH<sub>2</sub>CO<sub>2</sub>R, where R and R' are independently hydrogen or  $C_1$ - $C_{10}$  hydrocarbyl, in place of NCCH<sub>2</sub>CO<sub>2</sub>R provides a

compound in which carbonyl oxygen has been replaced by  $\mathrm{CO}_2\mathrm{R}$  moiety.

The method for producing vitamin A from farnesol can further include a step of reducing the ester group ( $CHCO_2R$ ) or the nitrile group (CHCN) to an alcohol.

Fig. illustrates a particularly preferred embodiment of vitamin A synthesis from farnesol 1. aldol condensation between acetone and farnesal 2, which is derived from oxidation of farnesol 1, results in a formation of dehydrofarnesyl acetone 3. A variety of 10 methods are available to synthesize dehydrofarnesyl acetone 3 from farnesal 2. In one aspect of the present invention, a mixture comprising farnesal 2 and acetone in the presence of a base is subjected to a reaction condition sufficient to produce the dehydrofarnesyl acetone 3. 15 The initial product of the aldol condensation reaction is  $\beta$ -hydroxy ketone, which typically undergoes elimination under the reaction condition to produce dehydrofarnesyl acetone 3. In some cases, however, some or all the  $\beta$ -hydroxy ketone intermediate can be obtained as the product. Where this is 20 the case, simply subjecting the  $\beta$ -hydroxy ketone to an acidic or basic condition can result in elimination of the hydroxy group to produce the desired dehydrofarnesyl acetone 3.

The dehydrofarnesyl acetone 3 can also be obtained from farnesal 2 by subjecting a mixture of farnesal 2 and

15

20

25

a compound of the formula  $R_1CH_2C\,(=\!0\,)\,CH_2R_2$  to a reaction condition sufficient to produce dehydrofarnesyl acetone 3, wherein  $R_1$  is a moiety of the formula  $-CO_2R_3$ ,  $R_2$  is hydrogen or a moiety of the formula  $-CO_2R_3$ , and  $R_3$  is a hydrocarbyl having from 1 to about 10 carbon atoms. In order to obtain dehydrofarnesyl acetone 3 from a reaction between farnesal 2 and a moiety of the formula  $R_1CH_2C$  (=0)  $CH_2R_2$ , it may be necessary to subject the resulting product decarboxylation condition to remove the  $R_1$  and/or  $R_2$ carboxylate group(s). Typically, this decarboxylation requires conversion of the ester group to carboxylic acid or a salt thereof, which can be achieved by saponification of the ester by either an acidic or a basic condition.

Referring again to Fig. 10, a mixture comprising dehydrofarnesyl acetone 3 and a compound of the formula  $XCH_2CO_2R$  (wherein R is hydrogen or  $C_1$ - $C_{10}$  hydrocarbyl and X is a halide) is subjected to a basic condition sufficient to produce  $C_{20}$ -glycidic ester 4. Preferably R is selected from the group consisting of methyl, ethyl, and t-butyl. Preferably X is selected from the group consisting of chlorine, bromide and iodide. The  $C_{20}$ -glycidic ester 4 is then subjected to a condition sufficient for rearrangement and dehydration to produce pseudoretinoic acid ester 5. Generally, the rearrangement is affected by contacting the  $C_{20}$ -glycidic ester 4 with an acid to form a  $C_{20}$ -hydroxy compound (not shown). The  $C_{20}$ -hydroxy compound is then

dehydrated under the reaction condition or is subjected to a separate dehydration condition to produce the desired pseudoretinoic acid ester 5. The dehydration of  $C_{20}$ -hydroxy compound can be achieved under either an acidic or a basic 5 condition. Subjecting the pseudoretinoic acid ester  ${\bf 5}$  to a condition sufficient for cyclization produces retinoic acid ester 6. A typical cyclization condition involves contacting the pseudoretinoic acid ester 5 with an acid. The acid should be strong enough to protonate an olefin 10 moiety, generating a carbonium ion, thus carbocation, which can undergo a cyclization. Also a relatively weak nucleophile, such as a halide and/or a carboxylic acid, can be added to trap the resulting cyclized carbocation. When a weak nucleophile is present, the resulting cyclized product may contain a nucleophile 15 which may undergo elimination under the reaction condition or it can be removed by elimination in a separate reaction. Preferably the acid is selected from the group consisting of hydrochloric acid; phosphoric acid; fluorosulfonic acid; sulfuric acid; and carboxylic acids such as formic acid, and acetic acid; and a mixture thereof. conditions for cyclization of a 1,5-diene, such as farnesyl acetate, using an acid are disclosed in Muntyan et al., Izev. Akad. Nauk SSSR, Ser. Khim., 1973, 633, and Stork and Burgstahler, J. Amer. Chem. Soc., 1955, 77, 5068, which are incorporated herein by reference in their entirety.

WO 00/01650 PCT/US99/15264

Alternatively, the pseudoretinoic acid ester 5 can be cyclized using an enzyme. For example, it is well known that lycopene cyclase cyclizes appropriate  $C_{40}$  chains to produce carotenoids. Similarly, a cyclase enzyme can be used to cyclize pseudoretinoic acid ester or its derivative to produce retinoic acid ester or its derivative.

Again referring to Fig. 10, in one particular embodiment, retinoic acid ester 6 is reduced to vitamin A (retinol). This reduction can be achieved by any of the known ester reduction reactions such as a hydride reduction using a compound including, but not limited to, LiAlH4, sodium bis(2-methoxyethoxy)aluminum hydride, and diisobutylaluminum hydride. Alternatively, retinoic acid ester 6 can be saponified or hydrolyzed under acidic or basic conditions to produce retinoic acid, which can then be reduced using a compound including, but not limited to, borane  $(B_2H_6)$  to selectively reduce the carboxylic acid group in the presence of olefins to produce vitamin A (retinol) 8.

As shown in Fig. 10, in another aspect of the present invention, the retinoic acid ester 6 is first reduced to retinal 7 by contacting the retinoic acid ester 6 with a first reducing agent. The retinal 7 is then contacted with a second reducing agent to produce vitamin A (8). The first reducing agent reduces an ester to an aldehyde. There are variety of methods and reducing agents currently

THE PARTY OF THE P

10

15

WO 00/01650 PCT/US99/15264

62

available for reducing an ester to an aldehyde. Such reducing agents include, but are not limited to, diisobutylaluminum hydride. The second reducing agent typically reduces an aldehyde to an alcohol, but some of these reducing agents can also reduce an ester directly to an alcohol. Exemplary second reducing agents include, but are not limited to, LiAlH4, diisobutylaluminum hydride, sodium bis(2-methoxyethoxy)aluminum hydride, and sodium borohydride.

5

TO THE PERSON OF THE PERSON OF

10 An acetate 9 or other vitamin A ester derivative can be obtained by contacting vitamin A with an acetylation agent or other acyl transfer agents at a condition sufficient to produce vitamin A acetate or other vitamin A ester derivatives, respectively. Exemplary acetylating agent and acyl transfer agent include, but are not limited 15 to, anhydrides or acyl chlorides of acetic acid, propanoic acid, formic acid, butanoic acid and mixed anhydrides. Typically, a catalyst or a base is also used in acyl transfer reactions. Exemplary bases useful in acyl transfer include, but are not limited to, hydroxides; 20 carbonates and bicarbonates of sodium, lithium and potassium; and amines such as pyridine and triethyl amine. An acyl transfer catalyst can also be used to facilitate the reaction and/or to shorten the reaction time. 25 Exemplary acyl transfer catalysts include, but are not

limited to, dimethylaminopyridine (DMAP).

15

20

also to a distribution of the

Another particularly preferred embodiment of producing vitamin from farnesal is shown in Fig. Dehydrofarnesyl acetone 3 (production described above) is subjected to a dehydrogenating condition sufficient to produce a bis(dehydro)-C<sub>18</sub>-ketone 10. Dehydrogenation of dehydrofarnesyl acetone 3 can be achieved by contacting dehydrofarnesyl acetone 3 with a dehydrogenating agent. Exemplary dehydrogenating agents include, but are not limited to, quinones such as 2,3-dichloro-5,6-dicyano-1,4benzoquinone (DDQ); metal catalysts such as palladium, platinum and nickel; and other suitable dehydrogenating agents.

The bis(dehydro)- $C_{18}$ -ketone 10 is then subjected to a condition sufficient to undergo a cyclization to form a cyclic  $C_{18}$ -ketone 11. Typical cyclization condition involves contacting the bis(dehydro)- $C_{18}$ -ketone 10 with an acid. A typical reaction condition for cyclization of a 1,5-diene, such as farnesyl acetate, is discussed above, and can be used for this cyclization. The cyclization can also be affected by a metal catalyst which are known to one skilled in the art, including nickel and rhodium. The bis(dehydro)- $C_{18}$ -ketone 10 can also be cyclized using an enzyme. Such useful enzymes are discussed above.

Referring again to Fig. 11, a mixture comprising the cyclic  $C_{18}$ -ketone 11 and a compound of the formula  $NCCH_2CO_2R$  is subjected to a reaction condition sufficient to form a

Barrier Brown and Carlo Brown and Carlo Brown

 $C_{20}\text{-nitrile 12, wherein R is hydrogen or }C_1\text{-}C_{10}$  hydrocarbyl. When R is hydrogen,  $\alpha\text{-nitrile}$  acetic acid is contacted with a base to deprotonate the carboxylic proton as well as the  $\alpha\text{-proton}$  of the carbonyl group. These two protons can be removed using two different bases, one for the carboxylic 5 proton and another for the  $\alpha\mbox{-proton,}$  or both protons can be removed using a base that is strong enough to deprotonate both protons. If R is  $C_1 - C_{10}$  hydrocarbyl, then a base which is strong enough to deprotonate  $\alpha$ -nitrile acetate is used. Since  $NCCH_2CO_2R$  contains two electron withdrawing groups, a 10 relatively weak base, such as a hydroxide or an amine, can be used to deprotonate an  $\alpha\text{-proton}$ . Deprotonated  $\alpha\text{-nitrile}$ acetate then undergoes a condensation reaction with the cyclic  $C_{18}$ -ketone 11, followed by dehydration decarboxylation processes to produce a  $\ensuremath{\text{C}_{20}}\text{-nitrile}$  compound 15 The dehydration can occur under the condensation 12. reaction condition or it can be affected in a separate reaction condition. If R is  $C_1-C_{10}$  hydrocarbyl, it is necessary to saponify, i.e., hydrolyze, the alkyl group to form a carboxylic acid or a carboxylate anion before 20 subjecting the condensed product to a decarboxylation condition. The decarboxylation condition of the condensed product generally requires subjecting the condensed product to an elevated temperature.

The  $C_{20}$ -nitrile 12 is then contacted with a first reducing agent at a condition sufficient to produce retinal

7, or it can be reduced with a sufficiently strong reducing agent to produce vitamin A (8). Retinal 7 can be reduced using a second reducing agent to provide vitamin A. Suitable reducing conditions and agents for these reductions are those described above. Vitamin A can further be converted to a vitamin A ester derivative by reacting vitamin A with an appropriate esterifying agent, as discussed above.

t 1920 til hall men er fra ett ett til state en en en ett til til state frætt folktigt for en med mør en en et

THE CONTRACTOR OF THE PROPERTY OF THE PROPERTY

In another embodiment of the present invention, retinal 7 that is produced by any of the above described 10 process is subjected to a condition sufficient to produce  $\beta$ -carotene 13. For example, as shown in Fig. 12, two molecules of retinal 7 undergo a coupling reaction when subjected to what is commonly known in the art as a McMurry coupling reaction condition. The McMurry coupling reaction 15 is well known in the art of organic chemistry and is described by John McMurry in U.S. Patent No. 4,225,734, which is incorporated herein by reference in its entirety. Briefly, the McMurry coupling reaction involves a 20 production of olefins from a reductive coupling of carbonyl groups such as ketones and aldehydes with reactive Ti(II) and/or Ti(0) species. Generally, the reactive species are generated in situ by reduction of Ti(III) or Ti(IV) with the reducing agent selected from the group consisting of 25 LiAlH<sub>4</sub>, Na, K, Zn, Mg, NaBH<sub>4</sub>, CaH<sub>2</sub> and LiBH<sub>4</sub>. Ti(III) and

Ti(IV) species are typically titanium halides such as TiCl3 and TiCl, respectively.

In another embodiment of the present invention,  $\beta$ carotene 13 is produced from vitamin A which is produced by any of the above described methods. As shown in Fig. 13, 5 the method generally involves reacting a retinyl halide 15 with retinylphenyl sulfone 14. A retinyl halide 15 can be produced by contacting vitamin A that is produced by the process described above with a reaction mixture selected from the group comprising HX,  $P(X)_3$ , and a mixture of  $P(R_4)_3$ 10 and  $X_2$  at a condition sufficient to produce the retinyl halide, wherein X is a halide,  $X_2$  is a halogen and  $R_4$  is  $C_1 C_{10}$  hydrocarbyl. The retinyl halide  ${\bf 15}$  is then contacted with an anion of retinylphenylsulfone 14 at a condition 15 sufficient to produce  $C_{40}$ -sulfone 16. In cases where retinylphenylsulfone 14 is deprotonated with the base prior to being contacted with the retinyl halide 15, the base is enough to deprotonate substantially all strong retinylphenylsulfone 14. Exemplary bases for deprotonating substantially all of retinylphenylsulfone 14 prior to contacting it with the retinyl halide 15 include, but are not limited to, lithium diisopropylamide (LDA), sodium hexamethyldisilazide (NaHMDS), methyl lithium, butyl lithium, t-butyl lithium, sec-butyl lithium, potassium hydride, sodium hydride, and t-butoxide. Alternatively, the retinyl halide 15, retinylphenylsulfone 14 and the base

\*

nthathatannanasasasas na milikansasas sa misa amangan peringgan milikananananan

20

25

are all combined in a reaction apparatus and the base is allowed to deprotonate some retinylphenylsulfone molecules which can react with the retinyl halide 15 to form the  $C_{40}$ -sulfone 16, *i.e.*, the reactive anionic species of retinylphenylsulfone 14 is generated in situ.

Again referring to Fig. 13, retinylphenylsulfone 14 can be produced by reacting a retinyl ester such as retinyl acetate 9 or a retinyl halide 15 with a reaction mixture comprising phenylsulfinic acid at a condition sufficient to produce retinylphenylsulfone 14. A base can be used to deprotonate phenylsulfinic acid which then undergoes a nucleophilic substitution reaction with retinyl acetate or the retinyl halide 15 to produce retinylphenylsulfone 14. Phenylsulfinic acid can be deprotonated substantially completely prior to contacting with retinyl acetate or the retinyl halide 15 by using a base such as LDA, methyl lithium, NaHMDS, t-butyl lithium, sec-butyl lithium, NaH, KH, or t-butoxide. Alternatively, deprotonated phenylsulfinic acid can be generated in situ by using a base, such as the hydroxides, bicarbonates and carbonates of lithium, sodium and calcium, amines such triethylamine, and diisopropyl ethylamine, and alkoxides such as methoxide, ethoxide, and t-butoxide.

5

10

15

20

3,53

The  $C_{40}$ -sulfone 16 which is produced by a reaction 25 between retinyl halide 15 and retinylphenylsulfone 14 is then subjected to a condition sufficient to eliminate

phenylsulfinic acid to produce  $\beta$ -carotene 13. The elimination of phenylsulfinic acid from the  $C_{40}$ -sulfone 16 can be achieved by contacting the  $C_{40}$ -sulfone 16 with a base. Exemplary bases useful for elimination reaction include, but are not limited to, LDA, methyl lithium, diisopropyl ethylamine, hydroxides, and alkoxides such as methoxide, ethoxide and t-butoxide.

The following Examples are provided to illustrate embodiments of the present invention and are not intended to limit the scope of the invention as set forth in the claims.

#### **EXAMPLES**

## Example 1

20

が、 これのできない。 これのでは、これのできない。 これのできない。 これのできないのできない。 これのできない。 これのできない。 これのできない。 これのできない。 これのできない。 これのできない。 これのできない。 これのできない。 これのでき

This example describes the creation of erg9 mutants by chemical mutagenesis of *S. cerevisiae* strain ATCC 28383 using nitrous acid.

As noted above, one way of increasing yields of farnesol or GG is to decrease or eliminate squalene synthase activity. In S. cerevisiae, squalene synthase is encoded by the ERG9 gene.

## A. <u>Mutagenesis</u>

Strain 28383 was obtained from the ATCC. It is the parent of strain 60431 used below in some experiments for comparative purposes (also obtained from ATCC). Strain 60431 is an erg9-1 mutant that produces farnesol.

A kill curve was performed using nitrous acid with ATCC 28383. Using information derived from the kill curve, a mutagenesis of ATCC 28383 with nitrous acid was performed as follows. The 28383 cells were incubated overnight at 30°C in YPD medium (1% Bacto-yeast extract, 2% Bacto-peptone, and 2% glucose) with shaking. The cells were washed and mutagenized. After mutagenesis, the cells were allowed to recover by culturing them in YPDC (YPD plus 4 mg/L cholesterol) at 22°C overnight. The culture was then washed and plated onto YPDC agar (YPDC plus 2% Bacto-agar) containing various levels of nystatin (20, 30, 40, 50 mg/L). These cultures were incubated for two weeks at 22°C.

and a first on the first of the

\*:×

15

20

25

The antifungal polyene antibiotic nystatin inhibits cell wall synthesis in growing cells by binding specifically to ergosterol, which, in turn, results in an alteration of selective permeability. Some strains that are resistant to nystatin have been shown to have decreased production of ergosterol. Nystatin has little, if any, affinity for cholesterol which, when supplied exogenously, can be used by sterol auxotrophs as efficiently as ergosterol.

Approximately 3,000 nystatin-resistant colonies were obtained. They were screened for temperature sensitivity (ts) and sterol auxotrophy. To determine temperature sensitivity, mutagenized cells were grown on YPDC at a permissive temperature (22°C) and subsequently replica

WO 00/01650 PCT/US99/15264

70

plated to YPD agar and incubated at a restrictive temperature (37°C). Any cells which fail to grow at the higher temperature would include those with both a conditionally lethal and a constitutively lethal defect in the sterol pathway. Temperature sensitive mutants were screened for sterol auxotrophy by replica plating to YPD agar (lacking cholesterol) and incubation overnight at 28°C. Of the 3,000 nystatin-resistant colonies, 170 were saved after confirmation of ts and sterol auxotrophy.

10

25

 $\mathcal{O}(i)$ 

5

## B. <u>Tube Assays</u>

The 170 strains were initially evaluated in tube assays the production of farnesol for and other intermediates of the isoprenoid pathway as follows. Cells were cultured in 10 ml YPDC in tubes with screw caps for 4815 hours at 28°C with shaking. The cells were centrifuged for 5-10 minutes at 2800 rpm, and the supernatant was transferred to another tube. The cells were washed once with 5 ml distilled water and centrifuged again for 5-10 20 minutes at 2800 rpm.

The cell pellet was extracted by adding 2.5 ml 0.2% pyrogallol (in methanol) and 1.25 ml 60% KOH (in distilled  $H_2O$ ), vortexing to mix, and incubating in a 70-75°C water bath for 1.5 hours. After this saponification, 5 ml hexane were added, and the tube was recapped and vortexed for 15-30 seconds. The tube was centrifuged at 2800 rpm for 5

and the second s

minutes to separate the phases. The hexane layer was recovered. If necessary, the sample can be concentrated by evaporating solvent under nitrogen and adding back an appropriate amount of hexane for analysis.

To extract the supernatant, 5 ml of hexane were added to the supernatant, and the tube was recapped and vortexed for 15-30 seconds. The tube was centrifuged at 2800 rpm for 25 minutes to separate phases. The hexane layer was recovered, and the sample was concentrated by evaporating under nitrogen and adding back an appropriate amount of hexane for analysis.

The hexane extracts from this primary screen were analyzed by thin layer chromatography (TLC) confirmation by gas chromatography (GC)/mass spectrometry (MS) for the presence of farnesol and other intermediates of the isoprenoid pathway. TLC was performed on reversedphase C18 silica gel plates using 6:4 (v/v) ethylacetate/acetonitrile (EtOAc/MeCN) as the mobile phase and 2% (w/v) phosphomolybdic acid (PMA) in ethanol for detection. GC/MS was performed using a Hewlett Packard 5890 GC and a 5970 series mass selective detector. The column used was a Restek Rtx-5MS (15 m length, 0.25 mm ID,  $1\mu m$  film Thirteen mutants were identified as system. producers of farnesol or other intermediates.

5

10

15

20

Company of the contract of the

Selection of the select

ndarina manaraman dalah darina mengarangan darina. Pendidikkan darina dan dentah darina dan darina darina

25

# C. <u>Shake Flask Assays</u>

These thirteen mutants were then screened in shake flasks, along with the parental strain, 28383, and the farnesol producing strain, 64031. Fifty ml of YPDC medium in 250 ml baffled Erlenmeyer flasks were inoculated with overnight cultures to an initial OD at 600 nm of 0.05 and incubated with shaking at 28°C. The flasks were sampled, and OD at 600 nm, dry weight and sterol content were determined. To measure dry weight, 5 ml of the culture were centrifuged at 8,000 rpm. The cells were washed twice 10 with distilled  $\mathrm{H}_2\mathrm{O}$ , and the cell pellet was resuspended in 3-5 ml distilled  $\mathrm{H}_2\mathrm{O}$  and transferred to a pre-weighed dry weight pan. The pan was placed in 100°C oven for 24 hours, then cooled in a desiccator, weighed on an analytical balance, and the dry weight in g/L determined from the 15 formula:

[Total weight (pan + cells) - pan weight] x 200 = dry weight in g/L.

For sterol determination, 20 ml of culture were processed,

the cell pellet and supernatant extracted, and farnesol and
other sterols measured as described above.

Seven of the 13 mutants appeared to produce intermediates in the ergosterol pathway and were evaluated further in other shake flask experiments (see below). All 13 mutants had been selected by resistance to the highest levels of nystatin.

WO 00/01650 PCT/US99/15264

73

Overnight cultures were used to inoculate 50 ml of YPDC medium in triplicate shake flasks for each of the seven mutant strains (MBNA1-1, MBNA1-5, MBNA1-9, MBNA1-10, MBNA1-11, MBNA1-13, MBNA1-14,), the parental strain 28383 and mutant strain 64031. The cells and medium were extracted separately at 24, 48, and 72 hours into hexane, as described above. Dry weight analysis (performed as described above) was performed at each of these time points to determine cell density. The hexane extracts were analyzed by GC/MS for their farnesol, squalene, cholesterol, and ergosterol levels. The farnesol results are presented in Table 3 below.

Low levels of farnesol were found in the culture supernatants with much higher levels accumulating in the cells. Strain MBNA1-1 produced 1% farnesol and also made 0.1% ergosterol at 72 hours. Strain MBNA1-5 did not make any farnesol, but produced 0.3% squalene. Strain MBNA1-9 produced 0.64% farnesol in 48 hours. MBNA1-10, MBNA1-11, and MBNA1-14 produced very low levels of farnesol in the cells and appeared to make ergosterol. MBNA1-13 showed the highest farnesol production (2.5%) based on cell dry weight (42,187 ng/ml culture) and did not show any ergosterol production. Thus, among the farnesol-producing strains (MBNA1-1, MBNA1-9 and MBNA1-13), there appeared to be different degrees of blockage in the ergosterol pathway, since MBNA1-1 and MBNA1-9 produced lower levels of farnesol

5

10

15

20

25

and did not require ergosterol for growth, and MBNA1-13 produced the highest level of farnesol and had a strict requirement for sterol supplementation for growth. The parental strain 28383 showed ergosterol production up to 0.4% (no farnesol production), and erg9 mutant strain 64031 showed farnesol accumulation to approximately 0.4%.

TABLE 3

Characterization of New Mutants in Shake Flask Experiment

Strain			Farnesol	T.
Name	Hours of Growth	Dry weight mg/ml	(ng/ml of culture)	Farnesol (% c cell dry weight)
MBNA1-1	24	0.16	0	0.00
1	48	1.12	1793	0.16
	72	1.26	13187	1.05
MBNA1-5	24	2.46	0	0.00
	48	1.6	0	0.00
	72	1.06	0	0.00
MBNA1-9	24	1.32	1122	0.09
	48	2.96	19062	0.64
<u> </u>	72	4.34	70625	0.00
MBNA1-10	24	4.76	4636	0.10
	48	9.44	444	0.00
	72	7.9	166	
MBNA1-11	24	1.82	0	0.00
	48	3.58	258	0.00
	72	2.36	281	0.01
MBNA1-13	24	0.18	0	0.01
	48	3.12	3657	0.00
	72	1.66	42187	0.12
MBNA1-14	24	2.42	0	2.54
1	48	8.98	0	0.00
	72	7.36	0	0.00
ATCC28383	24	7.36	0	0.00
	48	8.52	0	0.00

SUBSTITUTE SHEET (RULE 26)

MARTINE CO. OF A 19 CENTER CO. AND CO.

- Particles of the Second Control of the S

Strain Name	Hours of Growth	Dry weight mg/ml	Farnesol (ng/ml of culture)	Farnesol (% of cell dry weight)
	72	8.84	0	0.00
ATCC64031	24	1.58	90	0.01
	48	1.84	6845	0.37
	72	1.28	4874	0.38

#### D. <u>Enzyme Analysis</u>

For all enzyme assays, cells were grown in YPDE medium. (YPD medium containing 5 mg/L ergosterol). The cells were harvested by centrifugation. One gram of cells (wet weight) was suspended in 4 ml of 0.1 M Tris • HCl, pH 7.0. The cell suspension was then disrupted by passage through a French pressure cell (20,000 psi). The resulting (lysed) cell suspension was then centrifuged (15,000 x g) and the supernatant (cell free extract) was used directly for enzyme assays unless noted otherwise.

The mutants were assayed for squalene synthase activity. The squalene synthase assay involved incubation of a cell-free extract with FPP in the presence the reduced form of nicotinamide adenine dinucleotide phosphate, (NADPH), extraction into ethyl acetate, and squalene detection by GC. Specifically, 0.1 M Tris/HCl pH7 (XµL), 0.1 M DTT (2µL), 0.1 M MgCl<sub>2</sub> (10µL), 0.1 M NADPH (4µL), 1 mg/mL FPP (6µL), and cell-free extract (7000 x g supernatant) (YµL), where X + Y = 178 µL to make 200 µL total, were combined. This mixture was incubated in glass tubes at 37°C for 40 min. Then, it was extracted with 0.15

## SUBSTITUTE SHEET (RULE 26)

mL ethyl acetate. The extract was transferred to plastic vials and centrifuged at 15,000  $\times$  g for 5 min. The ethyl acetate extract was analyzed using GC/MS.

Table 4 shows squalene synthase levels for mutants MBNA1-1, MBNA1-9, MBNA1-13, and ATCC strains 64031 and 5 Squalene synthase activity was 0.12  $\mu g$  squalene formed/min x mg protein for the wild-type organism 28383. The activity levels for the other four strains were less than the detectable limits of this assay. Reduced squalene synthase levels would be expected for MBNA1-1, MBNA1-9 and 10 64031 since they have been characterized as being partially-blocked mutants that produce farnesol and low amounts of ergosterol. MBNA1-13 is a farnesol-producing mutant which cannot grow without added sterol, so this blocked mutant would be expected to have no detectable 15 level of squalene synthase. The extracts of these strains were reassayed with higher concentrations of cell-free extract and longer incubation times. Once again, squalene synthase was not detected in any of the mutants.

20 TABLE 4

Strain	Squalene Synthase Assay (µg/ min x mg protein)
MBNA1-1	ND
MBNA1-9	ND
MBNA1-13	
ATCC 64031	ND
ATCC 28383	ND
	0.12

ND = Not detected

30

25

The authorities of the extension of the property of the entire the entire the entire that the entire the entir

THE PROPERTY OF THE PROPERTY O

An enzyme analysis was performed for the farnesol-producing strains (MBNA1-1, MBNA1-9 and MBNA1-13) and their parental strain, 28283. The enzyme levels compared were those of the acetoacetyl CoA thiolase, HMG-CoA synthase, HMG-CoA reductase, FPP synthase, and a phosphatase. Cell-free extracts were prepared as described above.

For the FPP synthase assay, 0.1 M DTT (2μL), 0.1 M MgCl<sub>2</sub> (2μL), 1 mg/mL IPP (6 μL), 1 mg/mL GPP (6 μL), cellfree extract (Y), and 0.1 M Tris/HCl (pH 7.0) (X μL), where 10 X + Y = 84 μL, were combined, and incubated at 37°C for 15 min. This mixture was then extracted twice with 0.3 mL hexane to remove pre-existing farnesol. Next, 0.1 mL of 2 x glycine buffer (0.2 M glycine, 2 mM MgCl<sub>2</sub>, 2mM Zn Cl<sub>2</sub>), pH 10.4, and 33 units of alkaline phosphatase were added, and the mixture was incubated at 37°C for an hour. The mixture was extracted with 0.1 mL of ethyl acetate and dried with sodium sulfate. Farnesol was determined with GC. A no-phosphatase control was included in each assay.

HMG-CoA reductase catalyzes the reaction of HMG-CoA

with NADPH to form mevalonate, nicotinamide adenine
dinucleotide phosphate (NADP) and CoA (see Fig. 1). For
these assays, the cell-free extracts were prepared as
described above except that the disrupted cell suspensions
were centrifuged at 7,000 x g instead of 15,000 x g. The

reaction was followed by monitoring consumption of HMG-CoA
by high performance liquid chromatography (HPLC). For the

The Arthur 1975 A the Arthur 1988 A the Control of the Control of

monthannessensen, vranz namenneskihitenessen serienteres ereineren ereinisteres ereinteren erennese

And the second s

assay, a reaction mixture containing (in a final volume of 0.1 ml) 0.1 M Na<sub>2</sub>H<sub>2</sub>P<sub>2</sub>O<sub>1</sub>, pH 6.5, 2 mM DTT, 1 mM NADPH, 0.4 mM HMG-CoA, and cell-free extract (the volume of extract was varied, with the balance of the 0.1 ml reaction made up with 0.1 M Na<sub>2</sub>H<sub>2</sub>P<sub>2</sub>O<sub>1</sub>, pH 6.5) was incubated at 37°C for 15 minutes. The reaction was monitored with HPLC (Luna C18 (Phenomenex) reversed-phase column using a gradient of 0% Solvent B for 1 min. followed by 0-11 % B over 42 min. Solvent A was 86:14 (v/v) 40mM potassium phosphate (pH 6.0)/methanol. Solvent B was methanol. The wavelength for detection was 260 nm).

HMG-CoA synthase converts acetoacetyl CoA and acetyl CoA to HMG-CoA and CoA. The assay monitors the production of HMG-CoA by HPLC. For the assay, 0.1 M Na<sub>2</sub>H<sub>2</sub>P<sub>2</sub>O<sub>7</sub>, pH 6.5, (X μL), 20 mM acetoacetyl CoA (4 μL), 20 mM acetyl CoA (2 μL), and cell-free extract (Y μL), where X + Y is 94 μL (total volume 100 μL), were combined and incubated at 37°C for 5 minutes. Then, the reaction mixture was heated at 60°C for 5 minutes to inactive the enzyme, followed by centrifugation in a microfuge at full speed for 5 minutes. The supernatant was analyzed by HPLC.

Acetoactyl CoA thiolase catalyzes a reversible reaction whereby, in the forward direction, two molecules of acetyl CoA are reacted to form acetoacetyl CoA and CoA. The assay monitors the formation of acetyl CoA (reverse

The assay monitors the formation of acetyl CoA (reverse reaction) by HPLC. For the assay, 0.1 M Na<sub>2</sub>H<sub>2</sub>P<sub>2</sub>O<sub>7</sub>, pH 6.5,

10

15

20

The second of th

(X  $\mu$ L), 20 mM acetoacetyl CoA (2  $\mu$ L), 20 mM CoA (3  $\mu$ L), and cell-free extract (Y  $\mu$ L), where X + Y is 95  $\mu$ L (total volume 100  $\mu$ L), were combined and incubated at 37°C for 5 minutes. Then, the reaction mixture was centrifuged in a Microcon-10 (Amicon) centrifuge to separate the enzyme from the product. The supernatant was analyzed by HPLC.

The phosphatase assay quantitates phosphatase activity by measuring the formation of p-nitrophenol (increased absorbance at 400 nm). For the phosphatase assay, 0.1 M Tris-HCl, pH 7 (X ul), 1 M MgCl, (2 ul), 50 mM p-nitrophenyl phosphate (10 ul) and cell-free extract (Y ul), where X + Y = 1 mL, were combined and incubated at  $37^{\circ}$ C for 15 minutes, after which the absorbance at 400 nm was measured.

Table 5 shows the levels for each of the five enzymes in these four strains. The acetoacetyl CoA thiolase levels were comparable in all of these strains. The HMG-CoA synthase and HMG-CoA reductase levels appeared to be two to three times higher in the mutant strains. The FPP synthase levels were the same or lower in the mutants than in 28383. The phosphatase levels appeared to be elevated three to four fold in the mutant strains compared to the parent. Since all of these strains were isolated by classical mutagenesis, it is possible that other mutations exist in these strains, besides the erg9 mutation.

al Education and a confession of a second se

80

TABLE 5

	MBNA1-1	MBNA1-9	MBNA1-13	ATCC 2838
Acetoacetyl CoA Thiolase (nmol AcCoA / min x mg protein)	2.4 x. 10 <sup>2</sup>	2.7 x. 10 <sup>2</sup>		<del> </del>
HMG-CoA Synthase (nmol HMG-CoA / min x mg Orotein)	5.7	7.2	7.1	2.7
IMG-CoA Reductase nmol CoA / min x mg protein)	0.35			
	0.33	0.55	0.36	0.15
PP Synthase nmol Farnesol / min x mg rotein)	1.3	2.0	1.6	2.2
eneral Phosphatase nmol p-nitrophenol/min x mg rotein)	82	83	91	24

# E. ERG9 Genetic Analysis

25 Chromosomal DNA was prepared from strains ATCC 28383, MBNA1-1, MBNA1-9 and MBNA1-13 according to the method described in Sherman et al. (Sherman, F., G.R. Fink, and J.B. Hicks, 1989, Methods in Yeast Genetics, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY). The genomic DNA was digested with the restriction enzymes ApaI and 30 NsiI, and subjected to Southern blot analysis using a biotinylated ERG9 DNA fragment as a probe. The ERG9 probe consisted of a 2044 bp ERG9 DNA fragment isolated from an agarose gel after digestion of the plasmid pTWM103 with 35 Apal and Nsil. pTWM103 consists of the ERG9 gene and flanking sequences extending from position #10916 to #13868 of GenBank Accession #U00030 sequence. This plasmid was

# SUBSTITUTE SHEET (RULE 26)

constructed by polymerase chain reaction amplification of the ERG9 gene and flanking regions using the following two oligonucleotides:

5'-oligo = VE107-5 CTC AGT ACG CTG GTA CCC GTC AC (denoted herein as SEQ ID NO:1)

3'-oligo = VE105-3 gat gga TCC CAA TAT GTG TAG CTC AGG (denoted herein as SEQ ID NO:2)

Capital letters designate DNA sequences from ERG9 flanking region, while small letters designate bases added to create restriction sites. VE107-5 contains sequences 10 from position #10905 to position #10928 of GenBank Accession #U00030 sequence. VE105-3 contains the reverse complement of sequences from position #13868 to position #13847.

20 The amplification conditions were as follows: Template DNA was genomic DNA isolated from strain S288C (Yeast Genetic Stock Center, Berkeley, CA)

2 min. 94°C/1 cycle

1 min. 94°C, 1min. 52°C, 1.5 min. 74°C/30 cycles

5 min. At 74°C/1 cycle

The 2969 bp ERG9 DNA generated from this PCR reaction was digested with KpnI and BamHI, then ligated to KpnI, BamHI digested YEp352 to generate plasmid pTWM103. YEp352 is a yeast/E. coli shuttle vector (Hill, J.E., Myers, A.M., Koerner, T.J., and Tzagaloff, A., 1986, Yeast/E. coli Shuttle Vectors with Multiple Unique Restriction Sites, Yeast  $\underline{2}$ : 163-167).

DNA for the *ERG9* probe described above was obtained by digesting TWM103 with *ApaI* and *NsiI*, and purifying the 2044 bp fragment containing the *ERG9* gene and flanking sequences. The *ERG9* DNA was then biotinylated using random primer extension (NEBlot Phototope Kit, New England BioLabs, Beverly, MA).

Approximately 1 µg of biotinylated *ERG9* probe was 10 hybridized to the Southern blot of *ApaI*, *NsiI* digested genomic DNA from strains ATCC 28383, MBNA1-1, MBNA1-9, and MBNA1-13. The blot revealed that all four strains contained a single hybridizing sequence located on a 2044 bp fragment.

15 To clone the ERG9 genes from these four strains, genomic DNA from each was again digested with ApaI and NsiI. The yeast/E. coli shuttle vector pRS315 (Sikorski, R.S., and P. Hieter, 1989, A System of Shuttle Vectors and Yeast Host Strains Designed for Efficient Manipulation of DNA in Saccharomyces cerevisiae, Genetics, 122: 19-27) was 20 digested with ApaI and PstI (NsiI and PstI have compatible cohesive ends). The digested DNAs were separated on an agarose gel, and chromosomal DNA fragments in the size range from approximately 1.6 kb to approximately 3 kb, as well as the 3895 bp band corresponding to digested pRS316 25 were cut from the gel and purified using GeneClean (BIO

:

20

25

: ·:

To the control of the

101, Inc., Visa, CA). The purified genomic DNA fragments from each of the four strains was ligated to pRS316, and transformed into *E. coli*. Transformants containing the pRS316/ERG9 clones were identified by colony hybridization using the ERG9 probe described above. ERG9 clones derived from each of the four strains were isolated in this manner. The cloned ERG9 genes from each strain were sequenced by ACGT, Inc., Northbrook, IL, using an Applied Biosystems, Inc. automated DNA sequencer, Model ABI 100.

10 The sequence of the ERG9 gene from ATCC 28383 was identical to the sequence deposited in GenBank (Accession #U00030). The erg9 genes from MBNA1-2 and MBNA1-9 were found to have the same mutation, namely, a change from G to A at position #12386 of GenBank Accession #U00030, which changes a TGG codon to a TGA stop codon. This causes termination of the ERG9 protein at 237 amino acids instead of the normal 444 amino acids found in the wild-type ERG9 protein.

The erg9 gene from MBNA1-13 was found to contain a deletion of a C at position #12017 of GenBank Accession #U00030, which causes a frameshift and early termination of the ERG9 protein at 116 amino acids, with the last two amino acids being different from the wild-type ERG9 protein (due to the frameshift). The erg9 alleles from MBNA1-1 and MBNA1-9 retain low levels of activity. This was determined by transforming an ergosterol-requiring erg9 deletion

25

mutant with plasmids that carry the mutant erg9 genes from MBNA1-1 and MBNA1-9. The presence of the cloned genes in the erg9 deletion strains allowed these transformants to grow, albeit slowly, on medium lacking ergosterol. The erg9 allele from MBNA1-13 did not show any residual activity when tested in this manner. The erg9 deletion strain grew at wild-type levels when transformed with the ERG9 allele from ATCC 28383.

# F. Description of Secondary Mutations

Saccharomyces cerevisiae does not normally import 10 ergosterol from its environment under aerobic conditions. However, the isolated erg9 mutants were able to grow aerobically when supplemented with ergosterol cholesterol, therefore, must contain secondary and mutations that allow aerobic sterol uptake to occur. 15 methods used to isolate ergosterol pathway mutants, such as the erg9 mutant MBNA1-13, included not only a selection for ergosterol pathway mutants, but a selection for cells that import sterols under aerobic conditions as well, since only mutants with mutations in both a sterol pathway gene and a 20 sterol uptake gene would have survived.

In Example 3 below, the difficulty encountered when attempting to obtain *erg9* knockout mutations by molecular methods, even in a strain carrying the *upc2* mutation, which is reported to allow uptake of sterols under aerobic conditions (Lewis, T.L., G.A. Keesler, G.P. Fenner and L.W.

the more and the specific and the second

WO 00/01650 PCT/US99/15264

85

Parks, 1988, Pleiotropic mutations in Saccharomyces cerevisiae affecting sterol uptake and metabolism, Yeast 4: 93-106) is described. It appears that the upc2 mutation does not confer efficient aerobic sterol uptake in an erg9 mutant, and that the strains described in Example 3 acquired additional spontaneous mutations (at a low frequency rate) that improve their ability to take up sterols aerobically.

Having the appropriate mutations that enhance aerobic 10 uptake of ergosterol and cholesterol in an otherwise wild type strain allow one to isolate erg9 mutations in that strain at a much higher frequency than would be obtained with a non-sterol uptake mutant strain. In order to demonstrate that the erg9 mutant strain MBNA1-13 (and derivatives of this strain) had acquired a mutation(s) that 15 enhances uptake of sterols under aerobic conditions (referred to as sterol uptake enhancement or mutations), the frequency of creating an erg9 knockout in the MBNA1-13 background, which contains the sterol uptake 20 mutation, to the frequency of obtaining the erg9 knockout mutation in the ATCC 28383 parental background, which presumably lacks the sterol uptake mutation, was compared. This was done with the following two strains representing each strain background. SWE23-ΔHE9 (ura3, his3, sue) was derived from MBNA1-13 and contains a repaired ERG9 gene. 25 SWY5- $\Delta$ H1 (ura3, his3) is an auxotrophic mutant derived from

CONTROL OF THE PROPERTY OF THE

A section of the sect

5.5

strain ATCC 28383. The construction of SWE23- $\Delta$ HE9 and  $SWY5-\Delta H1$  is described in detail in Section G below. Since  $SWE29-\Delta HE9$  was derived from MBNA1-13, this strain served as the host carrying the sue mutation, whereas SWY5- $\Delta$ H, which was derived from ATCC 28383, served as the host without the sue mutation. Both strains were transformed with equal amounts (approximately 1 μg) of the erg9Δ::HIS3 DNA fragment obtained digesting pKML19-41 by construction described in Example 3) with BamHI and XmaI, and purifying the resulting 2.1 kb fragment. Cells were transformed with this 2.1 kb fragment using the LiAc transformation procedure (Gietz, R.D., R.H. Schiestl, A.R. Willems and R.A. Woods, 1995, Studies on the transformation of intact yeast cells by the LiAc/SS-DNA/PEG procedure, Yeast  $\underline{11}$ : 355-360), and transformants were selected on SCEura medium. SCE medium contains 0.67% Bacto yeast nitrogen base (without amino acids), 2% dextrose, 20 mg/L adenine sulfate, 20 mg/L uracil, 20 mg/L L-tryptophan, 20 mg/L Lhistidine, 20 mg/L L-arginine, 20 mg/L L-methionine, 30 mg/L L-tyrosine, 30 mg/L L-leucine, 30 mg/L L-isoleucine, 30 mg/L L-lysine, 50 mg/L L-phenylalanine, 100 mg/L Lglutamic acid, 100 mg/L L-aspartic acid, 150 mg/L L-valine, 200 mg/L L-threonine, 400 mg/L L-serine and 5 mg/L ergosterol. For agar plates, 2% Bacto agar is added to the SCE medium. SCE-ura medium is SCE lacking uracil.

TO STATES OF STA

5

10

15

20

25

10

15

20

to the term of the property of the control of the control of the section of the section of the section of the control of the c

2.00

total of HIS<sup>+</sup> colonies arose 24 transformation of SWY5- $\Delta$ H1, while 401 HIS $^{+}$  colonies were obtained from SWE23- $\Delta$ HE9. Since it was possible for the erg94::HIS3 gene to integrate at loci other than the ERG9 (and therefore allowing the cells to remain prototrophic for ergosterol), twenty of each type of transformant were tested for an ergosterol requirement by plating onto YPD medium (lacks ergosterol). All 20 of the  ${\tt HIS}^{\scriptsize +}$  colonies derived from SWY5- $\Delta {\tt H}$  were able to grow on YPD which indicated that they still contained a functional ERG9 gene, and suggested that the erg91::HIS3 gene was not integrated at the ERG9 locus. On the other hand, none of the 20  ${
m HIS}^+$  colonies derived from SWE23- $\Delta{
m HE9}$  were able to grow on YPD indicating that the erg94::HIS3 DNA had replaced the wild type ERG9 gene in this strain background at a relatively high frequency. To verify this, nine HIS\* colonies of each strain were analyzed by PCR to determine the types of *ERG9* alleles present in their genomes. Genomic DNA was prepared as described in Sherman et al. The oligonucleotides used for the analysis are (1989).given below.

5' oligo = 250 UpBam gcgcatCCACGGGCTATATAAA (SEQ ID NO:3)
3' oligo = 1764 LoBam gcggatCCTATTATGTAAGTACTTAG (SEQ ID NO:4)

PCR conditions were as follows: 94°C, 3 min.

94°C, 30 sec.; 50°C, 30 sec.; 72°C, 3 min.; 30 cycles 72°C, 7 min.

Oligonucleotides 250 UpBam contains sequences corresponding to position #11555 to #11570 of the GenBank Accession #J05091 sequence. Oligo 1764LoBam contains the 5 reverse complement of sequences from position #13049 to #13068 of the same GenBank sequence file. In all 9 of the  ${\rm HIS}^{+}$  transformants of SWE23- $\Delta{\rm HE9},$  the PCR product was 2.1 kbp indicating that the ERG9 gene had been replaced by the erg94::HIS3 gene. In 8 of the 9 HIS transformants of SWY5-10  $\Delta H1$ , the PCR products were 2.1 kbp and 1.5 kbp, indicating that the wild type ERG9 gene remained intact and that the erg94::HIS3 DNA had integrated elsewhere in the genome. The ninth HIS+ transformant showed only the 1.4 kbp PCR 15 product, also indicating that the ERG9 gene was intact in this strain. In this case, the HIS3 gene is believed to have integrated into the genome without carrying all of the erg9 sequences with it.

These results show that during the course of isolating strain MBNA1-13, an additional mutation(s), referred to herein as sue, arose in the strain. Based on the results described in Example 3 below, the sue mutation appear to be different from the previously reported upc2 mutation and confers more efficient uptake of sterols.

A Section of the

25 G. <u>Derivation of New Strains from MBNA1-13</u>

The state of the s

15

20

25

The second of the second secon

In order to use the erg9 mutant strain MBNA1-13 for molecular genetic manipulations, the strain was further developed so that it carried auxotrophic markers suitable for this purpose. MBNA1-13 was mutagenized using ethyl methane sulfonate using standard procedures and mutants resistant to 5-fluoroorotic acid (5-FOA) were obtained by plating the mutagenized cells on medium containing 5-FOA. The use of 5-FOA selection was described in Sikorski and Boeke, 1991 (Sikorski, R.S. and Boeke, J.D., 1991, In Vitro Mutagenesis and Plasmid Shuffling: From Cloned Gene to Mutant Yeast, Methods in Enzymology 194: 302-318). selection method allowed for the isolation of strains containing mutations in the URA3 gene, coding for orotidine-5'-phosphate decarboxylase. Several resistant strains were isolated that exhibited 5-FOA resistance (i.e., a ura phenotype). To determine which of these strains contained a mutation specifically in the URA3 gene, the ura strains were transformed with pRS316 (Sikorski and Hieter, 1989), which contains the intact URA3 gene, using the LiOAc transformation procedure (Gietz et al., 1995). Several strains were identified whose lack of growth on medium lacking uracil was restored by pRS316, indicating that those strains carried the ura3 mutation. One of these strains, EMS9-23 (ura3, erg9) was chosen for further modification.

Strain EMS9-23 was genetically altered to contain deletions in leu2, trp1, or his3 genes using gene transplacement plasmids described in Sikorski and Hieter 91989), and the pop-in/pop-out gene replacement procedure described in Rothstein (1991) (Rothstein, R., 1991, 5 Targeting, Disruption, Replacement, and Allele Rescue: Integrative DNA Transformation in Yeast, Methods in Enzymology 194: 281-301). The leu2, trpl and his3 mutants derived from MBNA 1-13 were named SWE23- $\Delta$ L1, SWE23- $\Delta$ T1 and SWE23- $\Delta$ H1, respectively. 10 Strain SWE23- $\Delta$ H1 was further manipulated to exchange the original erg9 frameshift mutation (see Section E) with the erg9\(\Delta::\text{HIS3}\) allele. This was done by transforming SWE23-ΔH1 (using the LiOAc procedure) with approximately 5 µg of a linear DNA fragment containing the  $erg9\Delta$ ::HIS3 cassette (the construction of 15 the erg91::HIS3 cassette is described in detail in Example The erg94::HIS3 cassette was obtained by digesting pKML19-40 with BamHI and XmaI, and purifying the 2.1 kbp DNA fragment containing the erg9A::HIS3 Transformants of SWE23- $\Delta$ Hl in which the erg9 frameshift 20 allele had been replaced by the erg91::HIS3 allele were selected by plating the transformants on SCE medium lacking histidine. One of the resulting strains is referred to as SWE23-∆E91.

25 Strain SWE23-DH1 was further modified so as to contain mutations in the *leu2* and *trp1* genes. These mutations were

HINGER HELDER OF STRONG CONTINUES CO

WO 00/01650 PCT/US99/15264

91

introduced using the gene transplacement plasmids (Sikorski and Hieter, 1981) and the pop-in/pop-out gene replacement procedure (Rothstein 1991) described above. One of the resulting strains is referred to as SW23-DH1 #42, and contains erg9, ura3, his3, leu2, trp1, and sue mutations. Strain SW23-DH1 #42 was further modified to exchange the original erg9 frameshift mutation with the erg9D::HIS3 allele. This was done by transforming SW23-DH1 #42 (using the LiOAc procedure) with approximately 5 mg of a linear DNA fragment containing the erg9D::HIS3 cassette as described above. HIS+ transformants in which the erg9 frameshift mutation had been replaced by the erg9D::HIS3 allele were selected on SCE-his medium. One of the resulting strains is referred to as SW23B, and carries mutations in the following genes: ura3, leu2, trp1, his3, erg9::HIS3, sue.

10

15

20

25

- A COMPANY CONTROL OF A COM

A summary of the strains derived from MBNA1-13 and their respective farnesol production in shake flask cultures is given in Table 6. The strains were grown overnight in YPDE medium (30°C with shaking at 180 rpm). These cultures were used to inoculate 25 ml of YPDE medium in a 250 ml flask such that the initial OD600 was 0.05. The cells were grown for 72 hours at 30°C (with shaking at 180 rpm). Samples of the whole broth (i.e., cells plus culture medium) were analyzed for dry cell weight and farnesol as described in Section C above.

Table 6 Growth and Farnesol Production in Strains Derived from MBNA1

	ms berived from MBNA1-13
Genotype	Farnesol (% of dry cell weight)
erg9, sue	7.9
erg9, ura3, sue	8.0
erg9, ura3, his3-Δ200, sue	7.9
erg9, ura3, leu2-Δ1, sue	9.3
	10.8
erg9∆::HIS3, ura3, his3, sue	8.0
	Genotype  erg9, sue  erg9, ura3, sue  erg9, ura3, his3-Δ200, sue  erg9, ura3, leu2-Δ1, sue  erg9, ura3, trp1-Δ63, sue

15

20

5

Strains MBNA1-13, EMS9-23 and SWE23- $\Delta$ E91 were further evaluated for growth and farnesol production in 1-L fermentors using the method described in Section H below. EMS9-23 and SWE23- $\Delta$ E91 were each transformed with plasmid YEp352, which contains the cloned URA3 gene. This obviated the need to add uracil to the fermentation medium for these two strains. Fig. 4 and Table 7 summarize the results of these fermentations. MBNA1-13 and EMS9-23/YEp352 performed similarly. Although the growth of SWE23- $\Delta$ E91/YEp352 lagged behind the other two strains, it did reach a cell density and farnesol production level comparable to the other strains.

Table 7

25	Comparison of MBNA1-	-13 and Stra	ins Derived from	a it in 1-r.	Formantana
	Strain/Plasmid	Time (hr)	Dry Cell Weight (g/L)		nesol
	1		W7		

1	Dry Cell Weight	Fa	mesol
	(9/2)	g/L	(% of dry cell weight)
191	40.8	2.25	5.5
191	42.6		5.8
239	37.2		6.0
	(hr) 191 191	(hr) (g/L)  191 40.8  191 42.6	(hr) (g/L) g/L  191 40.8 2.25  191 42.6 2.46

SUBSTITUTE SHEET (RULE 26)

CONTROL OF THE PROPERTY OF THE

Strains EMS9-23 and SWE23-AH1 were further manipulated by repairing their erg9 mutations back to wild type This was done by transforming the two strains function. 5 (using the LiOAc transformation procedure) with approximately 5  $\mu g$  of a DNA fragment containing the intact ERG9 gene. The ERG9 gene DNA fragment was obtained by digesting pTWM103 (see Section E above) with SacI and BamHI, and purifying the 2.5 kb DNA fragment containing the 10 ERG9 gene. Transformants of EMS9-23 and SWE23-ΔH1 in which the erg9 frameshift mutation had been replaced by the wild type ERG9 gene were obtained from each strain by selecting for cells that could grow on YPD medium lacking ergosterol. One erg9-repaired strain derived from EMS9-23, designated 15 SWE23-E9, and one erg9-repaired strain derived from SWE23-ΔH1, designated SWE23-ΔHE9, were chosen for further study. separate experiments, auxotrophic mutations introduced into the parental strain ATCC 28383. spontaneous ura3 mutant of ATCC 28383 was obtained after plating cells on medium containing 5-FOA as described 20 Mutants resistant to 5-FOA were transformed with (described above) to identify those that had pRS316 spontaneously acquired a mutation specifically in their URA3 gene. One strain, SWY5, exhibited a stable ura-25 phenotype (low reversion frequency), and was chosen for

further study. SWY5 was further manipulated to carry the his3 mutation by using the gene transplacement plasmid YRp14/ $his3-\Delta200$  described by Sikorski and Hieter (Sikorski and Hieter, 1989) and the pop-in/pop-out gene replacement procedure described by Rothstein (Rothstein, 1991). his3 mutant derived from SWY5, designated SWY5- $\Delta$ H, was chosen for further study.

Table 8 lists the repaired and auxotrophic strains described and their genotypes.

10

5

Table 8 Repaired and Auxotrophic Strains related to ATCC 28383 and MBNA1-13

Strain	Genotype	and MBNAI-13
SWE23-E9		Parent
	ura3, sue	EMS9-23
SWE23-AHE9	ura3, his3, sue	
SWY5		SWE23-AH1
	ura3	ATCC 28383
SWY5-AH	ura3, his3	SWY5

15

25

To test whether the erg9 mutant MBNA1-13 had acquired any additional nutritional requirements during the course of its isolation, a growth experiment was conducted in 20 shake flasks to compare the parental strain ATCC 28383, the erg9 mutant strain EMS9-23 and the erg9-repaired strain SWE23-E9. The cultures were grown in YPD medium at 30°C with shaking at 180 rpm. The EMS9-23 culture was also supplemented with 5 mg/L ergosterol. Growth was monitored by  $OD_{600}$ .

の - Common March - Common March - Common - Com

The results of this experiment, presented in Fig. 5, show that the growth of the erg9 mutant was reduced, but that the growth of the wild-type parent strain 28383 and the erg9-repaired strain SWE23-E9 grew similarly. The slightly lower final  $OD_{600}$  in the SWE23-E9 culture was probably due to the fact that this strain is a uracil auxotroph, and the concentration of uracil in the YPD medium was not optimal. These results indicate that the major cause of the growth defect in the erg9 mutants is the erg9 mutation itself. Other mutations in the erg9 mutants, such as the sue mutation(s), do not have a significant effect on growth.

#### H. One-Liter Fermentation

Strains MBNA1-13, EMS9-23/YEp352 and SWE23-aE91/YEp352 were grown in one-liter fermentors under fed-batch conditions as described below. Under these conditions, farnesol production by these strains ranged from 5.5-6.0% of dry cell weight (data shown in Section G above) in 191-20 239 hours.

## Fermentation Conditions And Materials:

The one-liter fementation was performed by first autoclaving for 45 minutes at 121℃, in the fermenter, the following solution:

	$(NH_4)_2SO_4$	10.0	g/L
	KH₂PO₄	10.0	g/L
	CaCl <sub>2</sub> -2H <sub>2</sub> O	0.5	g/L
30	NaCl	0.5	g/L

5	MgSO <sub>4</sub> -7H <sub>2</sub> O yeast extract (Difco) salt solution defoamer (Dow 1520) deionized water	3.0 2.0 20.0 4.0 500	g/L g/L mL drops
	•	300	mL.

After autoclaving, the following sterile solutions were added:

glucose solution (50%) w/v) 5.0 mL vitamin solution 15.0 mL ergosterol solution 0.2 mL.

The glucose and vitamin solutions were sterilized by passage through a 0.45 micron filter. The ergosterol solution is considered sterile (see below).

Glucose feed solution (made up in deionized water)

glucose solution (60% w/v) 360 mL yeast extract solution (12.5% w/v) 80 mL ergosterol solution 5.8 mL

Glucose, yeast extract sterilized by autoclaving; ergosterol considered sterile.

#### Inoculum

1 mL cell suspension frozen in 10% glycerol inoculated into 250 mL YPDE medium in 1000 mL baffled flask, inoculum per fermenter.

# Fermentation conditions

35

**Ž**odepretera, a se se se

28°C pH 4.5

Agitation 300 - 1000 rpm, aeration 50-200 mL/min as required to maintain dissolved oxygen at 10-60% of air saturation. Glucose feed solution added after initial glucose was depleted. Addition rate to achieve a growth rate of 0.04 hr<sup>-1</sup> considering that cell yield on glucose is 0.25. Maximum feed rate = 3.5 ml/hr.

45 Salt solution (given per liter in deionized water)

3,57

The second programme of the content of the content

The second of th

....

HC1

0.10 mL

Vitamin solution (given per liter in deionized water)

5	biotin	10	mg
	Ca-pantothenate	120	mg
	inositol	600	mg
	pyridoxine-HCl	120	mg
	thiamine-HCl	120	ma

Ergosterol solution

10

15

20

30

35

ethanol	20	mL
IGEPAL	20	mL
ergosterol	0.4	q

Heat at 50°C with mixing until dissolved, store at - 20°C. IGEPAL is 1,3,3 tetramethyl butyl phenoxy (ethoxy)<sub>8</sub> ethanol (Sigma Chemical Company, St. Louis, MO, Product IGEPAL CA-630, Cat. # I 3021).

#### Example 2

This example describes the production of erg9 mutants

by chemical mutagenesis of *S. cerevisiae* strain 64031

using ethylmethane sulfonate (EMS). Strain 64031 (obtained from ATCC) is an erg9-1 mutant that produces low levels of farnesol (see Example 1), and additional mutagenesis produced mutants exhibiting improved yields of farnesol.

A kill curve was performed using EMS, and a mutagenesis of 64031 was performed as described in Example 1. Selection was also performed as described in Example 1.

A total of 163 strains were found to be nystatinresistant, ts, sterol auxotrophs. They were cultured in
tubes and shake flasks, and farnesol production was
determined as described in Example 1. The amounts of
farnesol produced in the shake flask cultures are presented
in Table 9.

98

			TABLE 9		
	Strain	Farnesol (mg/ml)		Farnesol (% dry weight)	
		Cell	Medium	Cell extracts	Medium extracts
5	MBEMS8-1	0.038	0.019	1.7	
	MBEMS8-2	0.048	0.008	3.6	0.8
	MBEMS8-5	0.013	0.022	0.5	0.6
0	MBEMS8-6	0.045	0.016	5.6	1.0
	MBEMS8-11	0.024	0.003	2.0	2.0
	MBEMS8-12	0.043	0.006	6.9	0.2
	MBEMS8-16	0.026	0.001	3.5	1.0
	MBEMS8-18	0.040	0.009	1.4	0.2
5	MBEMS8-19	0.023	0.003	2.8	0.3
	MBEMS8-21	0.021	0.009	1.5	0.4
	MBEMS8-23	0.025	0.008	2.9	0.7
	MBEMS8-25	0.018	0.007	1.3	0.9
	MBEMS8-26	0.028	0.011	3.7	0.5
	MBEMS8-27	0.035	0.010	5.5	1.5
	MBEMS8-31	0.020	0.011	1.1	1.5
	MBEMS8-32	0.016	0.009	0.5	0.6
	MBEMS8-33	0.000	0.000	0.3	0.3
	MBEMS8-34	0.000	0.000	0	0
	MBEMS8-35	0.000	0.000	0	0
	ATCC64031	0.018	0.005	0.9	0
	ATCC28383	0.000	0.000	0.9	0.3

### Example 3

 $\sim :;$ 

In Example 1.G. above, the creation of an erg9Δ::HIS3
mutant of MBNA1-13 was described. In this example, the
construction of other haploid S. cerevisiae strains (not
derived from MBNA1-13) containing an erg9 deletion::HIS3
insertion allele is described.

15

20

र्वे का**स्त्राक्षणका अभव**ार के हैं। ते स्ट्र

The ERG9 gene was PCR amplified using genomic DNA isolated from strain S288C (according to the method of Sherman et al.) as template and the following two primers:

5' oligo = gag cat CCA CGG GCT ATA TAAA (SEQ ID NO:5);
5 250 BamUp

3' oligo = tcc ccc cg GGC GCA GAC TTC ACG CTC (SEQ ID NO:6); 1712 XmaLo

The PCR amplified ERG9 DNA was digested with BamHI and XmaI, then ligated to BamHI, XmaI digested pRS316 (Yeast/E. coli shuttle vector, Sikorski and Hieter, 1989).

The PCR conditions were:

A STATE OF THE S

94°C for 1 min. - 1 cycle 94°C for 30 sec. 58°C for 1 min 72°C for 1 min. - 1 cycle

The ERG9 gene cloned in this manner extends from position #11555 to position #13047 of GenBank Accession #U00030, and the resulting clone was named pJMB98-12. The construction of the deletion in ERG9 and the insertion of HIS3 DNA was done as follows:

The HIS3 gene was obtained by digesting the HIS3 containing plasmid pRS403 (Stratagene, LaJolla, CA) with Eco47III and SspI, and purifying the 1226 bp fragment containing the HIS3 gene.

The plasmid pJMB98-12 was digested with Van91I, then treated with T4 DNA polymerase to make it blunt-ended. The

. 1

plasmid was further digested with HpaI so that an internal 589 bp fragment within ERG9 was deleted. Into this site was ligated the 1226 bp Eco47III, SspI fragment containing the HIS3 gene. The resulting plasmid, pKML19-41, has the HIS3 gene cloned within the deleted ERG9 gene, with the HIS3 coding sequence in the same orientation as the ERG9 coding sequence.

To transform yeast with this erg9\L:HIS3 DNA, the plasmid pKML19-41was digested with SmaI and XbaI, and the 2141 bp fragment containing the erg9\L:HIS3 gene was isolated. DNA was purified from agarose gel slices by using GeneClean.

Approximately 5  $\mu g$  of purified  $erg9\Delta$ ::HIS3 DNA was used to transform diploid strain CJ3A X CJ3B (a/ $\alpha$ , ura3/ura3, his3/his3, leu2/leu2, trp1/trp1, upc2/upc2, 15 obtained from Dr. L. Parks, N.C. State University, Raleigh, NC) using the lithium acetate transformation procedure described in Gietz, et al. (1995). CJ3A X CJ3B is homozygous for the upc2 mutation. This mutation allows sterol uptake under aerobic conditions (Lewis, et al., 20 1988). It was believed that the upc2 mutation would allow the easy production of a haploid strain carrying a mutation in the erg9 gene. The histidine auxotrophy was necessary to select for strains carrying the plasmids that contain 25 the functional HIS3 gene.

では、これでは、「Manager Control of the Co

4:

The transformed cells were plated onto SCE medium (described in Example 1.F.) lacking histidine (SC-His) to select for HIS<sup>+</sup> transformants.

Hundreds of transformants were obtained. These HIS' cells were then patched onto SC-His and allowed to grow for 5 two more days. The transformants were then patched onto sporulation medium (Sherman, et. al, 1986). Sporulation medium contains (per liter of distilled water): potassium acetate, 0.1% Bacto yeast extract, 0.05% dextrose and 2% Bacto agar. The patches were then allowed to grow 10 and sporulate for 3-5 days. A portion of the cells was removed and placed in a solution of lyticase to digest the ascus cell wall. The cells were then spread in a thin line onto a YPD + 2 mg/L ergosterol (YPDE) plate. sporulated diploid cells form tetrads containing four 15 spores, and the individual spores were separated using a micromanipulator. These individual haploid spores will germinate with each containing a single copy of the chromosomes.

A 2:2 segregation was expected for erg91:HIS3 knockouts in this strain. Two spores should be viable on YPD since they would contain the copy of the chromosome which was not disrupted (meaning they would not need ergosterol since they have a functioning ERG9 gene and would be able to grow on YPD because histidine is present in the medium). The other two spores should grow on SC-His

+ 2 mg/L ergosterol (SCE-His) since, if the erg9\(\triangle ::\text{HIS3 DNA}\) integrated at the ERG9 site, the cells would require ergosterol, but would grow without histidine.

Tetrads from some of the pKML19-41 transformants were

analyzed for phenotypic determination of the erg9 knockout.

The results showed that only two of the four spores were viable when grown aerobically. When these were replicaplated to YPD these two spores survived, but they did not survive on SC-His or SCE-His. This indicated a 2:2 segregation and that the two surviving spores were of the parental type or auxotrophic for histidine. This indicated that the two that did not survive aerobically probably contained the erg9:HIS3 knockout.

PCR analysis confirmed the results of an erg9\(\alpha::\text{HIS3}\)

knockout in several of the strains. Total DNA was isolated using a rapid DNA isolation method from several of the diploid transformants that showed the 2:2 segregation. The total DNA was then used as template for PCR amplification with primers complementing sequence 5' and 3' to the ERG9 gene in the chromosome.

The oligonucleotides used for this analysis were as follows:

5'-oligo = 250 Bam Up (described above)

3'-oligo = 3ERG9-1 = gat ccg cg GCT CAA GCT AGC GGT ATT

25 ATG CC (SEQ ID NO:7)

the state of the state of the state of

..!

WO 00/01650 PCT/US99/15264

103

3ERG9-1 contains sequences corresponding to the reverse complement of sequences from position #14812 to position #14790 of the GenBank Accession #U00030 sequence.

Oligonucleotide 250 Bam Up lies within the sequence of the ERG9 clone used to construct the erg9a::HIS3 allele, whereas oligonucleotide 3ERG9-1 lies downstream of the boundary of the cloned ERG9 DNA. ERG9 sequences amplified from genomic DNA by these two primers must represent ERG9 genes located at the actual chromosomal ERG9 locus, and will not amplify erg9a::HIS3 sequences that integrated at other chromosomal locations.

5

10

15

20

25

est es en la la la la la fill de la combinación de la supplementarion de la combinación del combinación de la combinació

The results showed two bands at 3.271 and 3.908 kb, indicating the presence in the diploid strains of one functional copy of the *ERG9* gene and one interrupted copy that is kb 637 bp larger due to the *HIS3* gene insertion.

Southern blot analysis also was performed to verify the erg94::HIS3 interruption in the diploids. Genomic DNA from a parental diploid strain carrying two normal copies of ERG9 gene was compared to three different transformants believed to carry one normal ERG9 gene and one disrupted ERG9 gene. The DNA was digested with either Acc I or Xba I, separated by gel electrophoresis, transferred to an Immobilon S membrane, and probed with specific probes to examine the ERG9 genes present. The probe in this case was a 1.4 kb fragment containing a portion of the ERG9 gene.

一个人,我们的一个人,我们就是一个人,我们就是一个人,我们就是一个人,我们就是一个人,我们就是一个人,我们就是一个人,我们是一个人,我们就是一个人,我们就是一个人,我们

·;

The probe used for Southern blot analysis of genomic DNA was prepared from the PCR amplified *ERG9* gene using oligonucleotides 250 *Bam* Up and 1712 *Xma* Lo (described above). Plasmid pJMB98-12 was used as template. PCR conditions were:

94 °C for 1 min. - 1 cycle 94 °C for 30 sec. 58 °C for 1 min 72 °C for 1 min. - 1 cycle 1 cycle

The amplified ERG9 DNA was purified and biotinylated, as described above. Approximately 1  $\mu g$  of biotinylated probe was used to hybridize to the blot.

Hybridization of the probe to the specific DNA bands 10 conditions identified stringent complementary sequence being present. For the parental diploid, CJ3AxCJ3B, a single band was seen at 2.1 kb for the Acc I digest and a single band at 2.8 kb was seen with the Xba I digest. The putative erg94::HIS3 knockouts each contained 15 bands at 2.1 kb and 1.3 kb for the Acc I two bands: digest; and bands at 2.8 kb and 3.4 kb for the Xba I These results indicated the presence of one copy digest. of the wild-type ERG9 gene along with an erg94::HIS3 disruption in the transformed diploids.

Attempts were then made to grow the haploid cells anaerobically on YPDE agar. Strains that are blocked in the ergosterol pathway can take up sterols under anaerobic

A transfer of the form of the contract of the

A STATE OF A STATE OF

10

25

conditions. Two of the spores grew rapidly under anaerobic conditions (ERG9, his-) and two grew very slowly  $(erg9\Delta::HIS3)$ . The spores of three of the strains erg94::HIS3 (KML505, KML510, and KML521) that anaerobically on plates were grown in liquid medium under anaerobic conditions and showed farnesol production. Upon further incubation of the original YPDE plates aerobically, it appeared that a few of the haploid strains that tested positive for farnesol production under anaerobic growth Three such viable spores (derived from were growing. KML505) arose after prolonged aerobic incubation. aerobically-growing strains, designated as BKY1-2D, BKY1-7C, and BKY1-8D, all produced farnesol under aerobic conditions.

The parent strain KML510 (a/α, ura3/ura3, his3/his3, trp1/trp1, leu2/leu2, upc2/upc2, ERG9/erg9Δ::HIS3) containing either pJMB98-12 or pRS316 were sporulated and tetrads were dissected onto YPDE plates. The plates were incubated under aerobic conditions, and the following patterns of spore growth were observed.

Tetrad analysis of KML510/pJMB98-12 were done with 20 tetrads. 16 tetrads gave rise to two viable, fast-growing spores and two nonviable spores. All viable spores were his, erg. Three tetrads gave rise to two viable, fast-growing spores, one viable, slow-growing spore, and one non-viable spore. The viable, fast-growing were all his,

20

and the second of the second o

The second secon

AND THE LOT THE THE STATE OF TH

erg\*. The viable, slow-growing spores were all his\*, erg\*. One tetrad did not give rise to any viable spores. All of the his\*, erg\* spores were also ura\*, indicating that pJMB98-12 did not segregate into these spores during meiosis. One of the his\*, erg\* spores was used for further studies, and was named BTY19-9C.

Tetrad analysis of KML510/pRS316 was done with 20 tetrads. 18 tetrads gave rise to two viable, fast-growing spores and two non-viable spores. Two tetrads gave rise to two viable, fast-growing spores, one viable, slow-growing spore, and one non-viable spore. All fast-growing spores were his, erg. All slow-growing spores were his, erg. All his, erg spores were also ura, indicated that pRS316 did not segregate into these spores during meiosis. One of the his, erg spores was studied further, and was named BTY20-2A.

To confirm that BTY19-9C and BTY20-2A did not carry the wild-type *ERG9* gene, a PCR experiment was conducted using genomic DNA isolated from the two strains, and the oligonucleotides VE104-5 and VE105-3.

5'oligo = VE104-5 = gac tct AGA AGC GGA AAA CGT ATA

.. :

3'oligo = VE105-3 = described above

VE104-5 contains sequences corresponding to position #11631

25 to 116541 of GenBank Accession #U00030 sequence.

The predicted PCR product size for a functional ERG9 gene was 2.23 kb, and for the  $erg9\Delta$ ::HIS3 disruption, 2.87 kb. Strains BTY19-9C and BTY20-2A had a PCR product of approximately 2.87 kb, which indicated the presence of the  $erg9\Delta$ ::HIS3 disruption.

Five strains (BKY1-2D, BKY1-7C, BKY1-8D, BTY19-9C and BTY20-2A) were evaluated for farnesol production in shake flasks. Strains BKY1-7C and BTY20-2A gave the best production of farnesol of the five strains, but BKY1-7C grew very slowly.

Transformants KML505, KML510, and KML521 transferred to sporulation medium. Tetrads were dissected onto YPDE and allowed to grow for extended periods of time under aerobic conditions to look for growth of additional spores beyond the anticipated 2:2 segregation (viable:nonviable). Two additional spores were viable after further incubation under aerobic conditions. two strains, BJY7-5D and BJY8-1A, produced farnesol in a tube screen.

Strains BJY7-5D and BJY8-1A were evaluated in shake flasks. BJY8-1A gave the best farnesol production (0.29 mg/ml, 4.7% based on cell dry weight) after 72 hours incubation. BJY7-5D gave 0.18 mg farnesol/ml, (3.5% based on cell dry weight).

25

The second secon

--;

5

10

15

Example 4

WO 00/01650 PCT/US99/15264

108

This example shows the overexpression of HMG CoA reductase in strains with and without a functional  $\it ERG9$  gene.

: - ;

Construction of the second second second on the second sec

Continues of the contin

HMG CoA reductase has been proposed to be the key enzyme regulating the flow of carbon through the isoprenoid 5 pathway. In S. cerevisiae, two genes, HMG1 and HMG2, code for the two isozymes of HMG CoA reductase, designated HMGlp Regulation of HMG CoA reductase is achieved and HMG2p. through a combination of transcriptional and translational regulation as well as protein degradation. The segments of 10 the HMG1 and HMG2 genes that encode the catalytic domains of the HMGlp and HMG2p isozymes have been cloned under transcriptional control of the strong promoter from the GPD (glyceraldehyde-3-phosphate dehydrogenase) plasmids containing these constructions (pRH127-3 and 15 pRH124-31, containing the catalytic domains of HMGlp and HMG2p, respectively) were obtained from R. Hampton, U.C. San Diego. Strains of S. cerevisiae overexpressing the catalytic domain of HMGlp were reported to have an elevated flow of carbon through the isoprenoid pathway. 20 This increased carbon flow was manifested as squalene and ergosterol overproduction (Donald, K.A.G., Hampton, R.Y., and Fritz, I.B., 1997, Effects of Overproduction of the Catalytic Domain of 3-Hydroxy-3Methylglutaryl Coenzyme A 25 Reductase on Squalene Synthesis in Saccharomyces

te versit in the september of the section of the se

cerevisiae. Applied and Environmental Microbiology 63:3341-3344).

# A. <u>HMG CoA Reductase Overexpression in Strains with a Functional ERG9 Gene</u>

In order to confirm that overexpressing HMG CoA 5 reductase would result in increased carbon flow through the isoprenoid pathway in the strains derived from ATCC 28383, similar to other strains of S. cerevisiae (Donald, et. al., 1997), the strain SWY5, a ura3 mutant of the parental strain ATCC 28383, and SWE23-E9, the erg9 repaired version 10 of EMS9-23 (strains described in Example 1.G. above), were transformed with plasmids pRH127-3 and pRH124-31. Transformations were performed using the LiOAc procedure (Gietz, et. al., 1995). Control strains carrying the empty 15 vector YEp352 were also constructed. Representative transformants were tested for squalene and ergosterol production in a shake flask experiment. Cells were grown in 50 ml SCE-ura medium at 30°C, with shaking at 180 rpm for 48 hours. At 24 hours, 10 ml of the culture was 20 withdrawn, and the cells harvested for HMGCoA reductase assays as described in Example I.D. At the end of the 48hour growth period, an aliquot of the cultures was used to inoculate flasks containing 50 ml YPD medium such that the starting  $OD_{600}$  of the cultures was 0.1. The cultures in YPD medium were grown for 72 hours at 30°C, with shaking at 180 25 rpm, and then analyzed for dry cell weight, squalene and

ergosterol accumulation. The extraction method used for this analysis was as follows. Ten ml of the culture was pelleted by centrifugation at 1,500  $\times$  g for 10 minutes. The cell pellet was resuspended in 1 ml of deionized water, and the cells were repelleted. 5 Cell pellets were resuspended in 1 ml of deionized water and disrupted by agitation with zirconium silicate beads (0.5 mm diameter). The broken cell suspension was saponified with 2.5 ml of a 0.2% solution of pyrogallol (in methanol) and 1.25 ml of 60% potassium hydroxide solution at 75 degrees C for 1.510 The samples were then extracted with 5 ml of hours. hexane, vortexed for 3 minutes and centrifuged at 1,000  $\times$ g for 20 minutes to separate the phases. The hexane layer was then analyzed by GC-MS as described in Example 1.B.

The data from this experiment are shown in Table 10.

Compared to the control strains carrying only the Yep352 vector, the strains that overexpress the catalytic domains of either HMGlp or HMG2p contained high levels of HMGCOA reductase activity and elevated levels of squalene.

However, neither of the strains overexpressing HMGlp or HMG2p contained significantly increased levels of ergosterol. Nevertheless, these data show that increasing the activity of HMG CoA reductase in the MBNA1-13 strain lineage increases the carbon flow through the isoprenoid pathway.

20 to 1

Administration of the contraction of the contractio

10

15

20

25

30

The second control of the control of

Table 10.

Effect of Amplified HMGCoA Reductase Activity on Squalene and Ergosterol Production in Strains Having a Normal
Isoprenoid Pathway

Strain/plasmid	Dry Cell Weight	Sc	qualene	Erg	HMG CoA Reductase	
	(g/L)	µg/ml	% dry wt.	µg/ml	% dry wt.	Activity (nmol/min/ mg)
SWY5/ YEp352	7.68	0.18	0.003	2.9	0.038	2.4
SWY5/ pRH127-3	6.82	3.50	0.051	5.2	0.076	52
SWY5/ pRH124-31	7.49	4.15	0.055	2.9	0.039	27
SWE23-E9/ YEp352	6.96	0.33	0.005	5.5	0.079	2.7
SWE23-E9/ pRH127-3	6.89	6.78	0.099	8.3	0.121	55
SWE23-E9/ pRH124-31	6.90	4.90	0.071	6.1	0.088	29

# B. HMG CoA Reductase Overexpression in an erg9 Mutant

Having shown that amplification of HMGlp or HMG2p increased carbon flow to squalene, whether overexpression of HMG1 or HMG2 would increase farnesol production in a strain carrying the erg9 mutation was tested. Strain SWE23-ΔE91 (described in Example 1.G.) was transformed with plasmids pRH127-3 or pRH124-31. Transformation of SWE23-ΔE91 was accomplished using the LiOAc transformation procedure (Gietz et al, 1996). Approximately 2.5 μg, of pRH127-3 or pRH124-31 DNA were used in each transformation. Transformants were selected on SCE-ura plates, and several were chosen and restreaked for purification on SCE-ura plates. To test the effect of amplified HMG CoA reductase

on farnesol production, representative transformants were grown for 48 hours in liquid SCE-ura medium. A control strain, SWE23-ΔE91/YEp352, was also included in the experiment. At the end of the 48 hours growth period, aliquots of the cultures were used to inoculate flasks containing 50 ml of YPDE medium such that the initial  $OD_{600}$ was 0.5. These cultures were grown for 72 hours at 30°C, with shaking at 180 rpm. At the end of the incubation period, samples were analyzed for dry cell weight and 10 farnesol concentration. To confirm that the HMG CoA reductase genes were being overexpressed in the transformants, 20 ml of the cultures grown in SCE-ura were harvested by centrifugation at 1500 x g for 10 minutes, and HMG CoA reductase activity measured using the permeabilized cell method described in Example I.D. The data from this 15 experiment are shown in Table 11.

Table 11. Effect of Elevated HMG CoA Reductase Activity on Farnesol Production in an erg9:.-HIS3 Mutant Grown in Shake Flask Cultures.

Strain/plasmid	Dry Cell Weight	Far	nesol	HMG CoA Reductase
	(g/L)			Activity (nmol/min/mg)
SWE23-ΔE91/ YEp352	3.31	222	6.7	7.5
SWE23-ΔE91/ pRH127-3	3.87	104	2.7	47.0
SWE23-ΔE91/ pRH124-31	3.48	104	3.0	36.0

25

20

i dekretimmen in vissiki biras omransaran saman sekelektiven menden dekretimiski keraliki keralimisekan in mensamen menamen a

....

. . .

In both SWE23- $\Delta$ E91/pRH127-3 and SWE23- $\Delta$ E91/pRH124-31, the levels of HMG CoA reductase activity were elevated.

30 However, the farnesol production in these strains was lower

than the control strain SWE23- $\Delta$ E91/YEp352. This unexpected result was observed several times in independent experiments.

Despite the failure of amplified HMG CoA reductase activity to increase farnesol production in an  $erg9\Delta$ ::HIS3 strain grown in shake flask cultures, the strains listed in Table 12 were tested for farnesol production in 1-L fermentors using the protocol described in Example 1.H. Under these conditions, the expected result was observed; the strains overexpressing HMG CoA reductase produced significantly more farnesol than the control strain. The data are summarized in Figure 6 and Table 12. The elevation of HMG CoA reductase activity in strains SWE23- $\Delta$ E91/pRH127-3 and SWE23- $\Delta$ E91 /pRH124-31 was confirmed by direct enzyme assay using the permeabilized cell method. This is illustrated by the reductase activities at specific time points during the fermentation (shown in Table 12).

Table 12. Effect of Elevated HMG CoA Reductase Activity on Farnesol Production in an erg94::HIS3 Mutant Grown in 1-L Fermentors.

Strain/plasmid	Time (hr.)	Dry Cell Weight	Fan	nesol	HMG CoA Reductase	
		(g/L)	g/L	% dry cell weight	Activity (nmol/min/mg)	
SWE23-ΔE91/YEp352	239	37.2	2.23	6.0	"4;1	
SWE23- ΔE91/pRH127-3	310	35.0	3.06	8.7	20	
SWE23- ΔE91/pRH124-31	261	31.7	3.05	9.6	14	

Example 5

10

15

20

25

:

This example describes the overexpression of various GGPP synthases in erg9 mutants.

In order to convert FPP produced in erg9 mutant strains to GGPP (the precursor of desired product, GG), the genes coding for various GGPP syntheses in erg9 mutants were overexpressed. The genes cloned for this purpose were the BTS1 gene from Saccharomyces cerevisiae, the crtE gene from Erwinia uredovora, the al-3 gene from Neurospora crassa, and the ggs gene from Gibberella fujikuroi.

Plasmids carrying these genes were constructed as follows. 10

To clone the BTSI1 gene, genomic DNA was prepared from S. cerevisiae strain S288C according to the method described in Sherman, et. al. (1986). The gene was amplified by PCR using the following two oligonucleotides.

15

5'oligo = VE100-5 gactctAGAGTTTACGAGTCTGGAAAATC (SEQ ID NO:8)

3'oligo = VE101-3 gtaggATCCATGGAATTGAGCAATAGAG (SEQ ID NO:9)

20

25

CHARLES OF CASILLAND SERVE \$

The PCR conditions were: 94°C, 3 minutes; 94°C, 1 minute; 52°C, 1 minute; 74°C, 1.5 minutes; 30 cycles; then 74°C, 7 minutes (1 cycle). The PCR product was digested with XbaI and BamHI and ligated into Xbal, BamHI digested pPGK315 to generate pTWM101. The plasmid pPGK315 contains the  $\mathcal{S}$ . cerevisiae PGK promoter and terminator separated by a

WO 00/01650 PCT/US99/15264

multiple cloning site. Cloning the *BTS1* gene into pPGK315 as described above placed the *BTS1* gene under control of the strong PGK promoter. Plasmid pPGK315 was constructed by digesting plasmid pRS315 with *Sac*II and *Sma*I, then treating with T4 DNA polymerase to create blunt ends. The plasmid was religated to generate pRS315-DSS. Plasmid pRS315DSS was then digested with *Xho*I and ligated with a 994 bp *Sa*II, *Xho*I fragment obtained from plasmid pPGKMCS that contained the PGK promoter and terminator separated by a multiple cloning site. Plasmid pPGKMCS was constructed by digesting pPGK (Kang et. al., 1990, Mol. Cell. Biol., 10:2582) with *Eco*RI and *Bam*HI, then ligating with the following two annealed oligonucleotides.

7. A

- The State Control of the Control

• •

10

20

25

5'oligo = AATTCCAAGCTTGCGGCCGCTCTAGAACGCGTG (SEQ ID NO:10)
3'oligo = GATCCACGCGTTCTAGAGCGGCCGCAAGCTTG (SEQ ID NO:11)

Plasmid pTWM110-11 was constructed by ligating a 2397 bp KpnI-SalI fragment containing the PGK promoter/BTS1/PGK terminator (obtained by digestion of PTWM110 with KpnI and SalI) into KpnI-SalI-digested YEp352.

To clone the *crtE* gene, genomic DNA was isolated from *E. uredovora* strain 20D3 using the PureGene genomic DNA Isolation Kit (Gentra Systems, Inc., Minneapolis, MN) The *crtE* gene was amplified using the genomic DNA and the following two oligonucleotides.

5'oligo = 20D3Up gaattcGTTTATAAGGACAGCCCGA (SEQ ID

NO:12)

3'oligo = 20D3Lo ctgcagTCCTTAACTGACGGCAGCGA (SEQ ID

NO:13)

5

Oligo 20D3Up contains sequences corresponding to position #206 to #224 of the Genbank Accession #D90087 sequence. Oligo 20D3Lo contains the reverse complement of sequences from position #1117 to #1136 of the same Genbank sequence 10 file. The amplified DNA was ligated into the SrfI site of pCR-Script SK(+) (Stratagene, La Jolla, CA) to generate plasmid pSW1-B. This plasmid was then digested with EcoRI and SacI, and the 973 bp fragment containing the crtE gene was purified and ligated into EcoRI-SacI digested pAD314-956 to generate plasmid pSW2B. Plasmid pSW2-B was digested 15 with BamHI to generate a 2199 bp fragment containing the ADH1 promoter, crtE coding sequence, and ADH1 terminator, and this fragment was ligated into BamH digested YEp352 to generate pSW4A, which placed the crtE gene in the orientation opposite to that of the URA3 gene in the 20 plasmid, and pSW4B, which placed the crtE gene in the same orientation as the URA3 gene.

Plasmid pADH313-956 was generated in the following manner. Plasmid pRS313 (Sikorski and Hieter, 1989) was digested with SacI and XbaI, treated with T4 DNA polymerase to create blunt ends, then relegated to generate plasmid

with the second of the second second

WO 00/01650 PCT/US99/15264

117

pDSX313. This plasmid was digested with SmaI and ApaI, treated with T4 DNA polymerase to create blunt ends, and then relegated to generate pDSXSA313. Plasmid pAAH5 (Ammerer, G., 1983, Meth. Enzymol. 101:192-201), which carries the ADH1 promoter and terminator separated by a HindIII site, was digested with HindIII, then ligated to the following two annealed oligonucleotides to introduce a multiple cloning site and create pAAH5-MCS.

5' oligo =MCS1 AGCTGAATTCGAGCTCGGGTACCCGGGCTCTAGAGTC
GACCTGCAGGCATGCA (SEQ ID NO:14)

3' oligo = MCS2 AGCTTGCATGCCTCCAGGTCGACTCTAGAGCC
CG GGTACCGAGCTCGAATTC (SEQ ID
NO:15)

15

A PCR reaction containing pADH313-MCS as template and the following two oligonucleotides was performed, and a 1232 bp PCR product containing the ADH1 promoter, multiple cloning site, and ADH1 terminator was obtained.

20

5'oligo = ADH1A gacggatCCGTGGAATATTTCGGATATCC (SEQ ID NO:16)

3'oligo = ADH1B ctcggatccGGACGGATTACAACAGGTATTGTCC (SEQ ID NO:17)

:

Oligo ADH1A contains sequences corresponding to position #16 to #37 of the Genbank Accession #V01292 sequence. Oligo ADH1B contains the reverse complement of sequences from position #2092 to #2116 of the same Genbank sequence file. The 1232 bp PCR product was digested with BamHI and ligated into BamHI digested pDSXSA313 to generate plasmid pADH313-956.

To clone the  $N.\ crassa\ al-3$  gene, genomic DNA was isolated from N. crassa strain ATCC 14692 using the method described by Borges et al. in the methods section of the Fungal Genetics Stock Center's site (www.kumc.edu/research/fgsc/fgn37/borges.html). The gene wasamplified by PCR using the following two oligonucleotides.

15

10

5

• :

. . .

5'oligo = VE118-5 cagaatTCACCATGGCCGTGACTTCCTCCTC (SEQ ID NO:18)

3'oligo = VE119-3 caagatctCATACATTCAATCCTCATGGACAC (SEQ ID NO:19)

20

25

Oligo VE118-5 contains sequences corresponding to position #1216 to #1240 of the Genbank Accession #U20940 sequence. Oligo VE119-3 contains the reverse complement of sequences from position #2576 to #2599 of the same Genbank sequence file. The amplified DNA was ligated into the SrfI site of pCR-Script SK(+) (Stratagene, La Jolla, CA) to

generate pSW7-1 and pSW7-2, two independent PCR clones of the al-3 gene. These two plasmids were then digested with EcoRl and BglII, and the 1393 bp fragment containing the al-3 gene was purified and ligated into EcoRI, BamHI digested pPGK (Kang et. al., 1990) to generate pSW9-1 and pSW9-2, with the al-3 sequence in each derived from pSW7-1 and pSW7-2, respectively.

.....

・ The Control of th

. .::

- }

5

20

25

To clone the ggs gene, genomic DNA was prepared from Gibberella fujikuoï strain ATCC 12617, using the same procedure described above for Neurospora. The ggs gene was amplified by PCR using the following two oligonucleotides.

5'oligo = VE120-5 gagaattCTTAACACGCATGATCCCCACGGC (SEQ ID NO:20)

3'-oligo = VE121-3 ctggatcCGTCAAATCCGTGAATCGTAACGAG
(SEQ ID NO:21)

Oligo VE120-5 contains sequences corresponding to position #607 to #630 of the Genbank Accession #X96943 sequence. Oligo VE121-3 contains the reverse complement of sequences from position #1908 to #1932 of the same Genbank sequence file. The amplified DNA was ligated into the SrfI site of pCR-Script SK(+) to generate pSW8-1 and pSW8-2, two independent PCR clones of the ggs gene. These two plasmids were then digested with EcoRI and BamHI, and the 1335 bp fragment containing the ggs gene was purified and ligated

:

officerunterestricities and the strategies of the strategies and the continues and the strategies of the strategies and the strategies are strategies are

.÷¢;

into EcoRI, BamHI digested pPGK to generate pSW10-1 and pSW10-2, with the ggs sequence in each derived from pSW8-1 and pSW8-2, respectively.

Strain EMS9-23 (ura3, erg9, described in Example 1.G.) was transformed with the plasmids described above using the 5 LiOAc method, and transformants were selected on SCE-ura Transformants were picked and restreaked on SCEplates. ura plates for purification. Representative transformants were tested for GG production. The strains were grown at 30°C for 48 hours in liquid SCE-ura medium, then used to 10 inoculate flasks containing YPDE medium, such that the initial  $OD_{600}$  was 0.5. These cultures were incubated at 30°C with shaking for 72 hours and analyzed for dry cell weight, farnesol and GG levels. A second set of flasks containing 20 ml of SCE-ura medium was also inoculated from the same 15 starting cultures and was grown for 48 hours. The cells from these flasks were harvested, washed with 10 ml 50~mMBisTris-Propane buffer, pH 7.0, and repelleted. The cell pellets were then used to prepare permeabilized cell suspensions for GGPP synthase assays. 20 The cells were permeabilized by resuspending in 1 ml of 50 mM Bis-Tris-Propane buffer, pH 7.0, containing 0.1% Triton X100, and frozen at 80°C until needed. After thawing, permeabilized cells were used for GGPP synthase assays. 25 The GGPP synthase assay mixture contained 0.05M Bis-Tris propane buffer, pH 7.0 (X $\mu$ l), 0.1M dithiothreitol (1 $\mu$ l), 1

Committee of the Commit

15

20

25

mg/ml FPP (5 μl), 1 mg/ml IPP (5 μl) and permeabilized cells (Y μl), where X + Y = 87 μl. A control reaction was included in which the FPP and IPP were omitted. The assay mixtures were incubated at 37°C for 20 minutes. 0. 1 ml of 2X glycine buffer (0.2M glycine, 2mM MgCl<sub>2</sub>, 2mM ZnCl<sub>2</sub>, pH 10.4) and 63 units of alkaline phosphatase (Sigma Chemical Co., St. Louis, MO) were added, and the mixtures were incubated for 60 minutes at 37°C. The mixtures were then extracted with 0.2 ml 1:1 hexane:ethyl acetate, and analyzed for GG by GC/MS. GGPP synthase activity is expressed as nmol GGPP formed/min/mg protein.

The dry cell weights, farnesol production, GG production and GGPP synthase activities for the strains are summarized in Table 13. The control strain, EMS923/YEp352, which lacks a cloned GGPP synthase, made 8.7% farnesol (based on dry cell weight) and essentially no GG. The four other strains, each of which overexpressed a different cloned GGPP synthase, produced approximately the same amount of farnesol as the control (8.0 - 9.74%) and produced levels of GG ranging from 0.62 - 1.73%.

Table 13. GG Production in Shake Flask Cultures of Strains Overexpressing Four Different Cloned GGPP Synthase Genes.

Strain	Cloned GGPP synthase gene	Dry cell weight (g/L)	FOH (% of dry cell weight)	GC (% of dry cell weight)	GGPP synthase activity (nmol/min/mg)
EMS9-23/YEp352	•	3.38	8.7	0.01	ND
EMS9-23/pTWM110-11	BTS1	3.12	8.98	1.73	0.065
EMS9-23/pSW4B	crtE	2.02	9.74	1.68	0.094
EMS9-23/pSW9-1	al3	3.38	8.0	0.62	0.032
EMS9-23/pSW10-2	ggs	3.16	9.3	1.0	0.03

The effect of amplification of GGPP synthase activity on GG production was further evaluated in I-L fermentors. Strain EMS9-23 was transformed with plasmid pTWMI10-11, carrying the cloned *S. cerevisiae BTS1* gene. Strain SWE23-AE91 (described in Example 1.G. above) was transformed with either Yep352 (vector control) or pSW4A-3 (an individual isolate of plasmid pSW4A, carrying the cloned *crtE* gene). Strains SWE23-AE91/YEp352, EMS9-23/pTWM110-11 and SWE23-AE91/pSW4A-3 were grown in 1-liter fermentors using the method described in Example 1.H., and growth, farnesol production and GG production were compared.

The results are shown in Figure 7 and Table 14. The growth of the three strains was similar. Strain SWE23- $\Delta$ E91/YEp352 produced 2.32 g/L farnesol in 236 hours, and did not produce any detectable GG. 15 EMS9-23/pTWM110-11 produced 2.1 g/L farnesol in 239 hours and also produced  $0.42~{
m g/L}~{
m GG}$  in the same time period. Strain SWE23- $\Delta$ E91/pSW4A-3 produced 2.47 g/L farnesol in 236 hours and also produced 0.59 g/L GG in the same period. 20 synthase activity in the control strain was below detectable limits. The production of GG by strains EMS9-23/pTWM110-11 SWE23-AE91/pSW4A-3 and correlated increased GGPP synthase activity.

10

The court of the court of the control of the contro

· ::::

and the second s

Table 14.

Growth, Farnesol and GG Production in Strains

Overexpressing GGPP Synthases and Grown in 1-L Fermentors

Strain/Plasmid	Time (hr.)	Dry Cell	F	Famesol		GG	GGPP Synthase
		Weight (g/L)	g/L	% Dry Cell Weight	g/L	% Dry Cell Weight	Activity (nmol/min/m g)
SWE23-ΔE91/YEp352	236	43.9	2.32	5.3	0	0	not detected
EMS9-23/pTWM110-11	239	41.9	2.10	5.0	0.42	1.0	0.2
SWE23-ΔE91/pSW4A-3	236	43.5	2.47	5.7	0.59	1.4	1.1

#### Example 6

This example illustrates the effect of overexpressing the *ERG20* gene which encodes FPP synthase.

To determine the effects of elevating FPP synthase

levels in erg9 mutants, the ERG20 gene coding for FPP

synthase from Saccharomyces cerevisiae was cloned for

overexpression. The ERG20 gene was amplified by PCR using

genomic DNA from S. cerevisiae strain S288C (prepared

according to the method described in Sherman et al., 1986).

and the following two oligonucleotides.

- 5' oligo = BamFPPUp ggccggatccATATTACGTAGAAATGGCTTCAG
  (SEQ ID NO:22)
- 3' oligo = XhoFPPLo gccgctcgagGGTCCTTATCTAGTTTG
  25 (SEQ ID NO:23)

Oligo BamFPPUp contains sequences corresponding to position #790 to #810 of the Genbank Accession # J05091 sequence. Oligo XhoFPPLo contains the reverse complement

WO 00/01650 PCT/US99/15264

124

of sequences from position #1891 to #1907 of the same Genbank sequence file. The PCR product was digested with BamHI and XhoI, and ligated into a vector containing the S. cerevisiae GPD (glyceraldehyde-3-phosphate dehydrogenase) promoter and PGK terminator. The promoter/terminator vector was obtained by digesting a plasmid containing the catalytic domain of the S. cerevisiae HMG2 gene cloned between the GPD promoter and PGK terminator, namely pRH124-31 (described in Example 4), with BamHI and SalI to remove the *HMG2* DNA. The 6.3 kb band corresponding to the promoter/terminator vector was purified and ligated to the 1129 bp fragment containing ERG20 to generate pJMB1931 and pJMB19-32. Plasmids pJMB19-31 and pJMB19-32 were used to transform strain SWE23-ΔE91 (ura3, his3, erg9Δ::HIS3) using the LiOAc method, and transformants were selected on SCEura plates. Transformants were picked and restreaked on SCE-ura plates for purification.

10

15

20 To determine the effects óf FPP synthase overexpression in erg9 mutant strains, representative transformants constructed as described above were grown in shake flask cultures and compared for growth, farnesol production, GG production and FPP synthase and GGPP synthase activities. The strains were grown with shaking at 30°C for 48 hours in liquid SCE-ura medium, then used to inoculate flasks containing YPDE medium, such that the initial  $OD_{600}$  was 0.5. These cultures were incubated at  $30^{\circ}C$ 

the exercise of the first of the control of the con

with shaking for an additional 72 hours and analyzed for dry cell weight, farnesol and GG levels. A second set of flasks containing 20 ml of SCE-ura medium was also inoculated from the same starting cultures and was grown for 48 hours. The cells from these flasks were harvested, washed with 10 ml 50 mM BisTris-Propane buffer, pH 7.0, and repelleted. The cell pellets were then used to prepare permeabilized cell suspensions for FPP and GGPP synthase assays. The cells were permeabilized by resuspending in 1 ml of 50 mM Bis-Tris-Propane buffer, pH 7.0, containing 10 0.1% Triton X100, and frozen at 80°C until needed. After thawing, the permeabilized cells were used for assays. The GGPP synthase assay mixture was the same as described in Example 5. The FPP synthase assay mixture contained 0.05 M 15 Bis-Tris propane buffer, pH 7.0 (X µl), 0.1M dithiothreitol (1  $\mu$ 1), 0.5M MgCl<sub>2</sub> (2 $\mu$ 1), 1 mg/ml IPP (6  $\mu$ 1), 1 mg/ml geranyldiphosphate (GPP) (6  $\mu$ l), and permeabilized cells (Y  $\mu$ l), where X + Y = 85  $\mu$ l. A control reaction was included in which the IPP and GPP were omitted. The assay mixtures 20 were incubated at 37°C for 15 minutes. 0. 1 ml of 2X glycine buffer (0.2M glycine, 2mM MgCl<sub>2</sub>, 2mM ZnCl<sub>2</sub>, pH 10.4) and 63 units of alkaline phosphatase (Sigma Chemical Co., St. Louis, MO) were added, and the mixtures were incubated for 60 minutes at 37°C. The mixtures were then extracted 25 with 0.2 ml 1:1 hexane:ethyl acetate, and analyzed for

Farnesol by GC/MS. FPP synthase activity is expressed as nmol FPP formed/min/mg protein.

The data presented in Table 15 show that overexpression of FPP synthase did not increase farnesol production, but did, unexpectedly, increase GG production in these shake flask cultures. The level of GG produced by SWE23-AE91/pJMB19-31 or SWE23-AE91/pJMB19-32 was even higher than observed for the strain (EMS923/pTWM110-11) overexpressing the *S. cerevisiae BTS1* (GGPP synthase) gene.

10

Table 15. GG production in erg9 mutants overexpressing FPP synthase and GGPP synthase

Strain/plasmid	Cloned gene	0				7
	(enzyme encoded)	Dry cell weight (g/L)	FOH (% of dry cell weight)	GG (% of dry cell weight)	FPP synthas e activity (nmol/m in/mg)	GGPF synthat se activity (nmole min/m
EMS9-23/ YEp352	-	3.32	9.24	0.17	2.3	Not detecte
EMS9-23/ pTWM110-11	BTS1 (GGPP synthase)	3.12	8.98	1.73	Not tested	0.19
SWE23-ΔE-91/ DJMB19-31	ERG20 (FPP synthase)	3.11	7.85	2.28	53.0	Not tested
SWE23-ΔE-91/ SJMB19-32	ERG20 (FPP synthase)	3.28	8.08	2.29	51.0	Not tested

20

25

15

n ni an an and de la company and an and an an and an and an an and an an an and an an an an an and an an an an

...

The effect of amplification of FPP synthase activity on GG production was further evaluated in 1-L fermentors. Strains SWE23- $\Delta$ E91/YEp352 (control), EMS9-23/pSW4A3 (crtE, GGPP synthase) and SWE23- $\Delta$ E91/pJMB19-32 (ERG20, FPP synthase) were grown in 1-liter fermentors using the method

WO 00/01650 PCT/US99/15264

127

described in Example 1.H., and growth, farnesol production, GG production and GGPP synthase activity were compared (Figure 8 and Table 16). The growth of the three strains was similar, although SWE23-ΔE91/pJMB19-32 lagged behind before growing at a rate similar to the other strains. Strain SWE23- $\Delta$ E91/YEp352 produced 2.31 g/L farnesol in 258 hours, and did not produce any detectable GG. EMS9-23/pSW4A3 produced 2.52 g/L farnesol and 0.57 g/L GG in 258 hours. Strain SWE23-AE91/pJMB19-32 produced 1.95 g/L farnesol in 258 hours and also produced 0.59 g/L GG in the The unexpected GG production by SWE23same period. ΔE91/pJMB19-32 correlated to increased GGPP synthase activity in this strain (see below).

The second of th

And the first of the control of the

12.

5

10

No GGPP synthase activity was detected in the control 15 strain SWE23-AE91 /YEp352. Strain EMS9-23/pSW4A3, expressing the E. uredovora crtE (GGPP synthase) gene showed relatively high GGPP synthase activity (1.7 nmol/min/mg in cells from the 258-hour time point). expected, strain SWE23-ΔE91/pJMB19-32, which overexpresses 20 the S. cerevisiae FPP synthase, contained FPP synthase activity that was elevated >10-fold at all time points across the fermentation compared to a control having only levels of FPPsynthase (data not Surprisingly, however, strain SWE23-AE91/pJMB19-32 also had elevated GGPP synthase activity (Table 16). This activity 25

undoubtedly accounts for the unexpected GG production by this strain.

The elevated GGPP synthase activity detected in strain SWE23-ΔE91/pJMB19-32 could be а result of the overexpression of FPP synthase inducing the activity of the GGPP synthase (the BTS1 gene product). It is also possible, however, that the FPP synthase has some low level of GGPP synthase activity which is revealed in this strain because of the high degree of overproduction of the FPP synthase.

Table 16. Effect of Amplified FPP Synthase on Growth, Farnesol and GG Production of Strains Grown in 1-L Fermentors

Strain/plasmid	Time (hr.)			Farnesol		GG	GGPP Synthase
		(9/2)	g/L	% of Dry Cell Weight	g/L	% of Dry Cell Weight	Activity (nmol/min mg)
SWE23-ΔE91/ Yep352	258	42.2	2.31	5.5	0	0	Not detected
EMS9-23/pSW4A3	258	44.3	2.52	5.3	0.57	1.28	1.7
SWE23-ΔE91/ DJMB19-32	258	41.1	1.95	4.7	0.55	1.34	1.0

20

10

15

# Example 7

and the second s

This example evaluates several farnesol extraction procedures.

1

1

21 In the first experiment, a comparison was made between 25 extraction of the whole broth (cells plus medium) and separate extractions of the cell pellet and medium under

various conditions for MBNA1-13 (farnesol producer) and ATCC 28383 (ergosterol producer) (see Example 1). A 10 ml sample of culture was extracted generally as described in Example 1, but with the changes indicated in Table 17 below. Method 1 in Table 17 is the same as the extraction method described in Example 1. It was found that, for farnesol extraction, a whole broth extraction was just as efficient as a separate cell and medium extraction for methods 1, 2, 3, 5 and 7. The most farnesol was extracted by method 5, which is just a 2 ml addition of 0.2% pyrogallol in methanol prior to extracting the whole broth into hexane. The second highest extraction was method 1.

TABLE 17

1	ction hod	pyrogallol 0.2% in MeOH	60% KOH in dH2O	Incubation 75°, 1.5h	Hexane
	1	2ml	1ml	yes	5ml
	2	2ml	1ml	no	5ml
	3	2ml	0	yes	5ml
	4	0	1ml	yes	5ml
	5	2ml	0	no	5ml
	6	0	1ml	no	5ml
	7	0	0	no	5ml

Next, experiments were conducted to determine the

25 effects of the type of extraction solvent (method 1, whole
broth), times used for extraction (method 1, hexane
extraction, whole broth), and the amount of methanol added
prior to extraction (method 1, hexane extraction, whole

130

broth). The results are presented in the Tables 17-19 below.

Table 17

Solvent	Farnesol (ng)
Hexane	3273
Chloroform	2262
Ethyl acetate	3549
N-heptane	3560
Hexadecane	
Dodecane	Not determined* 3529
Toluene	1055
Carbon tetrachlor	
Isobutyl Alcohol	2892
1-Octanol	1814

\* Solvent peak coeluted with farnesol, making quantification of farnesol impossible using this method. making

20

: ;

Table 18

Vortex time (min)	Farnesol (ng)	
0	204	
0.25	2794	
0.5	2691	
1.0	2894	
1.5	3302	
2.0	3348	
2.5	3357	
3.0	3545	
3.5	3535	

\*\*

131

Table 19

	Methanol volume (ml)	Farnesol (ng)
	0	3440
5	0.2	2820
	0.4	3000
	0.6	3440
	0.8	3690
	1.0	3730
10	1.2	4580
	1.4	4350
	1.6	4020
	1.8	3880

- Further work was done to optimize and simplify the extraction procedure for farnesol, and to adapt the procedure for extraction of GG from fermentation broths.

  This work resulted in the final extraction protocol described below.
- Whole fermentation broth is used undiluted or diluted appropriately with water to a final volume of 2.0 ml in a 15 ml teflon capped glass test tube.
  - 2. 2.0 ml of hexane is added.
- 25
   2.0 ml of methanol is added.

- 4. The tube is vortexed at high speed for 3.5 minutes.
- 5. The sample is centrifuged at 2,800 rpm in a table top centrifuge for 25-30 minutes to separate the phases.

WO 00/01650 - PCT/US99/15264

132

6. The supernatant (organic phase) is removed and placed in a 2.0 ml teflon capped glass GC/MS vial for determination of farnesol and GG by GC/MS.

#### Example 8

The following example demonstrates the effect of HMG CoA reductase amplification on GG production by a strain over-expressing GGPP synthase.

In this experiment, a strain was constructed that contained a single copy of a plasmid integrated into its genome that allows the cells to over-express GGPP synthase. The integrating plasmid is known as pSW35-42, and was constructed as follows. Plasmid pSW4A (see Example 5) was digested with BamHI to generate a 2199 bp fragment containing a fusion of the ADH1 promoter, crtE coding sequence, and ADH1 terminator. This fragment was then ligated into BamHI digested YIp351 (Hill et al, 1986, Yeast/E. coli Shuttle Vectors with Multiple Unique Restriction Sites, YEAST 2:163-167) to generate pSW35-42.

plasmid was digested with the restriction endonuclease BstEII to introduce a single cut within the LEU2 gene. The linearized plasmid was purified and used to transform strain SWE23-DL1 using the LiOAc method. Transformants in which pSW35-42 had integrated at the LEU2 locus were selected on medium lacking leucine. One of the resulting transformed strains is referred to as SWE23-DL1::pSW35-42.

This strain was then transformed with either YEp352 (an empty vector control, Hill et al, 1986, YEAST 2:163-167) or with pRH124-31 (contains the catalytic domain of the HMG2 see Example 4), which resulted in SWE23-DL1::pSW35-42/YEp352 and SWE23-DL1::pSW35-42/pRH124, respectively. Strain SWE23-DL1::pSW35-42/YEp352 over-expresses GGPPsynthase while SWE23-DL1::pSW35-42/pRH124 over-expresses GGPP synthase and HMG CoA reductase.

10 Fermentation experiments of strains SWE23-DL1::pSW35-42/pRH124 and SWE23-DL1::pSW35-42/Yep352 were conducted to compare the GG production by these two strains. The strains were tested for GG production in 1-L fermentors using the protocol described in Example 1.H. 15 The fermentation data are presented in Table 20. experiment shows that the fermentation of SWE23-DL1::pSW35-42/pRH124 accumulated more GG than the fermentation of SWE23-DL1::pSW35-42/Yep352, and demonstrates that elevation of HMG CoA reductase activity in a strain designed to produce GG resulted in a further 20 elevation of GG levels as compared to a similar strain with un-amplified HMG CoA reductase.

5

134

TABLE 20

		Dry Cell				
	·	Weight				
	Strain	@192 hr Famesol @192 hr			GG @192 hr	
		g/l	g/l	% dry wt.	g/l	% dry wt.
5	SWE23-ΔL1::pSW35-42/Yep352	41.4	2.04	4.9	0.30	
	SWE23-AL1::pSW35-42/pRH124	44.0	2 27		0.30	0.72
•		77.0	3.27	7.4	0.60	1.36

A second approach to achieve over-expression of HMG CoA reductase and GGPP synthase in the same strain was 10 accomplished by cloning both genes into a high copy-number yeast vector, and transforming this plasmid into an erg9 mutant strain. The plasmid used for this purpose is referred to as pSW46-1, and this was constructed as follows. Plasmid pSW4A (see Example 5) was digested with 15 EcoRI and SacI and the 0.9 kb fragment containing the crtE gene was purified and ligated into EcoRI, SacI digested pADH313-956 to generate pSW38-10. Two regions of this plasmid were deleted by digestion with restriction enzymes, filling the ends of the DNA using Pfu polymerase, and 20 ligating to reform the circular plasmid. The regions deleted in this manner were between the NdeI and SpeI sites, and between the HindIII and PstI sites. The resulting plasmid is referred to as pSW43-5. pSW43-5 was digested with BamHI, and the resulting 2199 bp 25

。 "全国的时候,我们是是一个时间,我们是一个时间,我们是一个时间,我们是一个时间,我们是一个时间,我们是一个时间,我们是一个时间,我们是一个时间,我们是一个一个

10

15

fragment containing the ADH1 promoter, crtE gene, and ADH1 terminator (referred to as the ADHp/crtE/ADHt fragment) was purified and ligated into the BamHI site of YEp352. resulting plasmid is referred to as pSW44-17, and differs from pSW4A in that it contains one instead of two PstI sites.

Plasmid pRH124-31 was digested with XbaI and PstI and the 3.2 kB fragment containing the GPD promoter, HMG2 catalytic domain gene, and the PGK terminator (referred to as the GPDp/HMG2cat/PGKt fragment) was cloned into XbaI, PstI digested pSW44-17 to generate pSW46-1. This plasmid replicates to high copy number in yeast and contains both HMG2 and crtE genes, providing for over-expression of HMG CoA reductase and GGPP synthase. Plasmid pSW46-1 was transformed into the erg9 mutant strain SWE-DE91, and URA+ transformants were isolated. Several of the resulting transformants were tested in a shake flask experiment and were compared to a strain that over-expresses only GGPP synthase (EMS9-23/pSW4A). The results from that experiment are presented in Table 21, and demonstrate that higher 20 levels of GG accumulate in strains that over-express both HMG CoA reductase and GGPP synthase when compared to a strain that over-expresses only GGPP synthase.

The second of th

20

25

136

04	TABLE	21		
Strain	Over-expressed Genes	Dry Cell Wt.	GG	
			mg/ml	% Dry Wt.
SWE23-ΔE91/YEp352	control	4.35	0.0007	0.02
EMS9-23/pSW4A	GGPP synthase	2.82	0.0469	1.66
SWE23-ΔE91/pSW46-1	GGPP synthase HMG CoA reductase	3.45	0.0866	2.45

These data support the idea that over-expression of HMG CoA reductase in a strain that is capable of producing elevated levels of GG leads to a further increase in the amount of GG produced.

#### Example 9

The following example describes the production of more stable strains that over-exress HMG CoA reductase.

As described in Example 4, strains were constructed that over-expressed HMG CoA reductase due to the presence of high-copy number replicating plasmids containing the HMG1cat or HMG2cat genes. Since replicating plasmids can frequently be lost during cell division, this mitotic instablity of the replicating plasmids can lead eventually to cultures with a high proportion of cells containing only normal HMG CoA reductase levels. In order to obtain more stable strains that over-expressed HMG CoA reductase, copies of the gene coding for the catalytic domain of HMG2p were integrated into the genome of strain SW23B. This was accomplished by first constructing a plasmid that allowed for multiple integrations of the HMG2 gene into the spacer

15

20

region of the rRNA gene. This approach is modeled after the rDNA integration method described by Lopes et al, 1989 (Lopes, T. S., Klootwijk, J., Veenstra, A. E., van der Aar, P. C., van Heerikhuizen, H., Raue, H. A., and Planta, R. J. 1989. High-copy-number integration into the ribosomal DNA of Saccharomyces cerevisiae: a new vector for high-level expression. Gene 79:199-206).

PCR was used to amplify two regions of the rDNA locus that lie in the intergenic region between the gene coding for the 35S rRNA and the gene coding for the 5S rDNA, referred to here as the rDNA spacer region. The oligonucleotides used to amplify the first of the two rDNA spacer region fragments contained sequences corresponding to bases # 11161 to #11130 and the reverse complement of #10311 to #10330 of Gene Bank Accession #273326. oligonucleotide sequences are listed below. The lower case letters are used to indicate bases that were altered or added to create restriction endonuclease recognition sites, which are indicated in parentheses following oligonucleotide sequence.

#### SEO ID NO:24:

25 SEQ ID NO:25:

:

R7SacII Up 5'-ccgcggGCCGGAAATGCTCTCTGTTC-3'
(SacII)

The DNA fragment generated from PCR amplification using these two oligonucleotides is referred to herein as the R6/R7 fragment. The R6/7 fragment generated by PCR was cloned initially into the plasmid pCR-Script to generate pSW48-1, then cut from this plasmid by digestion with XbaI and SacII. The resulting 759 bp fragment was then cloned into XbaI, SacII digested pBluescript SK- (Stratagene) to generate pSW49-1.

The oligonucleotides used to amplify the second rDNA spacer region fragment contained sequences corresponding to bases #11247 to #11272 and the reverse complement of #12054 to #12072 of Gene Bank Accession #Z73326. The sequences of these oligonucleotides are listed below.

#### SEO ID NO:26:

R5Sal UpB 5'CACgtCgACCATTCAAACTTTACTAC-3' (SalI)

20 <u>SEO ID NO:27</u>:

પાસે જ 🗼

Portugues, organisation con construction and the second second second second second second second second second

. . . .

R4ApaI LoB 5'-GAGGGCccGGTCCAGACAT-3' (ApaI)

The DNA fragment generated from PCR amplification using the two oligonucleotides listed above is referred to herein as the R4/R5 fragment. The R4/R5 fragment generated

- - - XXX

والمساوية والمحاسبين والأراف فيجالهم

by PCR was digested with ApaI and SalI, and ligated into ApaI, SalI digested pSW49-1 to generate pSW52-11.

PCR was used to amplify the TRP1 gene such that the gene carried an incomplete promoter. The incomplete promoter was intended to reduce expression of the TRP1 gene, and thereby provide a means of selection for high copy number integration of the final expression cassette. The oligonucleotides used to the TRP1 gene contained sequences corresponding to bases #53 to #73 and the reverse complement of #804 to #823 of Gene Bank Accession #J01374. The oligonucleotide sequences are listed below.

#### SEO ID NO:28:

TRP1 SmaUp 5'-cccgggTATTGAGCACGTGAGTATACG-3'

15 (SmaI)

The state of the second subsection is a second seco

#### SEO ID NO:29:

TRP1 BamLo 5'-ggatccGGCAAGTGCACAAACAATAC-3'
(BamHI)

In the next step, pSW50-1 was digested with BamHI and SmaI, and the resulting 779 bp TRP1 fragment was purified. Plasmid pRH124-31 was digested with PstI and SmaI to generate a 3261 bp fragment containing the GPD promoter, HMG2 cat gene, and the PGK terminator (referred to as the GPDp/HMG2cat/PGKt fragment), and this fragment was purified. The TRP1 fragment and the GPDp/HMG2cat/PGKt

fragment were ligated into *PstI*, *BamHI* digested pSW52-11 in a three fragment ligation to generate pSW58-77 and pSW58-45.

DNA fragment containing the R6/R7-TRP1-GPD The p/HMG2cat /PGK t-R4/R5 gene fusions was cut from pSW58-77 5 by digestion with the restriction endonucleases KpnI and The 5671 bp fragment corresponding to the SacI. integrating construct was purified and used to transform strain SW23B. Transformants were selected on SCE-trp medium. Strains isolated in this manner were screened for 10 elevation of HMG CoA reductase activity and by Southern blot analysis for elevation of HMG2 gene copy number. Strains were identified that carried one copy of the integrating construct, two copies of the integrating construct, three copies of the integrating construct, and 15 eight copies of the integrating construct, and are referred as SW23B#19, SW23B#31, SW23B#40, and SW23B#74, respectively. Table 22 gives the specific activity of HMG CoA reductase as determined by in vitro enzyme assays, and copy number of the HMG cat gene as determined by Southern 20 blotting. The HMG CoA reductase assay was previously described (Quain, D. E. and Haslam, J. M. 1979. The Effects of Catabolite Derepression on the Accumulation of Steryl Esters and the Activity of  $\beta$ -Hydroxymethylglutaryl-CoA Reductase in Saccharomyces cerevisiae. J. Gen. Microbiol. 25 111:343-351).

ominent e es Salin our e renenantemente establishes en establishes establishes establishes en en en

TABLE 22

Strain	HMG CoA Reductase	GPDp/HMG2cat/PGKt
	nmol/min mg	copies/cell
SW23B	5.26	0
SW23B#19	14.53	1
SW23B#31	37.47	2
SW23B#40	50.33	3
SW23B#76	59.04	8

15

20

25

5

These strains require exogenously supplied leucine and uracil for growth due to the *leu2* and *ura3* mutations in these strains. To eliminate the need to supply these nutrients during fermentation experiments, the strains were transformed with a plasmid, pTWM138, containing functional copies of *URA3*, *LEU2*, and *TRP1*. The presence of this plasmid in these strains allowed the strains to grow without leucine and uracil supplementation.

Fermentation experiments were carried out to compare farnesol production by these strains. Also included in this experiment was the strain SWE23-DE91/pRH124-31 which contains the GPDp/HMG2cat /PGKt gene fusion on a high copy number plasmid (see Example 4.B). The strains were tested for farnesol production in 1-L fermentors using the protocol described in Example 1.H, and the data from this experiment are presented in Table 23.

142

TABLE 23

Strain	Genes Amplified	Ferm Time	Dry Cell Weight	- Fa	mesol
· · · · · · · · · · · · · · · · · · ·	copy no.	hr	g/l	g/I	% Dry Cell Wt.
SW23B/pTWM138	control	216	53.3	3.25	6.10
SW23B#19/pTWM138	HMG2 cat 1 copy	192	52.4	4.58	8.74
SW23B#74/pTWM138	HMG2 cat 8 copies	216	43.5	4.70	10.80
SW23B/pRH124-31	HMG2 cat >20 copies	192	43.8	4.89	11.16

15

5

These data support the idea that strains with elevated levels of HMG CoA reductase produce more farnesol than a strain with normal levels of HMG CoA reductase. also indicate that a strain containing eight integrated copies of the HMG2cat gene produce essentially as much farnesol as
extrachromosom
with strain SW
integrated copy
20 than the contra
with more copi
strains conta
accumulated me
with normal le
25 suggests that a
carbon flux in
enzyme activity a strain that carries more than farnesol as extrachromosomal copies of the HMG2cat gene as is the case with strain SW23B/pRH124-31. A strain containing a single integrated copy of the HMG2 cat gene produced more farnesol than the control strain, but slightly less than strains with more copies of the HMG2cat gene. In addition, the strains containing elevated HMG CoA reductase levels accumulated mevalonate in the culture while the strains with normal levels of HMG CoA reductase did not. suggests that a step downstream of HMG CoA reductase limits carbon flux in the pathway once the HMG CoA reductase enzyme activity has been elevated (see Example 10). Carbon

## SUBSTITUTE SHEET (RULE 26)

WO 00/01650 PCT/US99/15264

143

flux through the pathway is restricted by the activity of one of the enzymes downstream of HMG CoA reductase resulting in mevalonate accumulation in the medium.

## Example 10

10

15

20

25

the region of the second of th

. .:

•

This example shows the effects of over-expression of multiple isoprenoid pathway genes in a strain that has an erg9 mutation and elevated levels of HMG CoA reductase.

As shown in Examples 4 and 9, elevation of HMG CoA reductase levels led to higher carbon flux through the isoprenoid/sterol pathway. Over-expression of other isoprenoid pathway genes in strains containing amplified HMG CoA reductase may further increase carbon flux through this pathway. Amplification of isoprenoid pathway genes in strains that have elevated levels of HMG CoA reductase as well as a defective erg9 gene may result in further elevation of farnesol levels. Also, amplification of isoprenoid pathway genes may result in further elevation of GG levels in strains that have a defective erg9 gene and have elevated levels of HMG CoA reductase and GGPP synthase.

To test these ideas, plasmids were constructed that allowed for the over-expression of multiple isoprenoid pathway genes. One of the plasmids provided for the over-expression of mevalonate kinase, phosphomevalonate kinase, and diphosphomevalonate decarboxylase, coded by the ERG12, ERG8, and ERG19 genes respectively. This plasmid is

WO 00/01650 PCT/US99/15264

144

referred to as pSW77-69, and was constructed from DNA fragments obtained from a number of plasmids containing single isoprenoid pathway genes. The construction of those plasmids is described first.

PCR was used to amplify the ERG12 gene for cloning. 5 The oligonucleotides used to amplify the ERG12 gene contained sequences corresponding to bases #2827 to #2846 and the reverse complement of #5247 to #5229 of Gene Bank Accession #Z49809. The sequences of the oligonucleotides are given below. The lower case letters 10 are used for bases that were altered or added to create restriction endonuclease recognition sites, which are indicated in parentheses following the oligonucleotide sequence.

15

SEQ ID NO:30:

E12.4SN 5'-CCAAATATAACtCGAGCTTTG-3 (XhoI)

SEO ID NO: 31:

E12.SALI3 5'-GCAAAGTcCaCCACCGCAG-3 (SalI)

20

Lister Contraction of the Contra

The ERG12 gene was amplified using the two oligonucleotides E12.4SN and E12.SALI3 and genomic DNA from strain ATCC 28383. The resulting DNA was cloned into pCR-Script at the SfrI site to generate pSW68.

The oligonucleotides used to amplify the *ERG19* gene contained sequences corresponding to bases #911 to #937 of

Gene Bank Accession #271656 and the reverse complement of bases #1930 to #1962 of Gene Bank Accession #271658. The sequences of the two oligonucleotides are given below.

# 5 <u>SEO ID NO:32</u>:

E19 SMAI

5'-GCCACGTGCCCCCGGGTTTCTCTAGCC-3'

(SmaI)

SEQ ID NO:33:

E19 SACI3

5'-GGAAAAGagCtCGATAATTATTGATGATAGATC-3'

10 (SacI)

15

20

The ERG19 gene was amplified using the two oligonucleotides E19 SMAI, E19 SACI3, and genomic DNA from strain ATCC 28383. The resulting DNA was cloned into pCR-Script at the SfrI site to generate pSW69.

The oligonucleotides used to amplify the *ERG8* gene contained sequences corresponding to bases #2729 to #2749 and the reverse complement of #5177 to #5196 of Gene Bank Accession #Z49939. The sequences of the two oligonucleotides are given below.

## SEQ ID NO:34:

E8.2135N

5'-CCGTTTTGGATCCTAGATCAG-3'

(BamHI)

(SmaI)

SEQ ID NO:35:

25 E8SMAI3

5'-gttcccGGGTTATTGTCCTGCATTTG-3'

...

., 15.1907.

Control to the control of the contro

The *ERG8* gene was amplified using the two oligonucleotides E8.2135N, E8SMAI3, and genomic DNA from strain ATCC 28383. The resulting DNA was cloned into pCR-Script at the *SfrI* site to generate pSW71.

Plasmid pSW71 was digested with BamHI and SmaI, and the resulting 2459 bp fragment containing the ERG8 gene was purified. Plasmid pSW69-3 was digested with SmaI and SacI, and the resulting 2239 bp fragment containing the ERG19 gene was purified. The high copy number yeast vector YEp352 (containing a URA3 selection marker) was digested with BamHI and SacI and purified. The three purified DNA fragments were ligated together to generate pSW76-11.

Next, pSW68 was digested with SalI and XhoI and the resulting 2400 bp band containing the ERG12 gene was purified and ligated into SalI digested pSW76-11 to generate pSW77-69. This plasmid contains ERG12, ERG8, and ERG19, and provides for over-expression of mevalonate kinase, phosphomevalonate kinase, and diphosphomevalonate decarboxylase.

Another plasmid provided for the over-expression of mevalonate kinase, phospho-mevalonate kinase, diphosphomevalonate decarboxylase, and IPP isomerase, coded by ERG12, ERG8, ERG19, and IDI1 genes respectively. This plasmid is referred to as pSW78-68, and was constructed as follows. The IDI1 gene was amplified by PCR for cloning. The oligonucleotides used to amplify the IDI1 gene

WO 00/01650

contained sequences corresponding to bases #19577 to #19604 and the reverse complement of #17477 to #17502 of Gene Bank Accession #U43503. The sequences of the two oligonucleotides are given below.

5

## SEQ ID NO: 36:

ISO SACI5 5'-AAGAGCtcATCTGATAATAGATCAAGCG-3' (SacI)

## SEQ ID NO: 37:

ISO SACI3 5'-AGGAGCTCAACGACAATAAATGGCTG-3' (SacI)

10

25

:-::

The IDI1 gene was amplified using the oligonucleotides ISO SACI5, ISOSACI3, and genomic DNA from strain ATCC 28383. The resulting DNA was cloned into pCR-Script at the SfrI site to generate pSW73. pSW73 was digested with SacI and the resulting 2117 bp 15 fragment containing the IDI1 gene was ligated with SacI digested pSW77-69 to generate pSW78-68. This plasmid contains ERG12, ERG8, ERG19, and IDI1, and provides for over-expression of mevalonate kinase, phosphomevalonate 20 kinase, diphosphomevalonate decarboxylase, IPP isomerase.

Another plasmid provided for the over-expression of acetoacetyl CoA thiolase and HMG CoA synthase, coded by the *ERG10* and *ERG13* genes, respectively. This plasmid is referred to as pSW79-29, and was constructed as follows.

PCR was used to amplify the ERG13 and ERG10 genes for cloning. The oligonucleotides used to amplify the ERG13 gene contained sequences corresponding to the reverse complement of bases #21104 to #21127 and bases #18270 to #18292 of Gene Bank Accession #250178. The sequences of the two oligonucleotides are given below.

# SEQ ID NO:38:

E13 XBAI5 5'-GTCCTctAGATCTTGAATGAAATC-3' (XbaI)
SEO ID NO:39:

10 E13 SACI3 5'-CTTTGAGCtcGTACAAGAAGCAG-3' (SacI)

The *ERG13* gene was amplified using the two oligonucleotides E13 XBAI5, E13 SACI3, and genomic DNA from strain ATCC 28383. The resulting DNA was cloned into pCR-Script at the *SfrI* site to generate pSW72.

The oligonucleotides used to amplify the *ERG10* gene contained sequences corresponding to bases #4073 to #4093 and the reverse complement of #6542 to #6565 of Gene Bank Accession #U36624. The sequences of the two oligonucleotides are given below.

## SEQ ID NO: 40:

20

in and the second se

E10 HIND5 5'-CTAAGCttTGCGCCCGTGAAG-3' (HindIII)

SEQ ID NO:41:

25 E10 XBAI3-2 5'-GTTCTAGAAGTTTTCAAAGCAGAG-3'
(XbaI)

20

25

en est en en en en entre en entre de la companya de la contracta de la contracta de la companya de la companya

·- i

٠.

The *ERG10* gene was amplified using the two oligonucleotides E10 HIND5, E10 XBAI3-2, and genomic DNA from strain ATCC 28383. The resulting DNA was cloned into pCR-Script at the *SfrI* site to generate pSW70.

5 Plasmid pSW70 was digested with XbaI and HindIII, and the resulting 2482 bp fragment containing the ERG10 gene was purified. Plasmid pSW72-4 was digested with XbaI and SacI, and the resulting 2850 bp fragment containing the ERG13 gene was purified. The two purified DNA fragments were then ligated together with SacI, HindIII digested YEp351 (LEU2 selectable marker) to generate pSW79-30. This plasmid contains the ERG13 and ERG10 genes and allows for the over-expression of acetoacetyl CoA thiolase and HMG CoA synthase.

Strain SW23B#74 (contains eight integrated copies of the HMG2 cat gene, see Example 9) was transformed with pSW77-69 and pSW78-68, and transformants were selected on SCE-ura medium. The resulting strains are referred to as SW23B#74/pSW77-69 and SW23B#74/pSW78-68, respectively. These strains require added leucine for growth due to the leu2 mutation. To eliminate the need to supplement these strains with leucine during fermentation experiments, they were transformed with a linear fragment of DNA containing a functional LEU2 gene, and LEU+ transformants were isolated. These strains are referred as SW23B#74L/pSW77-69 and SW23B#74L/pSW78-68, respectively.

SW23B#74 was also transformed with pSW79-30, and transformants were selected on SCE-leu medium. SW23B#74/pSW79-30 requires uracil since it contains a mutation in the ura3 gene. To eliminate the need to supplement these strains with uracil during fermentation experiments, this strain was transformed with a linear fragment of DNA containing a functional URA3 gene, and URA+ transformants were isolated. This strain is referred to as SW23B#74U/pSW79-30.

SW23B#74 was also transformed with both pSW78-68 and pSW79-30, and transformants were isolated that were capable of growing on SCE-ura,-leu medium indicating that the transformants contained both plasmids. The resulting strain is referred to as SW23B#74/pSW78-68/pSW79-30.

Fermentation experiments were carried out with the strains described above to examine the effect of these gene amplifications on farnesol production. The strains were tested in 1-L fermentors using the protocol described in Example 1.H, and data from these experiments are presented in Table 24.

TABLE 24

Strain	Genes Amplified	Ferm. Time	Dry Cell Weight	Famesol		Mevalonate	
C) Poop #7.44		(hr)	g/l	g/l	% Dry Wt.	g/l	% Dry
SM23B#74/ pTWM138	HMG2cat	215	45.5	4.95	10.88	0.2	Wt. 0.4
SW23B#74L/ pSW77-69	HMG2cat, ERG8, ERG12, ERG19,	287	41.6	4.67	11.23	0	0
SW23B#74L/	HMG2cat,	215	46.4	4.87	10.50	0	0

ontoniones on the son of the section of a material and the section of the section

·÷.

pSW78-68	ERG8, ERG12, ERG19, IDI1						
SW23B#74U/ pSW79-30	HMG2cat, ERG10, ERG13	215	46.1	4.63	10.04	5.4	11.7

10

15

20

25

and and application and applicate the first training of the particular applications and the first training and the second applications and the second applications and the second applications and the second applications are second applications are second applications.

172.5

These data show that a strain which over-expresses HMG CoA reductase accumulates the isoprenoid pathway intermediate mevalonate in the culture medium. mevalonate accumulation is not observed in strains with normal levels of HMG CoA reductase, this demonstrates that carbon flux through the isoprenoid pathway has been increased by HMG CoA reductase amplification to the point where another step subsequent to HMG CoA reductase limits the conversion of pathway intermediates. Furthermore, over-expression of the first three enzymes in isoprenoid pathway, namely acetoacetyl CoA thiolase, HMG CoA synthase, and HMG CoA reductase (coded by ERG 13, ERG10, and HMG2cat, respectively) led to even higher accumulation of mevalonate in the medium. This demonstrates that carbon flux into the isoprenoid pathway has been increased further by amplification of the first three steps, and emphasizes that one of the enzymes downstream of HMG CoA reductase limits conversion of isoprenoid pathway intermediates. Since mevalonate serves as a precursor to farnesol and GG, the modifications described above can be used to increase carbon flux into the isoprenoid pathway, and, if the mevalonate can be more

WO 00/01650

15

20

25

efficiently metabolized, can lead to increased farnesol and GG accumulation.

In regard to this last point, enzymes downstream of HMG CoA reductase were amplified in a strain that over- . expressed HMG CoA reductase. The enzymes amplified were 5 HMG CoA reductase, mevalonate kinase, phosphomevalonate kinase, diphosphomevalonate decarboxylase, isomerase (coded by HMG2cat, ERG12, ERG8, ERG19, and IDI1, respectively). These strains accumulated less mevalonate 10 when compared to strains over-expressing only HMG CoA reductase, indicating that the increased flux through the isoprenoid pathway resulting from HMG CoA reductase overexpression was accommodated by elevated levels of the downstream enzymes. Although elevated farnesol levels were not observed in the experiment described above, this may be due to the low level of mevalonate available for conversion. However, these data suggest that amplification of one or more of the enzymes downstream of HMG CoA reductase in a strain with amplified levels of the first three pathway enzymes may lead to increased accumulation of farnesol and GG since flux to mevalonate is greatly increased in these strains. It is likely that overexpression of one or more genes downstream of HMG CoA reductase in a strain that over-expresses acetoacetyl CoA thiolase, HMG CoA synthase, and HMG CoA reductase will lead to significant increases in farnesol and GG accumulation.

WO 00/01650 PCT/US99/15264

153

#### EXAMPLE 11

5

10

15

20

25

on one experience for the second content of the second second content of the experience of the experience of the second of the s

This example describes an experiment in which squalene synthase is blocked by zaragozic acid in a strain with an intact and functional sterol pathway, including a functional *ERG9* gene, and the effect of this squalene synthase inhibitor on farnesol and GG accumulation is observed.

Zaragozic acids are a family of compounds that act as potent inhibitors of squalene synthase (Bergstrom, J. D., Dufresne, C., Bills, G. F., Nallin-Omstead, M., and Byrne, K. 1995. Discovery, Biosynthesis, and Mechanism of Action of the Zaragozic Acids: Potent Inhibitors of Squalene Synthase. Ann. Rev. Microbiol. 49:607-639). They are capable of inhibiting cholesterol biosynthesis in mammals and ergosterol biosynthesis in fungi. Since ergosterol is necessary for fungal cell growth, zaragozic acids are potent fungicidal compounds.

Strain SWE23-E9 (ura3, sue; see EXAMPLE 1.G) was used in this experiment because it contained the sue mutation that provided for the uptake of sterols under aerobic conditions. This allowed the yeast to grow in ergosterol-supplemented medium when squalene synthase was blocked by zaragozic acid. A strain without the sue mutation would not be able to take up sterols, including ergosterol, from the medium, and therefore could not grow in the presence of zaragozic acid.

10

15

20

SWE23-E9 containing either an empty vector (Yep352) or plasmids that allow for the over-expression of HMG Co  $\ensuremath{\mathtt{A}}$ reductase (pRH124-31), GGPP synthase (pSW4A), or both HMG Co A reductase and GGPP synthase (pSW46-1) were tested in shake flasks by first growing the strains in SCE-ura medium for 48 hr to select for the plasmids. Samples of these cultures were then inoculated into YPDE medium or YPDE medium containing zaragozic acid at 100  $\mu$ g/ml. (+/- zaragozic acid) cultures were incubated at 30°C for 48  $^{\circ}$ hr, then analyzed for dry cell weight and farnesol accumulation. The data from this experiment are shown in Table 25. All of the cultures treated with zaragozic acid exhibited elevated accumulation of farnesol relative to the untreated cultures. GG accumulation was not measured in this experiment.

TABLE 25

Strain	Zaragozic Acid	Dry Cell Weight	Fa	mesol
	@100µg/m	mg/ml	µg/ml	% Dry Wt.
SWE23-E9/Yep 352	+	7.65	43	0.56
SWE23-E9/Yep352	_	9.72	0	
SWE23-E9/pRH124-31	+	7.88		0
SWE23-E9/pRH124-31	_		11	0.14
SWE23-E9/pSW4A		9.89	0	0
SWE23-E9/pSW4A		7.03	45	0.64
		9.05	. 1	0
SWE23-E9/pSW46-1	+	7.09	51	0.72
SWE23-E9/pSW46-1	_	8.54	0	0

30

25

HOLLEY AL EL EL HINGESTATE EL L'ENTRE PORTE DE L'ESTATE MANTHENDE COMMENTANT MENTANTE MANTHE CONTRACT DE L'ESTATE DE L'ESTATE

٠٠:

In a separate experiment, SWE23-E9 containing either an empty vector (Yep352) or a plasmid that allows for over-expression of both HMG Co A reductase and GGPP synthase (pSW46-1) were tested in shake flasks by first growing the strains in SCE-ura medium for 48 hr to select for the plasmids. Samples of these cultures were then inoculated into YPDE medium or YPDE medium containing zaragozic acid at 100 mg/ml. The YPDE (+/- zaragozic acid) cultures were incubated at 30°C for 72 hr, then analyzed for dry cell weight and GG. The data are presented in Table 26. The culture of SWE23-E9/pSW46-1 treated with zaragozic acid exhibited a higher level of GG as compared to the same strain grown in the absence of zaragozic acid. experiments demonstrate that strains without mutations in the sterol biosynthetic pathway can be induced to accumulate farnesol by blocking the pathway using a squalene synthase inhibitor. The amount of farnesol or GG accumulated by the zaragozic acid treated cultures was much less than the amount accumulated by strains with completely defective erg9 genes indicating that a genetic block of squalene synthase is more effective than a block induced by a squalene synthase inhibitor.

TABLE 26

25

20

te in the in the extension of the territorial care of the case of the extension of the case of the c

 $\{ \gamma_i \}_{i=1}^{N}$ 

10

15

Strain	Zaragozic Acid	Dry Cell Weight	GG	
	@100µg/ml	mg/ml	μg/ml	% Dry Wt.
SWE23-E9/Yep352	+	7.17	0	0

SWE23-E9/Yep352				
		9.25	0	0
SWE23-E9/pSW46-1	+	6.68	17.0	<del></del>
SWE23-E9/pSW46-1			17.8	0.27
		8.41	6.7	0.08

-. Nedžinga ik dista sektauro istopenitopenitorenis pistopinies obištikšis ustais karostorkas tromomentis karo

-. §

25

CARACTER TO THE SECOND STORE OF THE SECOND STORE OF THE

## Example 12

An alternative pathway leading to FPP has been described in a number of bacteria and plants, and is referred to as the non-mevalonate or Rohmer pathway (Eisenreich, W., Schwarz, M., Cartayrade, A., Arigoni, D., 10 Zenk, M. H., and Bacher, A., 1998. The Deoxyxylulose Phosphate Pathway of Terpenoid Biosynthesis in Plants and Microorganisms. Chem. Biol. 5: R221-233. Paseshnichenko, V. A., 1998. A New Alternative Non-Mevalonate Pathway for isoprenoid Biosynthesis in Eubacteria 15 Plants. Biochemistry (Mosc) 63:139-148). Some of the enzymes of the non-mevalonate pathway and their genes have been identified and studied in  $E.\ coli,$  and these include the deoxyxylulose-5-phosphate synthase, deoxyxylulose-5phosphate reductase, IPP isomerase, and FPP synthase, coded 20 by the dxr, dxs, idi, and ispA genes, respectively.

In order to construct strains of *E. coli* that accumulate elevated levels of farnesol, plasmids were constructed for the over-expression in *E. coli* of the genes listed above. In some cases, additional genes adjacent to the known isoprenoid pathway gene were included in the cloned DNA.

10

St. Weiter in a constraint activities in the property of the constraint of the constraint

The *idi* gene coding for IPP isomerase was PCR amplified using the two oligonucleotides listed below and genomic DNA isolated from *E. coli* strain W3110. The oligonucleotides used to amplify the *idi* gene contained sequences corresponding to bases #42309 to #42335 and the reverse complement of #43699 to #43726 of Gene Bank Accession #U28375. The lower case letters are used for bases that were altered to create restriction endonuclease recognition sites, which are indicated in parentheses following the oligonucleotide sequence. A natural *EcoRI* site was used in VE145-5.

## SEO ID NO:42:

VE145-5 5'-GGGATTCGAATTCTGTCGCGCTGTAAC-3' (EcoRI)
SEQ ID NO:43:

VE146-3 5'-TGggATCcGTAACGGCTTTAGCGAGCTG-3' (BamHI)

The *idi* PCR product was digested with *EcoRI* and *BamHI*, and ligated into *EcoRI*, *BamHI* digested pUC19. The resulting clone is referred to as pHS-0182.

The dxr gene was PCR amplified using the two oligonucleotides listed below and genomic DNA isolated from E. coli strain W3110. The oligonucleotides used to amplify a region of DNA which included the frr, dxr, and yaeS genes contained sequences corresponding to bases #2131 to #2150 and the reverse complement of #5297 to #5315 of Gene Bank Accession #D83536.

SEO ID NO: 44:

DXR17.SN

GATTCCGCGTAAGgATCcCG

(BamHI)

SEO ID NO: 45:

DXR3179.ASN

CCAGCATCTAGACCACCAG

(XbaI)

5

The resulting PCR product was digested with BamHI and XbaI, and ligated into BamHI, XbaI digested pHS-0182 to generate pHS-0182R.

The ispA and dxs genes appear to be part of an operon that possibly include two other genes referred to as xseB10 and yajo. PCR was used to amplify a region of DNA which included xseB, ispA, dxs, and yaj0 using the oligonucleotides listed below and genomic DNA isolated from  $\it E.~coli$  strain W3110. The oligonucleotides contained sequences corresponding to bases #4157 to #4183 and the 15 reverse complement of bases # 8938 to #48956 of Gene Bank Accession #AE000148.

# SEO ID NO:46:

DXS.5619P 5'-gactgcagCTGGCCGCTGGGTATTCTGTCGTAGTT-3'

## SEQ ID NO: 47:

20

Contract of the second

DXS.820X 5'-gatctagaTCACGCGTACGCAGAAGGTTTTGC-3'
(XbaI)

10

The resulting PCR product was digested with XbaI and PstI and ligated to XbaI, PstI digested pUC19 to generate pHS-dxs.

The DNA fragment containing the dxs gene will be cut from pHS-dxs using XbaI and PstI, and ligated into XbaI, PstI digested pHS-0182R to generate a plasmid that contains dxs, dxr, ispA, and idi. The resulting plasmid will be transformed into E. coli, and a transformed strain containing the plasmid will be tested for production of farnesol in shake flask and fermentation experiments.

In order to construct strains of *E. coli* that accumulate elevated levels of GG, a plasmid was constructed for the over-expression in *E. coli* of GGPP synthase from *Erwinia herbicola*. The *crtE* gene coding for GGPP synthase was amplified by PCR using genomic DNA isolated from *Erwinia herbicola* strain Eho10 and the following two oligonucleotides. The oligonucleotides contained sequences corresponding to bases #3513 to #3531 and the reverse complement of bases # 4459 to #4481 of Gene Bank Accession #M87280.

## SEO ID NO:48:

Eho10E Up 5'-gaattcCAATTCAGCGGGTAACCTT-3' (EcoRI)

SEO ID NO:49:

Eho10E Lo 5'-aagcttTGCTTGAACCCAAAAGGGCGGTA-3'

25 (HindIII)

The American Control of the Control

er eine der eine eine eine der eine der eine der der eine der der der der der der der der eine der der eine de

THE PROPERTY CONTRACTOR OF THE PROPERTY OF THE PR

The resulting PCR product was digested with  $\mathit{EcoRI}$  and HindIII, and ligated into pET24d(+) (Novagen) so that expression of the ctrE gene was controlled by the T7 promoter. The resulting plasmid is referred to as pKL19-This plasmid can be transformed into E. coli strains 5 such as BL21(DE3) (available from Novagen) which contains an IPTG inducible gene coding for T7 polymerase. allows IPTG induction of the crtE gene in this strain. The T7 promoter/crtE gene fusion can be cut from pKL19-63 using BglII and HindIII, and ligated into BamHI, HindIII digested 10 pACYC184 (Accession #X06403) to construct a plasmid relying on chloramphenicol resistance for selection. This plasmid contains the p15A origin of replication and would be compatible with plasmids containing the ColE1 origin of replication such as the clones carrying the E. coli 15 isoprenoid pathway genes described above. These latter plasmids confer ampicillin resistance, and so E. coli transformants can be obtained that carry both the crtE plasmid and the plasmid containing the dxs, dxr, idi, and ispA genes by transforming E. coli with both plasmids and 20 selecting for resistance to chloramphenicol and ampicillin. Therefore, strains of E. coli BL21(DE3) will be obtained that contain plasmids for over-expression deoxyxylulose-5phosphate synthase, deoxyxylulose-5-phosphate reductoisomerase, IPP isomerase, FPP synthase, and GGPP 25

. . .

WO 00/01650 PCT/US99/15264

161

synthase. These strains will be tested for production of GG in shake flask and fermentation experiments.

## Example 13

e de la composition della comp

The following example describes the construction of strains of Saccharomyces cerevisiae that are engineered to produce elevated levels of farnesol and GG by expressing enzymes corresponding to the non-mevalonate pathway enzymes.

Biosynthesis of IPP occurs in many bacteria and plants 10 starting from pyruvate and glyceraldehyde-3-and proceeding through a series of enzymatic steps known as the nonmevalonate pathway, and includes the enzymes deoxyxylulosesynthase and deoxyxylulose-5-phosphate 15 reductoisomerase. The compound resulting from these two enzymatic steps is 2-C-methyl-D-erythritol 4-phosphate (also known as MEP), which is further metabolized by unknown enzymes to yield IPP. Plasmids are constructed that express the E. coli dxs and dxr genes in yeast by 20 fusing the coding regions of those genes to promoter elements that allow for expression in yeast. The dxs and dxs genes are amplified by PCR with oligonucleotides that include restriction sites to allow cloning into yeast expression vectors which contain promters such as the ADH1 25 promoter, PGK promoter, or GPD promoter. The two gene fusions are then combined into a single plasmid by

subcloning one gene fusion into the other plasmid. The resulting plasmid containing both genes is then transformed into an erg9 mutant of yeast. The resulting strain is capable of synthesizing MEP, which may be further metabolized to IPP by endogenous enzymes capable of carrying out the desired reactions to IPP. This capability may lead to increased accumulation of IPP, which may cause the cells to accumulate elevated levels of farnesol through the action of the endogenous IPP isomerase and FPP synthase enzymes. If this is done in a strain that also overexpresses GGPP synthase, then elevated levels of GG may accumulate in these strains.

# Example 14

5

10

である。 1987年 - 1987年 -

This example describes the construction of a strain of

Saccharomyces cerevisiae that over-expresses a mutated

ERG20 gene coding for an FPP synthase enzyme exhibiting

altered product specificity. Unlike strains over-expressing

wild-type FPP synthase, strains expressing the mutated FPP

synthase accumulated more GG than farnesol.

20 Comparison of the amino acid sequences of FPP synthases from a variety of organisms revealed several highly conserved domains including two aspartate rich domains, which are essential for catalytic activity. Researchers have reported that mutations effecting the 25 amino acid located at the fifth position before the first aspartate rich domain can alter the product specificity of

٠.,

25

the enzyme such that the enzyme readily catalyzes the formation of GGPP as well as FPP. This has been shown for both avian and Bacillus stearothermophilus FPP synthases (Tarshis, L.C., Proteau, Р. J., Kellogg, Sacchettini, J. C., Poulter, C. D. 1996. Regulation of Product Chain Length by Isoprenyl Diphosphate Synthases. Proc. Natl. Acad. Sci. USA 93:15018-15023; Ohnuma, S., Narita, K., Nakazawa, T., Ishida, C., Takeuchi, Y., Ohto, C., and Nichino, T. 1996. A Role of the Amino Acid Residue Located on the Fifth Position Before the First Aspartate-10 rich Farnesyl Motif of Diphosphate Synthase Determination of the Final Product. J. Biol. Chem. 271:30748-30754; U.S. Patent 5,766,911). In the case of the Bacillus enzyme, the amino acid in the fifth position 15 before the first aspartate rich domain was changed from tyrosine to serine. The avian enzyme contains a phenylalanine in this position. It is thought that aromatic amino acids in that position block extension of the isoprenyl chain beyond fifteen carbons, and that the 20 restriction can be alleviated by replacing phenylalanine with a less-bulky amino acid such as serine.

As in the Bacillus FPP synthases mentioned above, the FPP synthase from Saccharomyces cerevisiae has a tyrosine at the fifth position before the first aspartate rich domain. Site directed mutagenesis was used to alter the sequence of the ERG20 gene to code for a serine instead of

a tyrosine at that position. The method used to introduce the mutation relied on PCR amplification of the entire pJMB19-31 plasmid using mutagenic oligonucleotides that introduced the desired mutation, and is outlined in the instruction booklet for the QuikChange Site-Directed 5 Mutagenesis Kit (Stratagene). The oligonucleotides contained sequences corresponding to bases #1063 to #1097 and the reverse complement of bases # 1063 to #1097 of Gene Bank Accession #J05091. The sequences oligonucleotides are given below, with the changes 10 indicated by small case letters. An alteration of A to T was made at position #1084 to change the encoded amino acid from tyrosine to serine. Also, an alteration of T to C was made at position #1074 to create a new PstI site, which allowed for rapid identification of the mutant gene. This 15 latter mutation was silent in that it did not change the encoded amino acid.

## SEO ID NO:50:

Y95S-SN 5'-GCATTGAGTTGcTGCAGGCTTcCTTCGTCGCC-3'

# 20 <u>SEO ID NO:51:</u>

٠.:

element in de de la company de la company

and the second

Y95S-ASN 5'-GGCGACCAAGAAGGAAGCCTGCAGCAACTCAATGC-3'

The two oligonucleotides were used to amplify pJMB19-31, and the resulting PCR product was ligated to itself to reform the circular plasmid, except that *ERG20* gene now contained the desired mutation. The resulting plasmid is

referred to as pHS31.Y95S, and this plasmid was transformed into the erg9 mutant strain SWE23-DE91 to form SWE23-DE91/pHS31.Y95S. Shake flask experiments were carried out to compare farnesol and GG production by strains over-expressing the wild-type ERG20 gene and the mutated ERG20 gene. Strains were grown overnight in SCE-ura, and this was used to inoculate flasks containing YPDE medium. These cultures were grown at 30°C for 72 hr, then harvested for dry cell weight and isoprenoid analysis. The data from this experiment is presented in Table 27.

TABLE 27

Strain	FPP Synthase	Dry Cell Wt	Famesol		GG	
		mg/ml	mg/ml	% Dry Wt.	mg/ml	% Dry Wt.
\$WE23-DE91/ JMB19-31	. Wild type	4.7	0.22	4.76	0.05	1.1
SWE23-DE91/ pHS31.Y95S	Tyr to Ser Mutant	4.9	0.01	0.2	0.13	2.7

20

25

30

5

10

 $\{ x_i \}_{i=1}^n$ 

These data show that the farnesol:GG ratio is dramatically altered by over-expression of the tyr to ser mutant of the ERG20 gene in an erg9 mutant strain. The strain over-expressing the mutant ERG20 gene exhibited proportionally more GG than the strain over-expressing the wild-type ERG20 gene. In addition, the total amount of GG produced by the strain over-expressing the mutant ERG20 was higher while the total amount of farnesol was lower as compared to the strain over-expressing the wild-type ERG20 gene. The decrease in farnesol level was not completely

15

20

ATTENDED TO BE AND THE STORY OF THE STORY OF

reflected in the GG pool, suggesting that some of the FPP may be converted to other compounds besides GG. Alternatively, it is possible that feedback inhibition plays a role in regulating the amount of GG accumulated by these strains.

The foregoing description of the invention has been presented for purposes of illustration and description. Furthermore, the description is not intended to limit the invention to the form disclosed herein. Consequently, variations and modifications commensurate with the above teachings, and the skill or knowledge of the relevant art, are within the scope of the present invention. The embodiments described hereinabove are further intended to explain best modes known of practicing the invention and to enable others skilled in the art to utilize the invention in such, or other, embodiments and with the various modifications required by the particular applications or uses of the invention. It is intended that the appended claims be construed to include alternative embodiments to the extent permitted by the prior art.

*:* :

. . . . . .

The second of th

# What is claimed is:

- 1. A method for producing  $\alpha$ -tocopherol or  $\alpha$ -tocopheryl esters comprising:
- (a) biologically producing a compound selected from the group consisting of farnesol and geranylgeraniol; and
  - (b) chemically converting said compound into  $\alpha$ -tocopherol or an  $\alpha$ -tocopheryl ester.
- The method of Claim 1, wherein said compound is geranylgeraniol having a first, second, third and fourth
   olefin moieties and wherein said step of chemically converting comprises:
  - (a) reducing at least one of said second, third and fourth olefin moieties of said geranylgeraniol to form an allylic alcohol; and
- 15 (b) forming  $\alpha$ -tocopherol or an  $\alpha$ -tocopheryl ester from said allylic alcohol and a hydroquinone.
  - 3. The method of Claim 2, wherein said reducing step (a) comprises:

adding a protecting group to said geranylgeraniol to

20 protect the first olefin moiety of said geranylgeraniol

from reduction; and

reducing at least one of the second, third and fourth olefin moieties of said protected geranylgeraniol; and

のできた。 これには、1985年の1985年

removing said protecting group from said reduced protected geranylgeraniol to provide said allylic alcohol.

- The method of Claim 3, wherein said protecting
   group is a hydroxy protecting group.
  - 5. The method of Claim 4, wherein said hydroxy protecting group is an ester.
- The method of Claim 5, wherein said ester is selected from the group consisting of isobutyrate and pivaloate.
  - 7. The method of Claim 2, wherein said reducing step comprises hydrogenation.
  - 8. The method of Claim 2, wherein said allylic alcohol comprises phytol.
- 9. The method of Claim 2, wherein formation of said  $\alpha$ -tocopherol or an  $\alpha$ -tocopheryl ester comprises contacting said allylic alcohol with an acid in the presence of said hydroquinone.
- 10. The method of Claim 2, wherein said20 hydroquinone is a trimethyl hydroquinone.
  - 11. The method of Claim 10, wherein said trimethyl hydroquinone is 2,3,5-trimethyl hydroquinone.
- 12. The method of Claim 1, wherein said compound is farnesol and wherein said step of chemically converting 25 comprises:

25

Applease that Note is a second of the desired of the desired of the desired of the second of the desired of the

・ 1997年 - 1997年 - 1997年 - 1997年 - 1998年 - 19

- (a) converting farnesol to a first intermediate comprising sufficient carbon atoms to form a trimethyltridecyl substituent group of vitamin E when said intermediate is reacted with a hydroquinone to form vitamin E; and
- (b) reacting said intermediate compound with a hydroquinone to form vitamin E.
- 13. The method of Claim 12, wherein said converting step comprises:
- oxidizing said farnesol to farnesal; and forming a methyl ketone from said farnesal.
  - 14. The method of Claim 13, further comprising: reducing olefin moieties in said methyl ketone to form an alkyl methyl ketone; and
- forming an allylic alcohol from said alkyl methyl ketone.
  - 15. The method of Claim 12, wherein said intermediate comprises isophytol.
- 16. The method of Claim 12, wherein said20 hydroquinone is a trimethyl hydroquinone.
  - 17. The method of Claim 16, wherein said trimethyl hydroquinone is 2,3,5-trimethyl hydroquinone.
  - 18. The method of Claim 1, wherein said compound is farnesol and wherein said step of chemically converting comprises:
    - (a) oxidizing said farnesol to farnesal;

, . .

- Controller on some controller of the construction of the controller of the controller of the control of the c

- (b) forming a methyl ketone from said farnesal;
- (c) reducing olefin moieties in said methyl ketone to form an alkyl methyl ketone;
- (d) forming an allylic alcohol from said alkyl

  methyl ketone, wherein said allylic alcohol
  comprises a sufficient number of carbon atoms to
  form at least a trimethyltridecyl substituent group
  of vitamin E when vitamin E is formed from said
  allylic alcohol and a corresponding hydroquinone;
  and
  - (e) forming vitamin E from said compound and a hydroquinone.
  - 19. The method of Claim 18, wherein said allylic alcohol comprises isophytol.
- 15 20. The method of Claim 18, wherein said hydroquinone is a trimethyl hydroquinone.
  - 21. The method of Claim 20, wherein said trimethyl hydroquinone is 2,3,5-trimethyl hydroquinone.
- 22. The method of Claim 1, wherein said compound is 20 farnesol.
  - 23. The method of Claim 1, wherein said compound is geranylgeraniol.

24. A method for producing  $\alpha$ -tocopherol or  $\alpha$ -tocopheryl esters comprising:

reflection of the land of the second of the

The second secon

- (a) culturing a microorganism in a fermentation medium to produce a product selected from the group consisting of farnesyl phosphate, farnesol, geranylgeranyl phosphate and geranylgeraniol, wherein the action of squalene synthase of said microorganism is reduced;
  - (b) recovering said product; and
- 10 (c) chemically converting said product into  $\alpha$ -tocopherol or an  $\alpha$ -tocopheryl ester.
  - 25. The method of Claim 24, wherein said fermentation medium comprises a squalene synthase inhibitor.
- 15 26. The method of Claim 24, wherein said microorganism is genetically modified to decrease the action of squalene synthase.
- 27. The method of Claim 26, wherein said microorganism is further genetically modified to increase the action of HMG-CoA reductase.
  - 28. The method of Claim 27, wherein the action of HMG-CoA reductase is increased by overexpression of HMG-CoA reductase or the catalytic domain thereof in the microorganism.
- 25 29. The method of Claim 28, wherein said microorganism is further genetically modified to increase

the second second control of the second control

the action of a protein selected from the group consisting of acetoacetyl Co-A thiolose, HMG-CoA synthase, mevalonate kinase, phosphomevalonate kinase, phosphomevalonate decarboxylase, isopentenyl

- pyrophosphate isomerase, farnesyl pyrophosphate synthase, D-1-deoxyxylulose 5-phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate reductoisomerase.
  - 30. The method of Claim 29, wherein the microorganism has been genetically modified to increase the action of farnesyl pyrophosphate synthase.
    - 31. The method of Claim 30, wherein the microorganism has been genetically modified to overexpress farnesyl pyrophosphate synthase.
- 32. The method of Claim 24, wherein said 15 microorganism is an *erg9* mutant.
  - 33. The method of Claim 32, wherein said microorganism comprises a erg94::HIS3 deletion/insertion allele.
- 34. The method of Claim 24, wherein said recovering 20 step comprises recovering said product from said microorganism.
- 35. The method of Claim 24, wherein said product is secreted into said fermentation medium by said microorganism and wherein said step of recovering

  25 comprises purification of said product from said fermentation medium.

10

A CONTRACTOR OF THE CONTRACTOR

- 36. The method of Claim 24, wherein said microorganism is a fungi.
- 37. The method of Claim 36, wherein said fungi has been genetically modified to express at least a portion of the enzymes in the mevalonate independent pathway.
- 38. The method of Claim 37, wherein said fungi has been genetically modified to express an enzyme selected from the group consisting of D-1-deoxyxylulose 5-phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate reductoisomerase.
- 39. The method of Claim 36, wherein said fungi is a yeast and said yeast is blocked in the ergosterol pathway and is genetically modified to take up exogenous sterols under aerobic conditions.
- 15 40. The method of Claim 24, wherein said microorganism is a bacteria.
  - 41. The method of Claim 40, wherein said bacteria has been genetically modified to express at least a portion of the enzymes in the mevalonate pathway.
- 42. The method of Claim 41, wherein said bacteria has been genetically modified to express an enzyme selected from the group consisting of acetoacetyl Co-A thiolose, HMG-CoA synthase, HMG-CoA reductase, mevalonate kinase, phosphomevalonate kinase, and phosphomevalonate decarboxylase.

The rest on a second and the contract of the c

- 43. The method of Claim 24, wherein said microorganism is a microalgae.
- 44. The method of Claim 43, wherein said microalgae is selected from the group consisting of Chlorella and Prototheca.
- 45. The method of Claim 24, wherein said microorganism has been genetically modified to increase phosphatase action.
- 46. The method of Claim 29, wherein the

  microorganism has been genetically modified to increase
  the action of geranylgeranyl pyrophosphate synthase.
  - 47. The method of Claim 46, wherein the microorganism has been genetically modified to overexpress geranylgeranyl pyrophosphate synthase.

The control of the co

- 48. A method for producing  $\alpha$ -tocopherol or  $\alpha$ -tocopheryl esters comprising:
- (a) biologically producing a first compound selected from the group consisting of geranylgeraniol and geranylgeranyl pyrophosphate;
- (b) contacting said first compound with a geranylgeranyl reductase to form a second compound selected from the group consisting of phytol and phytyl diphosphate; and
- 10 (c) chemically converting said second compound into  $\alpha$ -tocopherol or an  $\alpha$ -tocopheryl ester.
  - 49. A method, as claimed in Claim 48, wherein said step of contacting is conducted in vivo using a microorganism having geranylgeranyl reductase activity.
- 50. A method, as claimed in Claim 48, wherein said step of contacting is conducted in a biotranformation process.
- 51. A method, as claimed in Claim 48, wherein said first compound is geranylgeraniol and said second20 compound is phytol.
  - 52. A method, as claimed in Claim 48, wherein said first compound is geranylgeranyl pyrophosphate and said second compound is phytyl diphosphate.
- 53. A method, as claimed in Claim 48, wherein said step of chemically converting comprises reacting said second compound or a derivative thereof with a

hydroquinone to form  $\alpha\text{-tocopherol}$  or an  $\alpha\text{-tocopheryl}$  ester.

- 54. A method, as claimed in Claim 48, wherein said step of contacting comprises purifying said first compound and transforming said first compound with isolated geranylgeranyl reductase or microorganisms having geranylgeranyl reductase activity.
  - 55. The method of Claim 54, wherein said microorganism is further genetically modified to increase the action of geranylgeranyl reductase.
    - 56. The method of Claim 55, wherein the action of geranylgeranyl reductase is increased by overexpression of geranylgeranyl reductase.

144.55

- 57. A method for producing a compound selected from the group consisting of farnesol and geranylgeraniol comprising:
- (a) culturing a microorganism in a fermentation
  5 medium comprising a compound selected from the group
  consisting of isoprenol and prenol to produce a product
  selected from the group consisting of farnesyl phosphate,
  farnesol, geranylgeranyl phosphate and geranylgeraniol;
  and
- 10 (b) recovering said product.
  - 58. The method of Claim 57, wherein said microorganism is further genetically modified to increase the action of dimethylallyl transferase.
- 59. The method of Claim 58, wherein the action of dimethylallyl transferase is increased by overexpression of dimethylallyl transferase in the microorganism.
  - 60. The method of Claim 59, wherein the microorganism has been genetically modified to increase the action of farnesyl pyrophosphate synthase.
- 20 61. The method of Claim 60, wherein the microorganism has been genetically modified to overexpress farnesyl pyrophosphate synthase.
- 62. The method of Claim 59, wherein themicroorganism has been genetically modified to increasethe action of geranylgeranyl pyrophosphate synthase.

- 63. The method of Claim 60, wherein the microorganism has been genetically modified to overexpress geranylgeranyl pyrophosphate synthase.
- 64. The method of Claim 57, wherein the

  5 microorganism has been genetically modified to increase
  the action of an enzyme selected from the group
  consisting of isoprenol kinase and prenol kinase.
- 65. The method of Claim 57, wherein the microorganism has been genetically modified to

  10 overexpress an enzyme selected from the group consisting of isoprenol kinase and prenol kinase.
  - 66. The method of Claim 57, wherein said microorganism is an *erg*9 mutant.

energy of the second of the second secon

No. po

4.4

20

The same of the second second

See a Color Colo

- 67. A method for producing farnesol comprising:
- (a) culturing a microorganism in a fermentation medium to produce a product selected from the group consisting of farnesyl phosphate and farnesol, wherein the action of squalene synthase of said microorganism is reduced; and
  - (b) recovering said product.
- 68. The method of Claim 67, wherein said fermentation medium comprises a squalene synthase inhibitor.
  - 69. The method of Claim 67, wherein said microorganism is genetically modified to decrease the action of squalene synthase.
- 70. The method of Claim 69, wherein said

  15 microorganism is further genetically modified to increase the action of HMG-CoA reductase.
  - 71. The method of Claim 70, wherein the action of HMG-CoA reductase is increased by overexpression of HMG-CoA reductase or the catalytic domain thereof in the microorganism.
  - 72. The method of Claim 70, wherein said microorganism is further genetically modified to increase the action of a protein selected from the group consisting of acetoacetyl Co-A thiolose, HMG-CoA
- 25 synthase, mevalonate kinase, phosphomevalonate kinase, phosphomevalonate decarboxylase, isopentenyl

25

pyrophosphate isomerase, farnesyl pyrophosphate synthase, D-1-deoxyxylulose 5-phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate reductoisomerase.

- 73. The method of Claim 72, wherein the
  5 microorganism has been genetically modified to increase
  the action of farnesyl pyrophosphate synthase.
  - 74. The method of Claim 73, wherein the microorganism has been genetically modified to overexpress farnesyl pyrophosphate synthase.
- 75. The method of Claim 67, wherein said microorganism is an *erg*9 mutant.
  - 76. The method of Claim 75, wherein said microorganism comprises a erg94::HIS3 deletion/insertion allele.
- 77. The method of Claim 67, wherein said recovering step comprises recovering said product from said microorganism.
- 78. The method of Claim 67, wherein said product is secreted into said fermentation medium by said

  20 microorganism and wherein said step of recovering comprises purification of said product from said fermentation medium
  - 79. The method of Claim 67, wherein said product is intracellular farnesyl phosphate and farnesol and said step of recovering comprises isolating said farnesyl phosphate and farnesol from said microorganism.

- 80. The method of Claim 67, wherein said product is intracellular farnesyl phosphate and said step of recovering further comprises dephosphorylating said farnesyl phosphate to produce farnesol.
- 5 81. The method of Claim 67, wherein said microorganism is a fungi.
  - 82. The method of Claim 81, wherein said fungi has been genetically modified to express at least a portion of the enzymes in the mevalonate independent pathway.
- 10 83. The method of Claim 82, wherein said fungi has been genetically modified to express an enzyme selected from the group consisting of D-1-deoxyxylulose 5-phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate reductoisomerase.
- 15 84. The method of Claim 81, wherein said fungi is a yeast and said yeast is blocked in the ergosterol pathway and is genetically modified to take up exogenous sterols under aerobic conditions.
- 85. The method of Claim 67, wherein said 20 microorganism is a bacteria.
  - 86. The method of Claim 85, wherein said bacteria has been genetically modified to express at least a portion of the enzymes in the mevalonate pathway.
- 87. The method of Claim 86, wherein said bacteria
  25 has been genetically modified to express an enzyme
  selected from the group consisting of acetoacetyl Co-A

thiolose, HMG-CoA synthase, HMG CoA reductase, mevalonate kinase, phosphomevalonate kinase, and phosphomevalonate decarboxylase.

- 88. The method of Claim 67, wherein said 5 microorganism is a microalgae.
  - 89. The method of Claim 88, wherein said microalgae is selected from the group consisting of Chlorella and Prototheca.

- And Andrews Andrew

- 90. A microorganism for producing farnesol by a biosynthetic process, said microorganism having a genetic modification to reduce the action of squalene synthase in said microorganism and a genetic modification to increase the action of a protein selected from the group consisting of acetoacetyl Co-A thiolose, HMG-CoA synthase, HMG-CoA reductase, mevalonate kinase, phosphomevalonate kinase, phosphomevalonate decarboxylase, isopentenyl pyrophosphate isomerase, farnesyl pyrophosphate synthase, D-1-deoxyxylulose 5-phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate reductoisomerase.
- 91. The microorganism of Claim 90, wherein said genetic modification to increase the action of a protein comprises integrating multiple copies of genes for said protein into the genome of said microorganism.
  - 92. The microorganism of Claim 91, wherein said genetic modification to increase the action of a protein increases the expression of a gene encoding said protein.
- 20 93. The microorganism of Claim 92, wherein said genetically modified microorganism is an *erg*9 mutant.

- 94. A method for producing geranylgeraniol comprising:
- (a) culturing a microorganism in a fermentation medium to produce a product selected from the group consisting of geranylgeranyl phosphate and geranylgeraniol, wherein the action of squalene synthase of said microorganism is reduced; and
  - (b) recovering said product.
- 95. The method of Claim 94, wherein said

  10 fermentation medium comprises a squalene synthase inhibitor.
  - 96. The method of Claim 94, wherein said microorganism is genetically modified to decrease the action of squalene synthase.
- 97. The method of Claim 96, wherein said microorganism is further genetically modified to increase the action of HMG-CoA reductase.
  - 98. The method of Claim 97, wherein the action of HMG-CoA reductase is increased by overexpression of HMG-CoA reductase or the catalytic domain thereof in the
- 20 CoA reductase or the catalytic domain thereof in the microorganism.
  - 99. The method of Claim 97, wherein said microorganism is further genetically modified to increase the action of a protein selected from the group
- consisting of acetoacetyl Co-A thiolose, HMG-CoA synthase, mevalonate kinase, phosphomevalonate kinase,

phosphomevalonate decarboxylase, isopentenyl pyrophosphate isomerase, farnesyl pyrophosphate synthase, D-1-deoxyxylulose 5-phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate reductoisomerase.

- 5 100. The method of Claim 99, wherein the microorganism has been genetically modified to increase the action of geranylgeranyl pyrophosphate synthase.
  - 101. The method of Claim 100, wherein the microorganism has been genetically modified to overexpress geranylgeranyl pyrophosphate synthase.
    - 102. The method of Claim 94, wherein said microorganism is an erg9 mutant.

10

15

٠.:

- 103. The method of Claim 102, wherein said microorganism comprises a erg9\(\alpha\)::HIS3 deletion/insertion allele.
  - 104. The method of Claim 94, wherein said recovering step comprises recovering said product from said microorganism.
- secreted into said fermentation medium by said
  microorganism and wherein said step of recovering
  comprises purification of said product from said
  fermentation medium.
- 106. The method of Claim 94, wherein said product is
  25 intracellular geranylgeranyl phosphate and intracellular
  and extracellular geranylgeraniol and said step of

recovering comprises isolating said geranylgeranyl phosphate and geranylgeraniol from said microorganism and isolating geranylgeraniol from said fermentation medium.

- 107. The method of Claim 94, wherein said product is intracellular geranylgeranyl phosphate and said step of recovering further comprises dephosphorylating said geranylgeranyl phosphate to produce geranylgeraniol.
  - 108. The method of Claim 94, wherein said microorganism is a fungi.
- 109. The method of Claim 108, wherein said fungi has been genetically modified to express at least a portion of the enzymes in the mevalonate independent pathway.
- 110. The method of Claim 109, wherein said fungi has been genetically modified to express an enzyme selected

  15 from the group consisting of D-1-deoxyxylulose 5phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate reductoisomerase.
- 111. The method of Claim 108, wherein said fungi is a yeast and said yeast is blocked in the ergosterol

  20 pathway and is genetically modified to take up exogenous sterols under aerobic conditions.
  - 112. The method of Claim 94, wherein said microorganism is a bacteria.

113. The method of Claim 112, wherein said bacteria 25 has been genetically modified to express at least a portion of the enzymes in the mevalonate pathway. WO 00/01650

5

- 114. The method of Claim 113, wherein said bacteria has been genetically modified to express an enzyme selected from the group consisting of acetoacetyl Co-A thiolose, HMG-CoA synthase, HMG-CoA reductase, mevalonate kinase, phosphomevalonate kinase, and phosphomevalonate decarboxylase.
- 115. The method of Claim 94, wherein said microorganism is a microalgae.
- 116. The method of Claim 115, wherein said
  10 microalgae is selected from the group consisting of
  Chlorella and Prototheca.

en en elektromitan antalasan ken antalasan kentan antalasan kentan antalasan kentan dalah sen en en en en en e

. اند

लिखा प्रदेशकान्य नक्षारा ४००० - ५०० - ५४० - ५०० -

- by a biosynthetic process, said microorganism having a genetic modification to reduce the action of squalene synthase in said microorganism and a genetic modification to increase the action of a protein selected from the group consisting of acetoacetyl Co-A thiolose, HMG-CoA synthase, HMG-CoA reductase, mevalonate kinase, phosphomevalonate kinase, phosphomevalonate kinase, phosphomevalonate carboxylase, isopentenyl pyrophosphate isomerase, farnesyl pyrophosphate synthase, D-1-deoxyxylulose 5-phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate reductoisomerase.
- 118. The microorganism of Claim 117, wherein said genetic modification to increase the action of a protein comprises integrating multiple copies of genes for said protein into the genome of said microorganism.
  - 119. The microorganism of Claim 117, wherein said genetic modification to increase the action of a protein increases the expression of a gene encoding said protein.
- 20 120. The microorganism of Claim 117, wherein said genetically modified microorganism is an erg9 mutant.

- 121. A method for producing vitamin A from farnesol comprising:
- (a) preparing an  $\alpha,\beta$ -unsaturated polyene carbonyl compound from farnesol; and
- 5 (b) cyclizing said  $\alpha,\beta$ -unsaturated polyene carbonyl compound to form a cyclic  $\alpha,\beta$ -unsaturated polyene carbonyl compound; and
  - (c) converting said cyclic  $\alpha,\beta$ -unsaturated polyene carbonyl compound to vitamin A.
- 10 122. The method of Claim 121, wherein said preparing step comprises:

oxidizing said farnesol to farnesal; and forming said  $\alpha,\beta$ -unsaturated polyene carbonyl compound from said farnesal.

15 123. The method of Claim 121, wherein said  $\alpha, \beta$ -unsaturated polyene carbonyl compound is of the formula:

wherein

Z is O or  $CHCO_2R$ , and R is  $C_1-C_{10}$  hydrocarbyl.

124. The method of Claim 121, wherein said cyclic  $\alpha,\beta$ -unsaturated polyene carbonyl compound is of the formula:

wherein

- }

Z is O or  $CHCO_2R$ , and

R is  $C_1$ - $C_{10}$  hydrocarbyl.

5 125. The method of Claim 124, wherein Z is  $CHCO_2R$ .

126. The method of Claim 125, wherein said converting step comprises reduction of an ester group to an alcohol group.

127. The method of Claim 124, wherein Z is O.

10 128. The method of Claim 127, wherein said converting step comprises:

conducting a chemical reaction to transform Z from O to  $CHCO_2R$  or CHCN; and

reducing Z to form vitamin A.

- 15 129. The method of Claim 121, wherein said farnesol is produced biologically.
  - 130. The method of Claim 129, wherein biological production comprises:
  - (a) culturing a microorganism in a
- fermentation medium to produce a product selected from the group consisting of farnesyl phosphate and farnesol, wherein the action of squalene synthase of said microorganism is reduced; and

The second of th

- (b) recovering said product.
- 131. The method of Claim 130, wherein said microorganism is genetically modified to decrease the action of squalene synthase.
- 5 132. The method of Claim 131, wherein said microorganism is further genetically modified to increase the action of HMG-CoA reductase.
- 133. The method of Claim 132, wherein the action of HMG-CoA reductase is increased by overexpression of HMG-CoA reductase or the catalytic domain thereof in the microorganism.
- microorganism is further genetically modified to increase the action of a protein selected from the group consisting of acetoacetyl Co-A thiolose, HMG-CoA synthase, mevalonate kinase, phosphomevalonate kinase, phosphomevalonate kinase, phosphomevalonate decarboxylase, isopentenyl pyrophosphate isomerase, farnesyl pyrophosphate synthase, D-1-deoxyxylulose 5-phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate reductoisomerase.
  - 135. The method of Claim 134, wherein the microorganism has been genetically modified to increase the action of farnesyl pyrophosphate synthase.
- 136. The method of Claim 130, wherein said
  25 microorganism is an erg9 mutant.

100 BB 1

のため、日本ののは、日本のは、日本のでは、「本本のでは、日本のでは、日本のでは、日本のでは、日本のでは、日本のでは、日本のでは、日本のでは、「本本のでは、日本のでは、日本のでは、「本本のでは、「本本のでは、「本本のでは、日本のでは、「本のでは、「本本のでは、「本本のでは、「本本のでは、「本本のでは、「本本のでは、「本本のでは、「本のでは、「本のでは、「本のでは、「本のでは、「本のでは、「本のでは、「本本のでは、「本のでは、「本のでは、「本本のでは、「まのでは、「本のでは、「まのでは、「本のでは、「ものでは、「本のでは、「本のでは、「本のでは、「本のでは、「本のでは、「本のでは、「本のでは、「本のでは、「本のでは、「本のでは、

- 137. The method of Claim 130, wherein said product is secreted into said fermentation medium by said microorganism and wherein said step of recovering comprises purification of said product from said fermentation medium.
- 138. The method of Claim 130, wherein said product is intracellular farnesyl phosphate and farnesol and said step of recovering comprises isolating said farnesyl phosphate and farnesol from said microorganism.
- 139. The method of Claim 130, wherein said product is intracellular farnesyl phosphate and said step of recovering further comprises dephosphorylating said farnesyl phosphate to produce farnesol.
- 140. The method of Claim 121, wherein said microorganism is a fungi.
  - 141. The method of Claim 140, wherein said fungi has been genetically modified to express at least a portion of the enzymes in the mevalonate independent pathway.
- 142. The method of Claim 141, wherein said fungi has
  20 been genetically modified to express an enzyme selected
  from the group consisting of D-1-deoxyxylulose 5phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate
  reductoisomerase.
- 143. The method of Claim 140, wherein said fungi is 25 a yeast and said yeast is blocked in the ergosterol

pathway and is genetically modified to take up exogenous sterols under aerobic conditions.

- 144. The method of Claim 130, wherein said microorganism is a bacteria.
- 5 145. The method of Claim 144, wherein said bacteria has been genetically modified to express at least a portion of the enzymes in the mevalonate pathway.
- 146. The method of Claim 145, wherein said bacteria has been genetically modified to express an enzyme

  10 selected from the group consisting of acetyl Co-A thiolose, HMG-CoA synthase, mevalonate kinase, phosphomevalonate kinase, and phosphomevalonate decarboxylase.
- 147. The method of Claim 130, wherein said

  15 microorganism is a microalgae.

THE TOTAL STATES OF THE PROPERTY OF THE PROPER

: ", *"* 

148. The method of Claim 147, wherein said microalgae is selected from the group consisting of Chlorella and Prototheca.

- 149. A method for producing  $\beta$ -carotene comprising:
- (a) chemically producing retinal from farnesol; and
- (b) subjecting said retinal to a reductive coupling condition to produce said  $\beta$ -carotene.
  - 150. The method of Claim 149, wherein said chemical step comprises:
  - (a) preparing an  $\alpha,\beta$ -unsaturated polyene carbonyl compound from said farnesol; and
- (b) cyclizing said  $\alpha,\beta$ -unsaturated polyene carbonyl compound to form a cyclic  $\alpha,\beta$ -unsaturated polyene carbonyl compound;
  - (c) converting said cyclic  $\alpha,\beta\mbox{-unsaturated}$  polyene carbonyl compound to retinol; and
- 15 (d) oxidizing said retinol to said retinal.
  - 151. The method of Claim 149, wherein said farnesol is produced biologically.
  - 152. The method of Claim 151, wherein biological production comprises:
- 20 (a) culturing a microorganism in a fermentation medium to produce a product selected from the group consisting of farnesyl phosphate and farnesol, wherein the action of squalene synthase of said microorganism is reduced; and
- 25 (b) recovering said product.

THE STATE OF THE S

WO 00/01650 PCT/US99/15264

195

153. The method of Claim 152, wherein said microorganism is genetically modified to decrease the action of squalene synthase.

15.4. The method of Claim 153, wherein said
5 microorganism is further genetically modified to increase
the action of HMG-CoA reductase.

155. The method of Claim 154, wherein the action of HMG-CoA reductase is increased by overexpression of HMG-CoA reductase or the catalytic domain thereof in the microorganism.

manaranan meneri dapatah tahun 1985 dan 1986 dan 1988 dan

On the first of the first terminal of the first of the fi

....

..:

10

- 156. The method of Claim 155, wherein said
  microorganism is further genetically modified to increase
  the action of a protein selected from the group
  consisting of acetyl Co-A thiolose, HMG-CoA synthase,
  meyalonate kinase, phosphomeyalonate kinase.
- mevalonate kinase, phosphomevalonate kinase,
  phosphomevalonate decarboxylase, isopentenyl
  pyrophosphate isomerase, farnesyl pyrophosphate synthase,
  D-1-deoxyxylulose 5-phosphate synthase, and 1-deoxy-Dxylulose 5-phosphate reductoisomerase.
- 20 157. The method of Claim 156, wherein the microorganism has been genetically modified to increase the action of farnesyl pyrophosphate synthase.
  - 158. The method of Claim 152, wherein said microorganism is an erg9 mutant.
- 25 159. The method of Claim 152, wherein said product is secreted into said fermentation medium by said

:¥::.

PCT/US99/15264

microorganism and wherein said step of recovering comprises purification of said product from said fermentation medium.

- 160. The method of Claim 152, wherein said product

  is intracellular farnesyl phosphate and farnesol and said
  step of recovering comprises isolating said farnesyl
  phosphate and farnesol from said microorganism.
- 161. The method of Claim 152, wherein said product is intracellular farnesyl phosphate and said step of recovering further comprises dephosphorylating said farnesyl phosphate to produce farnesol.
  - 162. The method of Claim 152, wherein said microorganism is a fungi.
- 163. The method of Claim 162, wherein said fungi has been genetically modified to express at least a portion of the enzymes in the mevalonate independent pathway.
  - 164. The method of Claim 162, wherein said fungi has been genetically modified to express an enzyme selected from the group consisting of D-1-deoxyxylulose 5-
- 20 phosphate synthase, and 1-deoxy-D-xylulose 5-phosphate reductoisomerase.

25

165. The method of Claim 162, wherein said fungi is a yeast and said yeast is blocked in the ergosterol pathway and is genetically modified to take up exogenous sterols under aerobic conditions.

- 166. The method of Claim 152, wherein said microorganism is a bacteria.
- 167. The method of Claim 166, wherein said bacteria has been genetically modified to express at least a portion of the enzymes in the mevalonate pathway.
- 168. The method of Claim 167, wherein said bacteria has been genetically modified to express an enzyme selected from the group consisting of acetyl Co-A thiolose, HMG-CoA synthase, HMG-CoA reductase, mevalonate kinase, phosphomevalonate kinase, and phosphomevalonate decarboxylase.
  - 169. The method of Claim 152, wherein said microorganism is a microalgae.
- 170. The method of Claim 169, wherein said

  15 microalgae is selected from the group consisting of

  Chlorella and Prototheca.

171. A method for producing  $\beta\text{-carotene}$  comprising: producing  $C_{40}\text{-sulfone}$  from a retinyl halide and retinylphenylsulfone; and

converting said  $C_{40}\mbox{-sulfone}$  to  $\beta\mbox{-carotene}.$ 

- 172. The method of Claim 171, wherein said producing step comprises contacting said retinylphenylsulfone with a base
  - 173. The method of Claim 171, wherein said converting step comprises an elimination process.

10

5

The second of the form of the second of the

FIG. 1A-i

:

Geranyl pyrophosphate

Farnesyl pyrophosphate

The second secon





FIG. 1A-III



Ergosterol

Contestination to the contestion of the contesti




FIG. 1B-i

Dimethylallyl pyrophosphate

是是是这种,我们是这种是一种,我们是一个人,我们就是这种人,我们就是这种人的,我们也是一个人,我们也不是一个人,我们也会是一个人,我们也会会会会会会会会会会会会

Isopentenyl pyrophosphate

Geranyl pyrophosphate

FIG. 1B-ii

The second of th




FIG. 18-III

ieniekkingen auszonalas sa sessasia seriesialakan sa tada asa sessasiala serasasasen se sessasia ses 🥫 🥫




FIG. 1B-iv

:ij; :-

The designation of the first of the structure being Historian resident and the structure of the structure of

FIG. 3




FIG. 4





FIG. 5

*:* 



THE BEST CONSTRUCTION OF THE PROPERTY OF THE P




FIG. 7




FIG. 8




FIG. 9-i

## geranyl pyrophosphate

FIG. 9-ii

farnesol

Control to recolutions of the reserver properties of the reconstitution of the reconstit

FIG. 11

FIG. 12

The state of the s

FIG. 13

### SEQUENCE LISTING

```
<110> Millis, James R.
        Saucy, Gabriel G
        Maurina-Brunker, Julie
        McMullin, Thomas W.
 <120> METHOD OF VITAMIN PRODUCTION
 <130> 3161-29
 <140> not yet assigned
 <141> 1999-07-06
 <150> 60/091,983
 <151> 1998-07-06
 <160> 51
 <170> PatentIn Ver. 2.0
 <210> 1
 <211> 23
 <212> DNA
 <213> Artificial Sequence
 <221> misc_feature
 <222> (1)..(23)
 <223> PRIMER
 <220>
<223> Description of Artificial Sequence: PRIMER
<400> 1
ctcagtacgc tggtacccgt cac
                                                                    23
<210> 2
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<222> (1)..(27)
<223> PRIMER
<220>
<223> Description of Artificial Sequence:PRIMER
<400> 2
gatggatccc aatatgtgta gctcagg
                                                                   27
<210> 3
<211> 22
<212> DNA
```

tara da tara da matematika mangantan da mangan tara da mangan da mangan da mangan da mangan da mangan da manga

<213> Artificial Sequence

```
<220>
 <221> misc_feature
 <222> (1)..(22)
 <223> PRIMER
 <220>
 <223> Description of Artificial Sequence: PRIMER
 <400> 3
gcgcatccac gggctatata aa
                                                                     22
 <210> 4
 <211> 26
 <212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<222> (1)..(26)
<223> PRIMER
<220>
<223> Description of Artificial Sequence: PRIMER
<400> 4
gcggatccta ttatgtaagt acttag
                                                                     26
<210> 5
<211> 22
<212> DNA
<213> Artificial Sequence
<220>
<221> misc feature
<222> (1)..(22)
<223> PRIMER
<220>
<223> Description of Artificial Sequence: PRIMER
<400> 5
gagcatccac gggctatata aa
                                                                    22
<210> 6
<211> 26
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<222> (1) .. (26)
<223> PRIMER
<220>
<223> Description of Artificial Sequence: PRIMER
```

Tradition and the second of the second of

--:

WO 00/01650	PCT/US99/15264
<400> 6	
tcccccggg cgcagacttc acgctc	26
<210> 7	
<211> 31	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> misc_feature	
<222> (1)(31)	
<223> PRIMER	
<220>	
<223> Description of Artificial Sequence:PRIMER	
<400> 7	
gateegegge teaagetage ggtattatge c	31
<210> 8	
<211> 29	
<212> DNA	
<213> Artificial Sequence	
<220>	•
<221> misc_feature '	
<222> (1)(29)	
<223> PRIMER	
<220>	
<223> Description of Artificial Sequence:PRIMER	
<400> 8	
gactctagag tttacgagtc tggaaaatc	29
<210> 9	
<211> 28	
212> DNA	
<213> Artificial Sequence	
:220>	•
221> misc_feature	
222> (1)(28)	
223> PRIMER	
220>	
223> Description of Artificial Sequence: PRIMER	
400> 9	
taggatcca tggaattgag caatagag	28
210> 10	
211> 33	
212> DNA	
213> Artificial Sequence	
220	

- Addition which a man and the contract of t

WO 00/01650	PCT/US99/1
<221> misc_feature <222> (1)(33) <223> PRIMER	
<220> <223> Description of Artificial Sequence: PRIMER	
<400> 10 aattccaagc ttgcggccgc tctagaacgc gtg	33
<210> 11 <211> 32 <212> DNA <213> Artificial Sequence	
<220> <221> misc_feature <222> (1)(32) <223> PRIMER	
<220> <223> Description of Artificial Sequence:PRIMER	
<400> 11 gatccacgcg ttctagagcg gccgcaagct tg	32
<210> 12 <211> 25 <212> DNA <213> Artificial Sequence	
<220> <221> misc_feature <222> (1)(25) <223> PRIMER	
<220> <223> Description of Artificial Sequence:PRIMER	
<400> 12 gaattegttt ataaggacag eeega	25
<210> 13 <211> 26 <212> DNA <213> Artificial Sequence	
<220> <221> misc_feature <222> (1)(26) <223> PRIMER	
<220> <223> Description of Artificial Sequence:PRIMER	
<400> 13 ctgcagtcct taactgacgg cagcga	26

. .

```
<210> 14
  <211> 52
  <212> DNA
  <213> Artificial Sequence
  <220>
  <221> misc_feature
  <222> (1) .. (52)
  <223> PRIMER
  <220>
 <223> Description of Artificial Sequence: PRIMER
 <400> 14
 agctgaattc gagctcggta cccgggctct agagtcgacc tgcaggcatg ca
                                                                     52
 <210> 15
 <211> 52
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_feature
 <222> (1)..(52)
 <223> PRIMER
 <220>
 <223> Description of Artificial Sequence: PRIMER
agettgeatg cetecaggte gaetetagag eeegggtace gagetegaat te
                                                                    52
 <210> 16
 <211> 29
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<222> (1)..(29)
<223> PRIMER
<220>
<223> Description of Artificial Sequence: PRIMER
<400> 16
gacggatccg tggaatattt cggatatcc
                                                                    29
<210> 17
<211> 34
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<222> (1) .. (34)
```

3::

WO 00/01650	PCT/US99/15264
<223'> PRIMER	
<220>	
<223> Description of Artificial Sequence:PRIMER	
<400> 17	
ctcggatccg gacggattac aacaggtatt gtcc	34
<210> 18	
<211> 31	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> misc_feature	
<222> (1)(31)	
<223> PRIMER	
<220>	
<223> Description of Artificial Sequence:PRIMER	
<400> 18	
cagaattcac catggccgtg acttcctcct c	31
<210> 19	
<211> 32	
<212> DNA	
<213> Artificial Sequence	
<220>	•
<221> misc_feature	
<222> (1)(32)	
<223> PRIMER	
<220>	
<223> Description of Artificial Sequence:PRIMER	•
<400> 19	
caagatetea tacatteaat eeteatggae ae	32
<210> 20	
<b>211&gt; 31</b>	
212> DNA .	
213> Artificial Sequence	
:220>	
221> misc_feature	
222> (1)(31)	
223> PRIMER	
:220>	
223> Description of Artificial Sequence:PRIMER	
400> 20	
agaattett aacaegeatg atececaegg c	21
	31

The second of the second of the second secon

<210> 21

```
<211> 32
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_feature
 <222> (1)..(32)
 <223> PRIMER
 <220>
 <223> Description of Artificial Sequence: PRIMER
 <400> 21
 ctggatccgt caaatccgtg aatcgtaacg ag
                                                                     32
 <210> 22
 <211> 33
 <212> DNA
 <213> Artificial Sequence
 <220>
 <221> misc_feature
 <222> (1) .. (33)
 <223> PRIMER
 <220>
<223> Description of Artificial Sequence: PRIMER
 <400> 22
ggccggatcc atattacgta gaaatggctt cag
                                                                    33
<210> 23
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<222> (1)..(27)
<223> PRIMER
<220>
<223> Description of Artificial Sequence:PRIMER
<400> 23
geogetegag ggteettate tagtttg
                                                                   27
<210> 24
<211> 38
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<222> (1)..(38)
<223> PRIMER
```

•

WO 00/01650	PCT/US99/152
<220> <223> Description of Artificial Sequence: PRIMER	
<400> 24 tctagaggca cctgtcactt tggaaaaaaa atatacgc	38
<210> 25 <211> 26 <212> DNA <213> Artificial Sequence	
<220> <221> misc_feature <222> (1)(26) <223> PRIMER	
<220> <223> Description of Artificial Sequence: PRIMER	
<400> 25 ccgcgggccg gaaatgctct ctgttc	26
<210> 26 <211> 26 <212> DNA <213> Artificial Sequence	
<220> <221> misc_feature <222> (1)(26) <223> PRIMER	
<220> <223> Description of Artificial Sequence:PRIMER	
<400> 26 cacgtegace atteaaactt tactac	26
<210> 27 <211> 19 <212> DNA <213> Artificial Sequence	·
<220> <221> misc_feature <222> (1)(19) <223> PRIMER	
<220> <223> Description of Artificial Sequence:PRIMER	
<400> 27 gagggcccgg tccagacat	19
<210> 28 <211> 27	17

<212> DNA

PCT/US99/15264 <213> Artificial Sequence <220> <221> misc\_feature <222> (1)..(27) <223> PRIMER <220> <223> Description of Artificial Sequence: PRIMER <400> 28 cccgggtatt gagcacgtga gtatacg 27 <210> 29 <211> 26 <212> DNA <213> Artificial Sequence <220> <221> misc\_feature <222> (1) .. (26) <223> PRIMER <220> <223> Description of Artificial Sequence: PRIMER <400> 29 ggatccggca agtgcacaaa caatac 26 <210> 30 <211> 21 <212> DNA <213> Artificial Sequence <220> <221> misc\_feature <222> (1)..(21) <223> PRIMER <220> <223> Description of Artificial Sequence:PRIMER <400> 30 ccaaatataa ctcgagcttt g 21 <210> 31 <211> 19 <212> DNA <213> Artificial Sequence <220> <221> misc\_feature <222> (1)..(19) <223> PRIMER

WO 00/01650

<220>

V.W

<223> Description of Artificial Sequence:PRIMER

```
<400> 31
gcaaagtcca ccaccgcag
                                                                    19
<210> 32
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<222> (1)..(27)
<223> PRIMER
<220>
<223> Description of Artificial Sequence:PRIMER
gccacgtgcc cccgggtttc tctagcc
                                                                    27
<210> 33
<211> 33
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<222> (1)..(33)
<223> PRIMER
<220>
<223> Description of Artificial Sequence:PRIMER
<400> 33
ggaaaagagc tcgataatta ttgatgatag atc
                                                                   33
<210> 34
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<222> (1)..(21)
<223> PRIMER
<220>
<223> Description of Artificial Sequence:PRIMER
<400> 34
ccgttttgga tcctagatca g
                                                                   21
<210> 35
<211> 26
<212> DNA
<213> Artificial Sequence
```

WO 00/01050	PCT/US99/15264
<220>∙	
<221> misc_feature	
<222> (1)(26)	
<223> PRIMER	
<220>	
<223> Description of Artificial Sequence:PRIMER	
<400> 35	
gttcccgggt tattgtcctg catttg	26
<210> 36	20
<211> 28	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> misc_feature	
<222> (1)(28) <223> PRIMER	
<223> PRIMER	
<220>	
<223> Description of Artificial Sequence:PRIMER	
1 Sequence: PRIMER	
<400> 36	
aagagctcat ctgataatag atcaagcg	
<210> 37	28
<211> 26	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> misc_feature	
<222> (1)(26) <223> PRIMER	
<223> PRIMER	
<220>	
<223> Description of Artificial Sequence: PRIMER	
<400> 37	
aggageteaa egacaataaa tggetg	24
<210> 38	26
<211> 24	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> misc_feature	
<222> (1)(24)	
<223> PRIMER	
<220>	
<223> Description of Artificial Sequence: PRIMER	
or Artificial Sequence: PRIMED	

WO 00/01650

<400> 38

charteries of the little of the state of the

WO 00/01650	PCT/US99/15264
gtcctctaga tcttgaatga aatc	24
<210> 39	_ <del>-</del>
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220> <221> misc_feature	
<222> (1)(23) <223> PRIMER	
<223> PRIMER	
<220>	
<223> Description of Artificial Sequence: PRIMER	
<400> 39	
ctttgagctc gtacaagaag cag	22
	23
<210> 40	
<211> 21	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> misc_feature	
<222> (1)(21)	
<223> PRIMER	
<220>	
<223> Description of Artificial Sequence: PRIMER	
<400> 40	
ctaagctttg cgcccgtgaa g	21
<210> 41	
<211> 24	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> misc_feature	
<222> (1)(24)	
<223> PRIMER	
<220>	
<223> Description of Artificial Sequence: PRIMER	
<400> 41	
gttctagaag ttttcaaagc agag	
generaland contradage agag	24
<210> 42	
<211> 27	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> misc_feature	

4.5

WO 00/01650 PCT/US99/15264 <222> (1) .. (27) <223> PRIMER <220> <223> Description of Artificial Sequence: PRIMER <400> 42 gggattcgaa ttctgtcgcg ctgtaac . 27 <210> 43 <211> 28 <212> DNA <213> Artificial Sequence <220> <221> misc\_feature <222> (1)..(28) <223> PRIMER <220> <223> Description of Artificial Sequence: PRIMER tgggatccgt aacggcttta gcgagctg 28 <210> 44 <211> 20 <212> DNA <213> Artificial Sequence <220> <221> misc\_feature <222> (1)..(20) <223> PRIMER <223> Description of Artificial Sequence: PRIMER <400> 44 gattccgcgt aaggatcccg 20. <210> 45 <211> 19 <212> DNA <213> Artificial Sequence <220> <221> misc\_feature <222> (1)..(19) <223> PRIMER <220> <223> Description of Artificial Sequence: PRIMER <400> 45

19

ccagcatcta gaccaccag

WO 00/01650 PCT/US99/15264 <210> 46 <211> 35 <212> DNA <213> Artificial Sequence <220> <221> misc\_feature <222> (1) .. (35) <223> PRIMER <220> <223> Description of Artificial Sequence: PRIMER gactgcaget ggccgctggg tattctgtcg tagtt 35 <210> 47 <211> 32 <212> DNA <213> Artificial Sequence <220> <221> misc\_feature <222> (1)..(32) <223> PRIMER <223> Description of Artificial Sequence: PRIMER <400> 47 gatetagate aegegtaege agaaggtttt ge 32 <210> 48 <211> 25 <212> DNA <213> Artificial Sequence <220> <221> misc\_feature <222> (1)..(25) <223> PRIMER <220> <223> Description of Artificial Sequence: PRIMER <400> 48 gaattccaat tcagcgggta acctt 25 <210> 49 <211> 29 <212> DNA <213> Artificial Sequence <220> <221> misc\_feature <222> (1)..(29)

and the second of the second o

Sent of the sent o

<223> PRIMER

```
<223> Description of Artificial Sequence: PRIMER
<400> 49
aagetttget tgaacccaaa agggeggta
                                                                     29
<210> 50
<211> 35
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<222> (1)..(35)
<223> PRIMER
<220>
<223> Description of Artificial Sequence: PRIMER
<400> 50
gcattgagtt gctgcaggct tccttcttgg tcgcc
                                                                     35
<210> 51
<211> 35
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_difference
<222> (1)..(35)
<223> PRIMER
<223> Description of Artificial Sequence: PRIMER
<400> 51
ggcgaccaag aaggaagcct gcagcaactc aatgc
                                                                     35
```

and the state of the

weeksteer en en de state e

k Kanapananininin ing pagamentan

# INTERNATIONAL SEARCH REPORT

International application No. PCT/US99/15264

A. CLA	ASSIFICATION OF SUBJECT MATTER	
IPC(6)	:C07C 45/41; C07D 301/03, 303/04, 311/74; C12F	P 1/02
According	:435/171; 549/408, 519; 560/104; 568/315 to International Patent Classification (IPC) or to bot	th national classification and IDC
	LDS SEARCHED	a national constitution and Inc
	documentation searched (classification system follow	red by classification and the
4	435/171;. 549/408, 519;. 560/104;. 568/315	ved by classification symbols)
0.3	433/171,:: 343/406,:513;::300/104;:2568/315	
Documenta	tion searched other than minimum documentation to the	the extent that such documents are included in the fields searched
		and the fields scatched
Electronic o	data base consulted during the international search (	name of data base and, where practicable, search terms used)
CAS-ONI	LINE	
}		
C. DOC	TIMENTS CONSIDERED TO BE DOLD TO THE	
C. DOC	CUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where a	appropriate, of the relevant passages Relevant to claim No.
Α	RANDALL et al. Protein Isoprenyl	lation in Suspension-Cultured 1-56, 121-148
	Tobacco Cells, Plant Cell, 1993. Vol	. 5. pages 433-442.
A	AVALOS et al. Terpenoid Biosynthesi	is in Cell Extracts of Wild-type 57-120, 149-173
	and Mutant Strains of Gibberella Fujik	uroi, Biochimica et Biophysica
	Acta, 1988. Vol. 966, pages 257-265	, especially pages 257-264.
A	MOSOUEDA CANO	
A	MOSQUEDA-CANO et al. Enviro	onmental and Developmental 149-173
	regulation of Carotenogenesis in the	e Dimorphic Fungus Mucor
	Rouxii, Current Microbiology, 1995	5. Vol. 31, pages 141-145,
	especially pages 141-143.	
		1
Furth	er documents are listed in the continuation of Box (	C. See patent family annex.
• Sp	ocial categories of cited documents:	"T" later document published after the international filing date or priority
"A" do	cument defining the general state of the art which is not considered be of particular relevance	date and not in conflict with the application but cited to understand the principle or theory underlying the invention
	tier document published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be
'L' doc	cument which may throw doubts on priority claim(s) or which is	considered novel or cannot be considered to involve an inventive step when the document is taken slone
crte	od to establish the publication date of another citation or other scial reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be
"O" doe	extra ent referring to an oral disclosure, use, exhibition or other ans	considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*P* document published prior to the international filing date but later then *&* document member of the same patent family		
Date of the actual completion of the international search  Date of mailing of the international search report		
08 SEPTE	MBER 1999	09 NOV 1999
Name and mailing address of the ISA/US Authorized officer		
Box PCT	Commissioner of Patents and Trademarks	
Washington, D.C. 20231 TAOFIQ A. SOLOLA		

#### INTERNATIONAL SEARCH REPORT

International application No. PCT/US99/15264

Box 1 Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. Claims Nos.:  because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Claims Nos.:      because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
Picase See Extra Sheet.
1. X As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1))(July 1992)\*

## INTERNATIONAL SEARCH REPORT

International application No. PCT/US99/15264

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s)1-56, drawn to biological process of making alpha-tocopherol.

Group II, claim(s) 57-89 and 94-116, drawn to biological process of making farmesol and geranylgeraniol.

Group III, claim(s) 90-93, drawn to microorganism for making famesol.

Group IV, claim(s)117-120, drawn to microorganism for making geranylgeraniol.

Group V, claim(s) 121-148, drawn to a chemical process of making vitamin A.

Group VI, claim(s) 149-173, drawn to a process of making beta-carotene.

The inventions listed as Groups I-VI do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical feature among groups I-VI is tocopherol which is known in the art.

The special technical feature in group I is that it is a biological process for making alpha-tocopherol. The special technical feature in group II is that it is a biological process for making farmesol and geranylgeraniol. The special technical feature in group III is that it is a microorganism for making farmesol. The special technical feature in group V is that it is a process for making vitamin A. The special technical feature in group VI is that it is a process for making beta-carotene.

Form PCT/ISA/210 (extra sheet)(July 1992)\*

THIS PAGE BLANK (USPTO)